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 Abstract 
 
ABSTRACT 
Although knowledge of metabolic adaptations in cancer has increased 
dramatically, little is known about the spontaneous adoptive adaptations of cancer 
cells to changing conditions in the body. This is particularly important for chronic 
lymphocytic leukaemia (CLL) cells which continually circulate between different 
microenvironments in the blood, bone marrow and lymph nodes. 
To study such metabolic adaptations, a nuclear magnetic resonance (NMR) 
based approach; capable of monitoring real-time metabolism in primary CLL cells 
was developed. Using this setup, this thesis demonstrates fast, reversible metabolic 
plasticity in CLL cells during transition from normoxic to hypoxic conditions, 
associated with elevated HIF-1α dependent glycolysis. This work also demonstrates 
differential utilisation of pyruvate in oxygenated and hypoxic conditions where in 
the latter, pyruvate was actively transported into CLL cells to protect against 
oxidative stress. Moreover, real-time NMR experiments provided initial evidence 
that CLL metabolism in hypoxia correlates with stage of disease, adding significant 
relevance of our method for patient stratification. Additionally, to further investigate 
alterations between normoxic and hypoxic metabolism, Metabolic Flux Analysis 
(MFA) was carried out using primary CLL cell extracts, revealing modifications in 
pyruvate carboxylase (PC) activity and the pentose phosphate pathway (PPP).  
  Abstract 
 
III 
 
Despite the recent advent of promising new agents, CLL currently remains 
incurable and new therapeutic approaches are required. Understanding CLL cell 
adaptation to changing oxygen availability will permit the development of therapies 
that interfere with disease aetiology. This study makes several significant 
contributions towards this goal. Moreover, the findings may be relevant to all 
migratory cancer cells, and may have importance for the development of strategies to 
prevent cancer metastasis. 
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TMSP Sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 
TNFα Tumour necrosis factor alpha 
TRX Thioredoxin 
Ub Ubiquitin 
UPLC Ultra performance liquid chromatography 
UV Ultraviolet 
VEGF Vascular endothelial growth factor 
WT Wild-Type 
α-KG α-ketoglutarate 
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1.1 HALLMARKS OF CANCER 
Cancer is a disease involving dynamic changes in the genome. The foundation 
of cancer research was set by the discovery of the mutations leading to the 
production of oncogenes, as well as tumour suppressor genes specific for different 
types of cancer. However studies carried out within the last two decades have shown 
that the features that regulate the transformation of normal human cells into 
malignant cancers are shared amongst cancers. Tumourigenesis is a multistep 
process and these steps reflect genetic alterations that drive the progressive 
transformation of normal human cells into highly malignant derivatives (Hanahan 
and Weinberg 2000). Ten essential alterations in cell physiology that collectively 
dictate malignant growth of the cell have been proposed (Figure 1.1). The main 
hallmarks shared between the majority of cancer types include: genome instability 
and mutations, self-sufficiency in growth signals, insensitivity to antigrowth signals, 
tumour promoting inflammation, resistance to programmed cell death (apoptosis), 
sustained angiogenesis, tissue invasion and metastasis, avoidance of immune 
destruction, limitless replicative potential and deregulated cellular energetics. The 
work presented in this thesis will focus on the final hallmark listed, the ability to 
modify, or reprogram cellular metabolism in order to meet the bioenergetic and 
biosynthetic demands of increased cell proliferation, and to survive environmental 
fluctuations in external nutrient and oxygen availability. 
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Figure 1. 1. Hallmarks of cancer cells. 
The main hallmarks shared between the majority of cancer types (Adapted from 
Hanahan and Weinberg 2011). 
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1.2 UNDERSTANDING CANCER METABOLISM 
The metabolism of cancer cells differs from healthy cells and various types of 
cancer are characterised by specific metabolic alterations. Despite many recent 
studies, our understanding of cancer metabolism remains enigmatic. It is crucial to 
improve our understanding of metabolic deregulations in cancer since they have also 
been shown to be linked to drug resistance in cancer therapy (Zhou, Zhao et al. 2010; 
Zhao, Liu et al. 2011). A better understanding of the reprogrammed cellular 
pathways in cancer is expected to lead to the identification of new therapeutic targets 
(Hamanaka and Chandel 2012). 
1.2.1 Metabolism pervades every aspect of biology 
Metabolism is defined as the sum of biochemical processes in living organisms 
that either consume or produce energy (DeBerardinis and Thompson 2012). At 
present, there are over 16,000 metabolites and 8,700 reactions annotated in the Kyoto 
Encyclopedia of Genes and Genomes (http://www.genome.jp /kegg/pathway.html). 
Core metabolism can be simplified to the pathways involving carbohydrates, fatty 
acids and amino acids essential to homeostasis and macromolecule synthesis. These 
pathways can be separated into three classes: anabolic pathways – energy requiring 
pathways that construct molecules from smaller units; catabolic pathways – which 
degrade molecules to release energy; and waste disposal pathways – which eliminate 
toxic by-products. 
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Most of these metabolic networks were defined during the ‚golden age of 
biochemistry‛ (1920s - 1960s). They include core pathways like glycolysis (Embden, 
Meyerhof, and Parnas), respiration (Warburg), the tricarboxylic acid (TCA) and urea 
cycles, glycogen catabolism (Cori and Cori), oxidative phosphorylation (Mitchell), 
and the importance of ATP in energy transfer reactions (Lipmann). In the latter half 
of the 20th century, interest in metabolism gradually disappeared as new areas of 
biology, such as genetics, became more popular (DeBerardinis and Thompson 2012). 
However, recent investigations of cell biology and disease have renewed interest in 
metabolism (Recent reviews: (McKnight 2010; Benjamin, Cravatt et al. 2012; Cantor 
and Sabatini 2012; Ward and Thompson 2012). Recent years have revealed new 
metabolites and connections between their pathways which could not have been 
predicted from the conventional understanding of biochemistry (Gross, Cairns et al. 
2010). This has resulted in our current awareness of the relevance of metabolism to 
all other cellular processes. 
Interest in the altered metabolism exhibited by cancer cells has grown with the 
discovery of oncogenic mutations in metabolic enzymes and has been aroused by the 
development of tools that monitor metabolism in living cells. Abnormal metabolism 
has now become the key target for anti-cancer therapies. 
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1.2.2 Lessons from Warburg 
Altered cancer metabolism contributes to its malignant transformation, as well 
as to the initiation, growth and maintenance of tumours (Chen, Hewel et al. 2007; 
Hanahan and Weinberg 2011). Common hallmarks for many cancer types are, energy 
production based on aerobic glycolysis, increased fatty acid synthesis and increased 
glutamine metabolism (Zhao, Butler et al. 2013). The principle of abnormal 
metabolism in cancer is long-standing, dating back to the early 1920s when Otto 
Warburg initiated investigations into cancer metabolism, studying the behaviour of 
tissue slices ex vivo. He observed that cancer cells tended to convert glucose to lactate, 
using anaerobic pathways (which are less efficient in ATP production), despite the 
presence of oxygen. This was interpreted as a fundamental change in the way 
glucose metabolism is regulated in cancer cells (Warburg, Wind et al. 1927; Warburg 
1956). Amongst Warburg’s many other seminal contributions to biochemistry 
(including work on respiration for which he received the Nobel Prize in 1931) he is 
best remembered and most frequently cited for this observation, now called the 
Warburg effect. Warburg suggested that the reason for these metabolic alterations 
may be a consequence of mitochondrial defects that inhibited the ability of cancer 
cells to effectively oxidize glucose carbon to CO2 (Koppenol, Bounds et al. 2011). A 
later extension to this hypothesis, that dysfunctional mitochondria caused cancer was 
also proposed (Koppenol, Bounds et al. 2011). Warburg’s seminal finding was 
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supported by many studies performed on various cancer types. Later, other 
hypotheses appeared claiming that mitochondria are functional in most tumour cells 
and able to carry out oxidative phosphorylation and produce the majority of ATP for 
cancer cells (Weinhouse 1976). Nowadays, Warburg’s observation of increased 
glucose fermentation by cancer cells is successfully exploited in clinics for diagnostic 
purposes, to detect tumours in the body. Using 2-18F-fluoro-2-deoxy-D-glucose 
(FDG), a radiolabelled glucose analogue, positron emission tomography identifies 
malignant tissues which consume much more glucose than healthy tissues (Gambhir 
2002). 
1.2.3 The advantage of altered cancer metabolism 
The current challenge is to understand why cancer cells utilise a less efficient 
metabolic pathway, despite their need to intensively grow and divide. In order to 
determine the reason for increased aerobic glycolysis, it is important to realise the 
purpose of cell metabolism in general and what the specific requirements of a cancer 
cell may be. All cells take up nutrients from their environment and incorporate them 
into pathways in order to sustain homeostasis. Cells need to carry out many 
reactions that are energetically unfavourable, such us maintaining ion gradients 
across membranes, actively transporting molecules through the membranes and 
synthesising proteins. The coupling of these reactions with ATP hydrolysis, 
providing free energy, enables them to proceed.  
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Cancer cells need efficient ways to produce ATP, but they must also adapt to 
their specific environment. As a consequence of irregular vascularization, the tumour 
microenvironment is often lacking nutrients (Hirayama, Kami et al. 2009; Ackerman 
and Simon 2014). Therefore, cancer cells are forced to shift their metabolism to 
anabolic reactions. It has been proposed that in order to produce all of the necessary 
metabolites, cells attempt to save glucose for the synthesis of those that can solely be 
produced from glucose – such as ribose for nucleotides. Other metabolites such as 
lipids, are produced from alternative sources e.g. glutamine (Anastasiou and Cantley 
2012). 
In general, cancer cells benefit from their abnormal metabolism in several 
ways. Firstly, their metabolism ensures that they have a ready supply of the building 
blocks required for the synthesis of NADPH, acetyl-CoA, ATP and other 
macromolecules. Secondly, by claiming more nutrients than healthy cells, tumour 
cells contribute to the starvation of neighbouring cells, gaining more space for 
expansion and growth (Kaelin and Thompson 2010). Thirdly, an excessive uptake of 
nutrients may lead to the increased generation of reactive oxygen species (ROS), if 
reactions in the TCA occur at a rate exceeding the capacity of electron capture within 
the electron transport chain (Wellen and Thompson 2010). High ROS levels may 
promote cancer-cell proliferation by inactivating growth-inhibiting phosphatase 
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enzymes. Enhanced ROS may also lead to an enhanced mutation rate by inducing 
DNA damage (Kaelin and Thompson 2010). 
1.2.4 Role of ROS in cancer cells 
 Reactive oxygen species are a diverse class of radical species which retain a 
more reactive state than molecular oxygen and are produced in all cells as a normal 
metabolic by-product. ROS are heterogeneous in their properties and cause various 
effects, depending on their levels. At low concentrations, ROS contribute to cell 
proliferation and survival through the post-translational modification of 
phosphatases and kinases (Lee, Yang et al. 2002; Giannoni, Buricchi et al. 2005). The 
production of low ROS levels is also required for homeostatic signalling events, cell 
differentiation and cell mediated immunity. Moderate levels of ROS induce the 
expression of stress-responsive genes such as HIF-1α, triggering the expression of 
pro-survival proteins (Gao, Zhang et al. 2007). On the other hand, high levels of ROS 
may lead to damage to cellular macromolecules including lipids, proteins, 
mitochondrial and nuclear DNA and cause the induction of senescence (Takahashi, 
Ohtani et al. 2006). The permeabilisation of mitochondria, resulting in the release of 
cytochrome c and apoptosis can also be caused by ROS (Garrido, Galluzzi et al. 
2006). In order to neutralise the destructive effect of ROS, cells produce antioxidant 
molecules, such as reduced glutathione (GSH) and thioredoxin (TRX) as well as a 
range of antioxidant enzymes (Nathan and Ding 2010). These molecules reduce 
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excessive levels of ROS, preventing irreversible cellular damage and restoring redox 
homeostasis.  
The first time a link between ROS and cellular transformation was identified 
was in 1981, when it was shown that insulin elevated intracellular H2O2 levels and 
increased the proliferation of tumour cells (Oberley 1988). Cancer cells have a high 
demand for ATP due to their increased proliferation rate. However, the consequence 
of this uncontrolled energy production is the accumulation of ROS. In order to 
ensure their survival, transformed cells protect themselves by up-regulating 
antioxidant systems, creating a paradox of high ROS production in the presence of 
high antioxidant levels (Schafer, Grassian et al. 2009). Many studies have evaluated 
ROS levels and production under various circumstances, with the goal of 
characterising the stages at which ROS are oncogenic or tumour suppressive 
(Trachootham, Alexandre et al. 2009).  
At low to moderate levels, ROS have been shown to contribute to tumour 
formation either by acting as signalling molecules or, by promoting DNA mutations. 
For example, ROS can stimulate the phosphorylation of mitogen-activated protein 
kinase (MAPK) and extracellular signal-regulated kinase (ERK), cyclin D1 expression 
and JUN N-terminal kinase (JNK) activation, which promotes growth and survival of 
cancer cells (Martindale and Holbrook 2002; Ranjan, Anathy et al. 2006). ROS have 
also been shown to reversibly inactivate tumour suppressors such as phosphatase 
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and tensin homolog (PTEN) and protein tyrosine phosphatases (PTPs) because of the 
presence of the redox-sensitive cysteine residues in their catalytic centre (Leslie, 
Bennett et al. 2003).  
At high levels, ROS promote severe cellular damage and cell death. Cancer 
cells need to fight high levels of ROS, especially at early stages of tumour 
development. It has been shown that conditions inducing oxidative stress also 
increase the selective pressure on pre-neoplastic cells to develop potent antioxidant 
mechanisms. High ROS levels are also induced by detachment from the cell matrix. 
This aspect represents a challenge for metastatic cancer cells that need to survive 
during migration to distant organs (Schafer, Grassian et al. 2009; Gorrini, Harris et al. 
2013). Therefore, cancer cells have a high antioxidant capacity that regulates ROS to 
levels that are compatible with their cellular functions but still higher than in healthy 
cells. Targeting these enhanced antioxidant defence mechanisms may represent a 
strategy that can specifically kill cancer cells, including tumour-initiating cells, while 
leaving healthy cells intact. 
1.2.5 Glutamine metabolism 
Although mitochondrial dysfunction was considered a feature of cancer cells 
that contributes to the Warburg effect, more recently it has been shown that the 
mitochondria of cancer cells are fully functional and required for cancer cell 
metabolism (Wallace 2012). However since glucose is mainly used in aerobic 
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glycolysis, glutamine becomes the major substrate required for the TCA cycle and 
production of NADPH and fatty acids. In fact some cancer cell lines display 
‘addiction’ to glutamine (Yuneva, Zamboni et al. 2007; Wise, DeBerardinis et al. 
2008). This is particularly interesting due to the fact that glutamine is a nonessential 
amino acid that can be synthesised from glucose. It has been observed that as an 
artefact of in vitro culture, glutamine is switched from a nonessential to an essential 
amino acid (Eagle 1955). These are aspects that may explain why some cancers seem 
not to be able to survive in the absence of exogenous glutamine.  
The role of glutamine in cell growth and signalling pathways has been widely 
explored in recent years (DeBerardinis, Mancuso et al. 2007; Wise and Thompson 
2010). The most obvious role for glutamine is in providing nitrogen for protein and 
nucleotide synthesis. The growing cancer must synthesise nitrogenous compounds in 
the form of nucleotides and non-essential amino acids. When glutamine donates its 
amide group it is converted to glutamate. Glutamic acid is the primary nitrogen 
donor for the synthesis of alanine, serine, aspartate and ornithine, as well as 
contributing its carbon and nitrogen to proline synthesis. Serine is a precursor for 
glycine and cysteine biosynthesis, ornithine is a precursor of arginine, and aspartate 
is a precursor for asparagine biosynthesis (Newsholme, Procopio et al. 2003).  
The contribution of glutamine in amino acid biosynthesis explains its key role 
in the protein translation needs of cancer cells. Moreover, glutamine also plays an 
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important regulatory role in protein translation (Hurtaud, Gelly et al. 2007). It has 
been shown that glutamine starvation activates the general amino acid control 
(GAAC) pathway, which results in the up-regulation of amino acid transporters, 
leading to increased amino acid uptake. This elevates the intracellular amino acid 
level, which results in an elevation of the mammalian target of rapamycin complex 1 
(mTOR1) (Chen, Zou et al. 2014). This complex is an evolutionarily conserved master 
regulator of cell growth that activates protein translation and inhibits the 
macroautophagy pathway which is a vacuolar degradation process (Wullschleger, 
Loewith et al. 2006). The essential glutamine requirements of proliferating cells were 
described for the first time by Harry Eagle in 1955, when it was observed that cells 
could not proliferate in the absence of glutamine and that many of them did not 
maintain their viability (Eagle 1955). Later it was observed that carbons from 
glutamine can be incorporated into carbon dioxide that is released by cells and that 
the consumption of glutamine in certain cancer cells is substantially higher than any 
other amino acid (Kovacevic 1971). Using NMR analysis with labelled glutamine, it 
was shown that in a glioblastoma cell line, a significant fraction of carbon from 
glutamine is converted into lactic acid (DeBerardinis, Mancuso et al. 2007). 
Anaplerotic pathways (those that replenish TCA cycle intermediates) are dominant 
in most cancer cells (DeBerardinis and Cheng 2010; Wise and Thompson 2010) and 
they are often a consequence of pyruvate kinase M2 (PKM2) activity (Mazurek, 
Boschek et al. 2005), resulting in a decoupling of glycolysis and the TCA cycle. It can 
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also be caused by the deactivation of pyruvate dehydrogenase (PDH) by pyruvate 
dehydrogenase kinases (PDK), thus preventing it from catalysing the acetylation of 
coenzyme A (coA) and therefore blocking this entry point into the TCA cycle. 
In cancer cells, glutamine catabolism is also regulated by multiple oncogenic 
signals, including those transmitted by the Rho family of GTPases and by c-Myc. 
Activation of c-Myc, makes cells glutamine-dependent for survival (Yuneva, 
Zamboni et al. 2007). Myc induces glutaminase which transforms glutamine into 
glutamate and also inhibits the expression of microRNA miR-23a and miR-23b which 
are translational inhibitors of glutaminase. It has been shown that glutamate can be 
converted to α-ketoglutarate which fuels the TCA cycle in order to produce 
oxaloacetate (OAA), showing that glutamine is the major anaplerotic substrate for 
proliferating glioblastoma cells (DeBerardinis, Mancuso et al. 2007; Wise, 
DeBerardinis et al. 2008; Wise and Thompson 2010). This anaplerotic activity is 
required to maintain the TCA cycle when rapidly proliferating cells are using citrate 
as a precursor for lipid biosynthesis. Another product of glutaminolysis, ammonia, 
has been shown to promote basal autophagy, limit proliferation under physiological 
stress and prevent cells from TNFα- induced apoptosis (Sakiyama, Musch et al. 
2009).  
Intriguing recent research suggests that under hypoxic conditions, the Krebs 
cycle may proceed in the reverse direction (Metallo, Gameiro et al. 2012). Glutamine 
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derived α-KG produces citrate through reductive carboxylation to support de novo 
synthesis of fatty acids. This phenomenon was shown in some cancer cell lines (such 
as renal cell carcinoma (Mullen, Wheaton et al. 2012) or melanoma (Filipp, Scott et al. 
2012)) but has not been reported for other cancers (including leukaemia) so far. 
Flexibility of metabolism to use either of the anaplerotic pathways, as well as 
possible altered pathways in various cancer cells must be taken into consideration 
when thinking about therapies targeting metabolism of specific cancer types. 
Distinct inhibitors of glutaminase have been identified, these are glutamine 
mimetics such as 6-diazo-5-oxo-l-norleucine (Ahluwalia, Grem et al. 1990; Griffiths, 
Keast et al. 1993) or selective inhibitors such as 968 and BPTES [bis-2-(5-
phenylacetamido-1,2,4-thiadiazoyl-2-yl)ethyl sulfide] (Robinson, McBryant et al. 
2007; Wang, Erickson et al. 2010). The potential to selectively block cellular 
transformation, may contribute to successfully targeting glutamine metabolism in 
cancer therapy (Lukey, Wilson et al. 2013). 
1.3 THE HYPOXIC TUMOUR ENVIRONMENT 
A fundamental problem for solid tumours is that they consume all their 
oxygen supplies from blood and so must survive in hypoxia – usually defined as the 
condition when the level of O2 < 1% (compared to 2 to 9% O2 in the adjacent tissue) 
(Favaro, Lord et al. 2011). Existence of tumour hypoxia has been validated using 
biochemical markers of hypoxia, such as EF5 and pimonidazole, or endogenous 
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molecular markers, such as hypoxia inducible factor (HIF) and carbonic anhydrase 9 
(CAIX). As shown in a series of studies, hypoxia induces a wide range of biological 
changes, such as decreased cell proliferation (Evans, Hahn et al. 2001), increased 
expression of genes responsible for drug-resistance (Wartenberg, Ling et al. 2003), 
selection of clones resistant to apoptosis (Graeber, Osmanian et al. 1996), enhanced 
tumour invasion and metastasis (Subarsky and Hill 2003) and elevated mutagenesis 
(Subarsky and Hill 2003). These mechanisms undoubtedly contribute to the evolution 
of malignant tumour cells. However, it remains to be fully understood why hypoxic 
tumour cells tend to be more aggressive in nature and more resistant to treatment 
than non-hypoxic tumour cells within the same tumour, despite their similar genetic 
background (Kim, Lin et al. 2009).  
1.3.1 HIF-1α 
Hypoxia-induced signalling is primarily mediated by HIF, which accumulates 
and promotes the transcription of over 200 genes. Many of these genes support cell 
survival, promote glycolysis and supress oxidative phosphorylation. HIFs are 
transcription factor complexes comprised of an α and β subunit and they function as 
an integral part of the hypoxia response, allowing cell survival during periods of low 
oxygen supply. Although HIF plays an important protective role during 
development and oxygen stress, it has been shown to enhance tumourigenesis and 
promote the development of a more malignant phenotype. HIF activity is high in 
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most, if not all tumours, either owing to hypoxia or conditions leading to HIF 
stabilization under normoxia (pseudohypoxia) (Gottlieb and Tomlinson 2005).  
Accumulation of HIF is supressed by oxygen-dependent prolyl hydroxylase 
domain (PHD) enzymes. On the other hand, changes in the levels of reactive oxygen 
species or TCA cycle metabolites such as fumarate and succinate may promote HIF 
accumulation (Kaelin and Thompson 2010). HIF-1α regulation is presented in Figure 
1.2. Understanding of the role of HIF in hypoxic metabolism could lead to the 
development of chemotherapies that specifically target the hypoxic regions of 
tumours. 
 
 
 
 
 
 
 
 
 
Chapter One - Introduction 
 
18 
 
 
 
Figure 1. 2. HIF-1α regulation by proline hydroxylation. 
In response to hypoxia, HIF-1α accumulates and translocates to the nucleus. There, HIF-
1α dimerises with HIF-1β, binds to hypoxia-response elements (HREs) within the 
promoters of target genes and recruits transcriptional co-activators such as p300/CBP for 
transcriptional activity. A range of cell functions are regulated by the target genes, as 
indicated. Chetomin, a commonly used inhibitor of HIF-1α transcriptional activity, binds 
to p300, disrupting its interaction with HIF-1α and attenuating hypoxia-inducible 
transcription. In response to normoxia, HIF-1α is hydroxylated by proline hydroxylases 
(PHD). Hydroxylated HIF-1α (OH) is recognised by pVHL (the product of the von 
Hippel–Lindau tumour suppressor gene), which, together with a multisubunit ubiquitin 
ligase complex, tags HIF-1α with polyubiquitin; this allows recognition by the 
proteasome and subsequent degradation. Acetylation of HIF-1α (OAc) also promotes 
pVHL binding. *Abbreviations: CBP, CREB-binding protein; Ub, ubiquitin; α-KG, α-
ketoglutarate. 
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1.4. HAEMATOLOGICAL CANCERS 
It is likely that haematological malignant transformation begins in the bone 
marrow, where blood cells are produced, leading to their uncontrolled growth and 
abnormal functions. Tumour cells interfering with normal haematopoiesis disrupt 
blood functions such as protection from infection or prevention of bleeding. There 
are three main types of blood cancer: lymphoma, myeloma and leukaemia.  
The lymphomas are a complex group of tumours of lymphocytes and present 
predominantly at localised sites in lymphoid tissues such as lymph nodes and 
spleen. Myeloma is a cancer of plasma cells (antibody producing lymphocytes). 
Myeloma invariably arises within the bone marrow. The leukaemias are a complex 
group of cancers but are united by the presence of significant circulating leucocytes 
in the blood. The term leukaemia is derived from the Greek for ‘white blood’. 
Leukaemia can be of myeloid or lymphoid origin and either acute or chronic; giving 
rise to the categories: acute myeloid (AML), acute lymphoid (ALL), chronic myeloid 
(CML) and chronic lymphocytic (CLL). Some of the metabolic aspects are common 
for all types of leukaemia, while others are entirely unique to a particular leukaemia 
type (Jitschin, Hofmann et al. 2014; Wang, Israelsen et al. 2014). Moreover, metabolic 
pathways may differ between cells of the same origin and are dependent on their 
microenvironment (Bailey, Wojtkowiak et al. 2012). 
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1.4.1 Inhibitors of glycolysis in leukaemic cells 
During the last decade, there has been a strong focus on neoplastic related 
metabolism in cancer research. Many solid tumours are known for their altered, 
highly glycolytic metabolism described as the Warburg effect but the occurrence of 
this phenomenon in blood cancers has only recently been reported. There is 
significant evidence that targeting glycolytic pathways in leukaemic cells may re-
program cells and inhibit cancer proliferation. Compounds such as 3-bromopyruvate 
(3BrPa), are known inhibitors of glycolytic pathway, however, are required in high 
concentrations due to low solubility and biodistribution. Such concentrations often 
result in toxicity (Ko, Smith et al. 2004; Xu, Pelicano et al. 2005). New inhibitors used 
in combination with or without standard chemotherapy, may present a new 
therapeutic strategy (Leni, Parakkal et al. 2013). In this respect, it is important to 
identify the enzymes and metabolic processes that are crucial for haematological 
cancer cell proliferation and survival.  
So far, studies focused on AML and ALL have shown that they are dependent 
on glycolysis in aerobic conditions (Boag, Beesley et al. 2006). Levels of HIF-1α and 
the HIF-1α dependent proteins; GLUT1, GLUT3, CA9 and GAPDH, were 
significantly higher in the blood of AML and ALL patients compared to cells derived 
from the blood of healthy donors. Moreover, leukaemias with higher glycolytic rates 
showed stronger resistance to chemotherapy. For example, it has been shown that 
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inhibition of glycolysis using 2DG (2-deoxyglucose) rendered otherwise resistant 
leukaemia cells, susceptible to glucocorticoid treatment (Hulleman, Kazemier et al. 
2009). 2DG was also shown to affect the pentose phosphate pathway and alter 
protein glycosylation. However decreased viability of cells also observed in 
normoxia, may indicate that 2DG toxicity in aerobic conditions results from the 
inhibition of glycosylation, rather than glycolysis (Kurtoglu, Maher et al. 2007). 
Combinations of the glycolytic pathway inhibitor, 3BrPa, with antimycin A – an 
inhibitor of electron transport in the mitochondrial complex III - showed a dramatic 
decrease of ATP in cancer cells followed by increased cell death (Ko, Smith et al. 
2004). This data shows that acute leukaemia depends on glycolysis but also that 
oxidative respiration is important for survival. It is however still unclear how this 
inhibitor combination affects healthy cells.  
In order to potentiate the effects of inhibition of glycolysis, mTOR inhibitors 
could be used as additional therapeutics. mTOR plays multiple roles in supporting 
cancer cell survival directly, by affecting cell cycle regulators and indirectly, by 
sustaining nutrient supply. mTOR is also responsible for the regulation of energy 
metabolism and cellular survival of cancer cells (see Figure 1.3). Therefore, combined 
inhibition of glycolysis and mTOR would induce severe metabolic deregulation and 
cell death. It has been shown that in leukaemia and lymphoma cells, a combination 
of 3BrPa with rapamycin effectively depleted ATP, limited the nutrient uptake, cell 
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proliferation and cell survival. Importantly, this combination has been shown to have 
low toxicity to healthy cells (Xu, Pelicano et al. 2005). 
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Figure 1. 3. The role of mTOR activation in supporting cancer cell survival. 
Overactivation of mTOR due to dysregulation of upstream pathways, leading to 
abnormal activities in cell angiogenesis, cell metabolism, apoptosis and proliferation, has 
been implicated in various cancer types (based on (Advani 2010)). 
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Studies with metabolic inhibitors have also shown promising results in the in 
vivo model of multiple myeloma. Dichloroacetate (DCA) inhibits pyruvate 
dehydrogenase kinase which limits Acetyl-coA production from pyruvate. As a 
result more Acetyl-CoA is produced and more NADH electrons may be donated to 
the electron transport chain. This may lead to increased ROS production, 
contributing to the loss in generation of membrane potential and ultimately the 
suppression of cell proliferation (Fujiwara, Kawano et al. 2013). 
Targeting glycolysis in haematological malignancies has emerged as a 
promising approach. However more studies are needed to investigate molecular 
mechanisms and potential chemoresistance. 
1.4.2 IDH1/2 mutations 
Gene sequencing studies identified somatic mutations in isocitrate 
dehydrogenase 1 (IDH1) in AML and glioma patients but not in those suffering from 
other human malignances (Dang, White et al. 2009; Mardis, Ding et al. 2009; Zhao, 
Lin et al. 2009). Mutated IDH1 transforms α-ketoglutarate to the oncometabolite 2-
hydroxyglutarate (2-HG). The ability of 2-HG to alter the epigenetic landscape 
(through the inhibition of a family of αKG-dependent Jumonji-C domain histone 
demethylases) has contributed to changing the way we think about metabolism and 
its effects on other cellular processes. When the wild-type IDH1/2 converts isocitrate 
to α-KG, NADPH is produced; this contributes significantly to the synthesis of 
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glutathione, protecting cells from ROS. In IDH1 mutants however, during the 
reaction in which 2-HG is produced, NADPH is consumed. Moreover, the level of α-
KG also decreases. α-KG is known to activate proline hydroxylases that inactivate 
HIF-1α as a result of IDH (Xu, Yang et al. 2011). Therefore the overall effects are 
increased levels of ROS and HIF-1α.  
Inhibitors of IDH tested in different types of leukaemias were found to reduce 
the amount of 2-HG and inhibit the growth of cancer cells (Popovici-Muller, 
Saunders et al. 2012). IDH inhibition led to histone demethylation and to the 
induction of haemopoietic/neural differentiation, suggesting that these agents might 
induce differentiation in IDH-mutant cells through alterations in the epigenetic state 
(Rohle, Popovici-Muller et al. 2013; Wang, Travins et al. 2013). Extensive in vivo 
studies in IDH-mutant models are still being reported and the role of IDH in 
malignant cells after oncogenic transformation requires additional, extensive 
investigation. 
1.4.3 Mitochondrial uncoupling 
Leukaemia cells, like most cancers, are ’addicted’ to glucose in the generation 
of energy, but recent research shows that they also have the ability to reduce 
molecular oxygen, utilising electrons from carbon sources other than pyruvate to 
grow and evade cell death (Samudio, Fiegl et al. 2008; Samudio, Fiegl et al. 2009). 
Recent evidence suggests that fatty acid derived acetyl-CoA can fuel Krebs cycle 
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activity and the molecular reduction of oxygen (Samudio, Harmancey et al. 2010). In 
leukaemia cells mitochondrial uncoupling – the continuing reduction of oxygen 
without the synthesis of ATP – can mimic the Warburg effect in the absence of 
permanent alterations to the oxidative capacity of cells. However, the benefits of this 
metabolic shift to cells are not fully understood. 
The model proposed by Velez (Velez, Hail et al. 2013) presents reprogrammed 
pathways of intermediary metabolism in leukaemic cells. In this model, pyruvate is 
converted to lactate in order to regenerate NAD+. This results in the absence of OAA 
production from pyruvate. In this situation, the only source of α-KG that can supply 
the TCA cycle is glutamine, however OAA may also be produced through aspartate 
anaplerosis. Regeneration of the citrate pool, on the other hand, would rely on acetyl-
CoA derived from fatty acids. 
It has been shown that in several human solid tumours, DCA shifts pyruvate 
metabolism from glycolysis and lactate production to glucose oxidation in the 
mitochondria, which results in high ROS production, leading to cell death (Bonnet, 
Archer et al. 2007). This shows that using an alternative source of carbon to pyruvate 
for oxygen reduction may protect against cell death. Despite not yet being shown in 
leukaemia cells, this possibility should be considered. 
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1.5. CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) 
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia 
in Western countries (D'Arena, Di Renzo et al. 2003; Chiorazzi, Rai et al. 2005). 
Although there have been recent improvements in prolonging survival with 
combination chemoimmunotherapy regimens, the disease remains incurable using 
current therapies. Patients suffering from CLL present highly variable clinical 
courses. Some patients die within two years of initial diagnosis, while others may 
lead an almost normal life without the need for treatment (Chiorazzi, Rai et al. 2005). 
There are two widely accepted staging methods of CLL: the Binet and the modified 
Rai systems (presented in Table 1.1.). These staging systems are simple and 
inexpensive, based only on standard laboratory tests and physical examination. 
Staging is useful to predict prognosis and also to stratify patients to achieve 
comparisons for interpreting specific treatment results. 
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Table 1.1. Binet and Rai staging systems for classification of CLL.  
System Stage Description 
Median 
survival 
(years) 
Binet system* 
 A Haemoglobin ≥ 10 g/dL and platelets ≥ 
100,000/mm
3
 and ˂ 3 involved nodal 
areas  
11.5 
B Haemoglobin ≥ 10 g/dL and platelets ≥ 
100,000/mm
3
 and ≥ 3 involved nodal 
areas  
8.6 
C Haemoglobin ˂ 10 g/dL and/or 
platelets ˂ 100,000/mm
3
 and any 
number of involved nodal areas  
7.0 
Rai system 
 0 
(low risk) 
Lymphocytosis, lymphocytes in blood 
> 15,000 / mcL and > 40% 
lymphocytes in the bone marrow 
11.5 
I 
(intermediate 
risk) 
Stage 0 with enlarged node(s) 11.0 
II 
(intermediate 
risk) 
Stage 0-I with splenomegaly, 
hepatomegaly, or both 
7.8 
III 
(high risk) 
Stage 0-II with haemoglobin < 11.0 
g/dL or haematocrit <33% 
5.3 
IV 
(high risk) 
Stage 0-III with platelets < 100,000 
/mcL 
7.0 
The International Workshop on CLL has recommended integrating the Rai and Binet 
systems as follows: A0, AI, AII, BI, BII and CIII, CIV (1989). Adapted from the 2008 NCI 
guidelines (Hallek, Cheson et al. 2008), *Areas of involvement considered for staging are as 
follows: head and neck, axillae, groins, palpable spleen, palpable liver. 
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CLL is characterised by both circulating peripheral disease, as well as 
accumulation of proliferating monoclonal B-lymphocytes in bone marrow and 
lymphoid organs (Caligaris-Cappio 2000). Clinical data show that, although 
therapies are often effective at killing CLL cells in the peripheral blood, residual 
disease remains in the bone marrow and lymph nodes (Davids and Burger 2012). It is 
likely that these malignant cells sequestered in the tissue, receive protection from a 
wide variety of treatments through pro-survival signals and inhibition of apoptosis, 
fostered by the stromal microenvironment (Ramsay and Rodriguez-Justo 2013). The 
complex biology underlying how these CLL cells are recruited, maintained, and 
released from the stroma is an area of active investigation (see Figure 1.4).  
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1) CLL cells rest on the stromal cells due to CXCR4-CXCL12 (SDF-1) interactions. 
Additionally, activated T cells in the presence of CXCL12 enhance the activation and 
proliferation of the leukemic clone. When stimulated, CLL cells are activated and divide, 
regulating CD5, internalising CXCR4 and detaching from stroma. The process could be 
ligand-induced (for example, BCR or toll-like (TLR) or other pathways) or spontaneous. 
Recently divided (low CXCRX4) CLL cells are more likely to exit solid tissue and reach 
peripheral blood. 2) Recently born/divided CLL cells reach peripheral blood. Over time, 
possibly because of a lack of trophic input from the solid tissue microenvironment, cells 
begin to re-express CXCR4 to return to nutrient-rich niches. 3) CXCR4 bright CLL cells 
have the greatest chance of re-entering lymphoid solid tissue and receiving pro-survival 
stimuli. Those that do not re-enter, die by exhaustion. (Based on (Calissano, Damle et al. 
2011) and (Borge, Nannini et al. 2013), background picture adapted from 
http://dxline.info/). 
Solid tissue 
Blood 
Blood 
Stromal cells 
T cells CLL 
resting 
Release 
CLL 
 
CLL 
   Exit 
CLL 
CLL 
CLL 
CLL 
Proliferative  
compartment 
Bulk 
Resting, re-entry 
compartment 
             Death 
Li
fe
 
1 
2 3 
CLL 
CLL 
BCR signalling 
TLR signalling 
Low 02 
High 02 
CXCL12 
CXCR4 
T- 
cell 
T- 
cell 
T- 
cell 
 Figure 1.4. Model of the lifecycle of a CLL B cell. 
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In order to allow transit between different environments, the metabolism of 
CLL cells must be able to quickly adapt to new conditions. Levels of oxygen and pH 
differ between peripheral blood and between centres of proliferation in lymph nodes 
and bone marrow, thus influencing metabolism (Star-Lack, Adalsteinsson et al. 2000; 
Sison and Brown 2011). Understanding the changes in metabolism of CLL cells 
linked to the transition between oxygen states, may lead to the development of new 
therapeutic targets.   
1.5.1 CLL microenvironment 
Recent reports have emphasised the importance of the microenvironment in 
the development and pathophysiology of malignancies. Although most of these 
reports investigated interactions between stromal and neoplastic cells, hypoxia has 
emerged as another component of the microenvironment. Although hypoxia in solid 
tumours is well studied, it is unclear what role, if any, it has in the physiology of 
haematological neoplasias. Lymphomas in this context may resemble solid tumours, 
but the hypoxic sanctuary for leukaemias is thought to be bone marrow. There is an 
additional interest in comparisons of the role of hypoxia within the bone marrow of 
healthy individuals and cancer patients, as it may affect haematopoietic progenitors 
and their differentiation as well as bone metastases (Fiegl, Samudio et al. 2010).  
The cellular microenvironment of CLL cells in the bone marrow and 
secondary lymphatic tissues, consists of stromal cells and matrix (Burger, Ghia et al. 
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2009). Interactions of CLL cells with their cellular environment affect the survival of 
CLL cells and proliferation and provide drug resistance that may be responsible for 
residual disease after conventional therapy. Key cellular players were shown to be 
mesenchymal stromal cells, monocyte-derived nurse-like cells (NLCs), and T cells 
(Panayiotidis, Jones et al. 1996; Burger, Tsukada et al. 2000; Bagnara, Kaufman et al. 
2011). The B-cell Receptor (BCR) expressed on CLL cells is responsible for the 
maintenance and expansion of the CLL clone, through its downstream kinases such 
as the spleen tyrosine kinase (Syk), Bruton’s tyrosine kinase (BTK), and 
phosphatidylinositide 3-kinase (PI3K). Chemokine receptors such as CXCR4 and 
CXCR5, together with adhesion molecules, regulate CLL cell trafficking and tissue 
homing (Burger, Burger et al. 1999). Members of tumour necrosis factor (TNF) family 
such as the CD40 ligand, B cell-activating factor of the tumour necrosis factor family 
(BAFF), and a proliferation-inducing ligand (APRIL) activate CLL cells, and promote 
immune recognition and survival which leads to the expansion of malignant cells 
(Nishio, Endo et al. 2005). Moreover, as a consequence of BCR activation, CLL cells 
secrete cytokines (such as CCL3), which influence the microenvironment by 
attracting accessory cells such as monocytes and T cells (Burger, Quiroga et al. 2009). 
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1.5.2 Current CLL therapies 
At present, CLL remains incurable without allogeneic stem cell 
transplantation, although treatment outcomes have improved considerably in the last 
decade through the use of novel therapeutic agents, as well as risk stratification 
(Bottcher, Ritgen et al. 2012).  
The standard first-line treatment of fit CLL patients is the combination of the 
monoclonal antibody rituximab, with the cytostatic drugs fludarabine and 
cyclophosphamide (FCR) or with bendamustine (BR) (Keating, O'Brien et al. 2005; 
Eichhorst, Busch et al. 2006). Rituximab is an antibody against the B-cell antigen 
CD20, expressed on the CLL cell surface and has been shown to activate 
complement-dependent cytotoxicity, opsonisation to macrophages causing antibody-
dependent cell-mediated cytotoxicity (ADCC) and apoptosis (Maloney, Smith et al. 
2002). Another CD20 antibody, oftatumimab which targets a different epitope of 
CD20, was shown to be efficient both in combination with chemotherapeutics, and as 
a single agent; unlike rituximab which has limited efficacy as a monotherapy 
(Wierda, Kipps et al. 2010). Obinutuzumab (GA101) is another antibody targeting 
CD20 characterised by increased antibody-dependent cellular cytotoxicity and 
inducing a direct, non-apoptotic lysosome mediated cell death (Alduaij, Ivanov et al. 
2011). In cases of fludarabine-refractory CLL, alemtuzumab - the CD52 antibody - 
has been confirmed to be effective (Faderl, Thomas et al. 2003). However, 
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alemtuzumab was withdrawn from the market in Europe and the US for treatment of 
CLL and is available only through named patient programmes (Tausch, Mertens et 
al. 2014). 
Another class of CLL treatments are immune modulatory drugs such as 
Lenalidomide. This compound acts by inhibiting cytokines such as TNF-α, 
interleukin-7, and VEGF and stimulating T and natural killer cells. In addition, it 
resolves immunosuppressive mechanisms against healthy T cells induced by 
lymphoma cells. Lenalidomide is a replacement of thalidomide with fewer side 
effects and improved potency (Sharma, Steward et al. 2006).  
The B-cell receptor signalling pathway has been shown to be essential for CLL 
cell survival (Wiestner 2013) and inhibition of this pathway became a new 
therapeutic target. The small-molecule ibrutinib is one of the new drugs in clinical 
development that is effective in CLL through inhibition of this pathway. Ibrutinib 
binds to the cysteine 481 of the Bruton’s tyrosine kinase and interrupts activation of 
the BCR pathway, resulting in reduced migration and proliferation of the malignant 
cells and induced apoptosis. Importantly, ibrutinib is a very well tolerated drug, with 
few side effects (Byrd, Furman et al. 2013). Another agent targeting the BCR pathway 
is the (PI3K) inhibitor, idelalisib. Activated PI3K is linked to the nuclear factor-
kappa-B (NFkB) activation and expression of B-cell lymphoma (BCL)-XL and Mcl-1, 
mediating inhibition of pro-survival pathways (Longo, Laurenti et al. 2008). 
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Moreover, PI3K inhibition has been shown to decrease chemotaxis of CLL cells into 
protective tissue microenvironments, resulting in higher susceptibility to 
chemotherapy (Hoellenriegel, Meadows et al. 2011). 
Another promising drug, ABT-199 is an orally bioavailable antagonist of the 
anti-apoptotic protein BCL-2. It induces apoptosis by mimicking the BH3 domain. 
ABT-199 has been shown to dramatically reduce the number of CLL cells within 12 
hours after administration. Currently ABT-199 is in clinical development as a 
monotherapy as well as in combination with antibodies and chemotherapy (Souers, 
Leverson et al. 2013).  
As presented above, a broad range of novel agents with different mechanisms 
of action have entered clinical trials in the last decade (See Figure 1.5). They have 
already proven their efficacy as well as improved safety profile compared to 
chemotherapy, showing a potential to change the treatment paradigm of CLL. 
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Figure 1.5. New therapeutic agents and their targets in a chronic lymphocytic 
leukaemia cell. 
BCL2, B-cell lymphoma 2; BCR, B-cell receptor; BTK, Bruton’s tyrosine kinase; NFkB, 
nuclear factor kappa B; PI3K, phophoinositide 3-kinase; PKC, protein kinase C; PLC, 
phospholipase C. (Adapted from (Tausch, Mertens et al. 2014)). 
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1.5.3 CLL cell metabolism 
Recent technological developments have allowed global analyses of 
biochemical alterations in cancer and enabled the discovery of potential molecules 
involved in cancer cell survival and drug resistance. It was found that GSH is 
particularly important for CLL cells, owing to the unique biological properties of this 
leukaemia. CLL cells intrinsically have higher levels of reactive oxygen species (ROS) 
when compared with normal lymphocytes, and are highly sensitive to agents that 
induce further oxidative stress (Zhang, Trachootham et al. 2012). The elevated ROS 
level renders CLL cells more dependent on cellular antioxidants such as GSH to 
maintain the redox balance. However, CLL cells are unable to maintain GSH once 
they are isolated from patients and cultured in vitro, exhibiting a high level of 
spontaneous apoptosis (Collins, Verschuer et al. 1989; Silber, Farber et al. 1992). 
Recently, it was shown that the bone marrow stromal cells promote GSH metabolism 
in CLL cells and enhance leukaemia cell survival and drug resistance (Zhang, 
Trachootham et al. 2012). This finding could lead to a novel therapeutic strategy. 
Alongside this, the adaptations of CLL cells to ROS by up-regulating the stress-
responsive heme-oxygenase-1 (HO-1), may be a feasible metabolic alteration to target 
therapeutically. However, due to the limited knowledge in the area of CLL cell 
metabolism, further exploration is required (Jitschin, Hofmann et al. 2014). 
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1.5.4 Metabolism of quiescent cells 
Unlike CLL cells present in proliferation centres, CLL cells circulating in the 
peripheral blood are in the reversible, cell-cycle arrest state, called quiescence. The 
transition between proliferation and quiescence has been shown to be associated 
with changes in gene expression, histone modification and the extension of 
chromatin compaction; although it remains unclear if chromatin state changes are 
responsible for cell cycle exit, initiating quiescence (Evertts, Manning et al. 2013). 
Entry into the quiescent state is often correlated with dramatic changes in 
metabolism, as the requirements of proliferating and quiescent cells are different. 
Many, but not all quiescent cells down-regulate their protein synthesis. In some 
cases, cellular quiescence is associated with lower metabolic activity, characterised by 
low glucose consumption and glycolysis, decreased translation rates and activation 
of autophagy in order to provide nutrients for survival (Valcourt, Lemons et al. 
2012).  
In different quiescence models including mammalian lymphocytes, 
haematopoietic stem cells and Saccharomyces cerevisiae, the PI3Kinase/TOR signalling 
pathway is involved in growth control. Quiescent fibroblasts are an example of cells 
that exhibit metabolism where glucose uptake and flux are not reduced. They 
maintain comparable metabolic rates to proliferating fibroblasts, however the 
mechanism through which metabolites enter the TCA cycle is different. In quiescent 
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fibroblasts, pyruvate is transformed into oxaloacetate by pyruvate carboxylase, while 
in dividing fibroblasts, metabolic intermediates enter the TCA cycle from pyruvate 
via transfer of the acetyl group of acetyl-CoA to oxaloacetate. A possible explanation 
for the maintenance of high metabolic rates during quiescence of fibroblasts is that in 
this state, they have an important biosynthetic function, the secretion of extracellular 
matrix proteins (Lemons, Feng et al. 2010). 
Different metabolic adaptations to quiescence are shown by adult 
haematopoietic stem cells (HSCs). They maintain a quiescent state in order to avoid 
cellular damage from ROS and to ensure life-long tissue renewal capacity (Jang and 
Sharkis 2007). Slow cycling cells are more resistant to cytotoxic agents such as UV, 
ionising radiation and chemicals affecting cells that are in the S or M phase of the cell 
cycle. Quiescent HSCs depend more on glycolysis than on oxidative phosphorylation 
for ATP production, although it is not clear if this metabolic program is intrinsically 
required for stem cell self-renewal, or if it is an adaptive response to the hypoxic 
environment (Shyh-Chang, Daley et al. 2013). This phenotype has been shown to be 
programmed by the HSC transcription factor MEIS1, via its target HIF-1α which up-
regulates many glycolytic enzymes. Therefore HIF-1α plays an essential role in the 
maintenance of HSC quiescence and stress resistance (Takubo, Goda et al. 2010; 
Shyh-Chang, Daley et al. 2013).  
 
Chapter One - Introduction 
 
40 
 
1.6 TOOLS USED FOR INVESTIGATING CANCER METABOLISM 
Recently, there has been increasing interest in investigating metabolic flux in 
cells. Technological advances in instrumentation have allowed for the quantification 
and analysis of dynamic changes in metabolites under either biological or certain 
culture conditions, or in response to treatment. This approach is described by the 
term metabolic flux analysis (MFA), often using an experimental approach based on 
isotopically labelled tracers. This is distinctly different from ‘metabolomics’ which 
describes the analysis of complete sets of metabolites, simply based on profiles 
arising from metabolite concentrations (Griffin and Shockcor 2004). MFA is a more 
powerful tool for the study of metabolism as the distribution of isotopically labelled 
metabolic precursors allows for the monitoring of metabolic fluxes and mapping of 
metabolic pathways. By using different tracer molecules, MFA can detect fluxes even 
for steady-state concentrations. This chapter will focus on the capabilities and recent 
achievements in the field of nuclear magnetic resonance (NMR) spectroscopy for 
investigating metabolic flux in cancer cells. 
1.6.1 Spectroscopic methods used in metabolic analysis 
Understanding the aetiology and progression of disease through metabolic 
profiling is not a new concept — 31P, 1H and 13C NMR spectroscopy, along with gas 
chromatography– mass spectrometry (GC–MS) and liquid chromatography – mass 
spectrometry (LC-MS) are tools that have been widely used for metabolic analysis 
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since the early 1970s (Hoult, Busby et al. 1974; Gates and Sweeley 1978). NMR 
spectroscopy has also been used to differentiate between different cancer cell lines 
(Florian, Preece et al. 1995; Florian, Preece et al. 1995; Lodi, Tiziani et al. 2013) and to 
monitor metabolic processes that occur in cancer cells during events such as 
apoptosis (Hakumaki, Poptani et al. 1998; Williams, Anthony et al. 1998). However, 
due to technical challenges, current methods still face many limitations which 
prevent them from reaching this ideal. Using NMR-based approaches, 20–40 
metabolites can typically be detected in tissue extracts while 100–200 can be detected 
in urine samples. Using the more sensitive approach of LC–MS, around 1,000 
metabolites can be detected in these sample types. Various other analytical tools can 
also be used for metabolomics, provided that the data sets are rich in molecular 
information. Fourier-transform infrared (FT-IR) spectrometry, metabolite arrays 
(Bochner, Gadzinski et al. 2001), Raman spectroscopy (Hanlon, Manoharan et al. 
2000) and Thin-Layer Chromatography (TLC) (Tweeddale, Notley-McRobb et al. 
1998) have been used in metabolomics analysis. However, these techniques do not 
allow for the distinguishing of metabolites within the same class of compounds. As a 
result, they may only be useful for initial screening. The advantages and 
disadvantages of the most commonly used techniques are compared in Table 1.2.  
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Table 1.2. Comparison of analytical methods used for metabolomics. Adapted from 
(Vernocchi, Vannini et al. 2012). 
Analytical 
method Advantages Disadvantages Comments 
NMR • Rapid analysis 
• High resolution 
• No derivatisation  
• Non-destructive 
• Easy sample 
preparation 
• Fully quantitative 
• Highly reproducible 
• Non-selective 
(detects all 
metabolites 
simultaneously) 
• Low sensitivity 
• Convoluted spectra 
• More than one peak 
per component 
• Slow 
• Chemical consideration: gives 
detailed structural information for 
individual metabolites, particularly 
using 2D NMR 
• Chemical bias: NMR has no 
chemical bias and can be used 
directly on the sample 
• Speed: few minutes to hours, 
depends on the concentration of 
samples and on the NMR 
instrument (strength of the 
magnet, type of probes) 
GC-MS • Sensitive 
• Robust 
• Large linear range 
• Large commercial 
and public libraries 
• Slow 
• Often requires 
derivatisation 
• Many analytes 
thermally- unstable 
or too large for 
analysis 
• Chemical consideration: on its 
own will not generally lead to 
metabolite identification. 
However coupled with MS is very 
powerful for analyte identification 
• Chemical bias: solvent extraction 
bias: non-polar vs. polar analytes. 
Need for chemical derivatisation 
• Speed: very useful separation, 
typically takes 10-30 min 
LC-MS • No derivatisation 
required 
• Many models of 
separation available 
• Large sample 
capacity  
• High sensitivity, can 
identify ~2000 
compounds 
• Slow 
• Limited commercial 
libraries 
• Quantification 
requires isotope 
labelled libraries 
• Chemical consideration: on its 
own will not lead to metabolite 
identification. However coupled 
with MS is very powerful for 
analyte identification 
• Chemical bias: solvent bias means 
it is usually more applicable to 
polar compounds; lipid analysis 
requires a second sample 
• Speed: typically takes 10-30 min 
FT-IR • Rapid analysis 
• Complete 
fingerprint of 
sample chemical 
composition 
• No derivatisation 
needed 
• Extremely convoluted 
spectra 
• Many peaks per 
component 
• Difficult identification 
of metabolites in 
mixtures  
• Requires samples 
drying 
• Chemical consideration: provides 
limited structural information, but 
useful for identification of 
functional groups 
• Chemical bias: these methods 
have little chemical bias and can 
be used directly on the sample 
• Speed: 10-60 sec 
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Among all of these techniques, the most powerful and commonly used are 
NMR spectroscopy and Mass Spectrometry. They both provide structural and 
quantitative information on multiple classes of compounds in a single analytical run. 
1H-NMR is a universal detector that will give a spectrum for all homogeneous 
samples, if the molecule containing protons (1H) is present above the detection limit. 
NMR spectroscopy permits analysis of all metabolites present in a biofluid at the 
same time, while MS usually requires samples to be fractioned prior to analysis. 
Therefore, MS is coupled to a chromatography technique such as HPLC or UPLC. 
Both techniques provide information on a wide range of metabolites, without the 
need for selection of a particular analyte to focus on (Lindon, Holmes et al. 2006). The 
remainder of this chapter presents NMR spectroscopy as a leading tool for metabolic 
studies.  
1.6.2 Metabolic Flux analysis  
Isotope tracer-based metabolic flux analysis has developed over the past two 
decades as the primary approach to quantifying the rates of turnover of metabolites 
through metabolic pathways; that is, metabolic fluxes. MFA utilises isotopically 
labelled metabolic precursors such as glucose and glutamine as tracers and observes 
the flux of individual-labelled atoms across metabolic networks. This allows for the 
monitoring of metabolic fluxes and the mapping of metabolic pathways and it is 
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especially important for detecting the fate of metabolites which are part of many 
different pathways.  
Tracing metabolic profiles has the potential to reveal crucial enzymatic steps 
that could be targeted in the drug discovery process. It is well known that tumours 
are associated with substantial rewiring of metabolic networks. Many recent studies 
show approaches for the analysis of metabolism that make it possible to 
simultaneously assess metabolite concentrations and pathway fluxes for a large 
number of the key components involved in the central metabolism of human cells. 
Labelled cell extracts can be analysed by mass spectrometry or by NMR. There are 
several reports where one-dimensional 13C-NMR spectra have been used, although 
two-dimensional NMR analysis using HSQC spectra has been shown to have great 
advantages (Szyperski 1995). Comprehensive isotopomer models, predicting the 
tracer label distribution facilitate the quantitative analysis of fluxes through key 
central metabolic pathways including glycolysis, pentose phosphate pathway, 
tricarboxylic acid cycle, anaplerotic reactions, and biosynthetic pathways of fatty 
acids and amino acids (Günther et al., 2014). The validity and strength of this 
approach is illustrated by its application in a number of perturbations to cancer cells, 
including exposure to hypoxia, drug treatment and tumour progression. 
The term ‚Metabolic Flux Analysis‛ is also used in the context of 
computational biology, using flux balance analysis (FBA) where metabolic pathways 
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are modelled across a network of biochemical reactions on a genome scale (Wiechert 
2001).  
1.6.3 NMR as a tool for metabolomics studies 
Spin ½ isotopes behave like small magnets when placed in a magnetic field.  
The spins align with or against the magnetic field. Because of the energy difference 
between parallel and anti-parallel aligned spins, the parallel state is populated more 
than the anti-parallel state, causing magnetisation of the entire sample. By applying a 
radiofrequency to the nuclei, one can cause the nuclei to switch to the opposing 
magnetic state and this transfer is associated with the generation of transverse 
magnetisation. When there is transverse magnetisation, the magnetisation starts to 
precess around the axes of the external magnetic field, which can be detected as a 
radio frequency. Nuclei in different molecules as well as in different chemical 
environments exhibit distinct resonance frequencies resulting in a unique pattern of 
chemical shifts visible in the NMR spectrum. This property makes NMR a useful tool 
for chemical analysis as structure elucidation is possible based on these frequency 
differences. 
NMR analysis for metabolomics has centred on 1H and 13C NMR spectroscopy, 
although 31P NMR spectroscopy has been used to measure high-energy phosphate 
metabolites (such as ATP) and phosphorylated lipid intermediates. Other nuclei such 
as 2H and 19F have also been used, the latter is found in a range of neuroleptic drugs, 
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and has been introduced as a tracer for drug discovery approaches (Dalvit and 
Vulpetti 2011). 
NMR is a relatively insensitive technique but has the strong advantage that it 
can be used in a non-invasive manner, allowing metabolic profiling of intact tissue. 
This has formed the basis for MRI, the most common application of NMR. The non-
invasiveness of NMR has been exploited in this thesis where intact human cells were 
studied. Various approaches have been used to study intact tissue by NMR, starting 
from measuring structural and functional properties of proteins in whole cells (in-cell 
NMR) (Selenko and Wagner 2007; Borcherds, Theillet et al. 2014), through to small 
pieces of intact tissue measured by high-resolution magic angle spinning (MAS) 1H 
NMR spectroscopy (Cheng, Lean et al. 1996; Griffin, Sang et al. 2002), or in vivo 
spectroscopy of whole organs (Pfeuffer, Tkac et al. 1999). Alternatively, tissue 
extracts can be used for the analysis of hydrophilic metabolites (Beckonert, Keun et 
al. 2007). 
The detection limit for 1H-NMR spectroscopy is typically in the order of 10 μM 
in a tissue extract or biofluid, although lower concentrations can be measured using 
excessively long acquisition times. Typical acquisition times for one-dimensional 1H-
NMR spectra are about 10 minutes. NMR-spectroscopy analysis of biofluids has been 
shown to be highly reproducible, as samples analysed by this method have produced 
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similar results to those measured on other types of spectrometers (Lindon, Nicholson 
et al. 2003; Dona, Jimenez et al. 2014). 
1.6.3.1 Metabolic profiles of cancer cells 
Metabolomics in cancer has developed almost in parallel with a new era of 
research in cancer metabolism. Although these two fields are closely related, they 
represent the expertise of two different scientific communities: cancer biologists and 
analytical chemists. Over the last decade, collaborations of scientists from these fields 
have resulted in significant advancements in our knowledge. 
NMR spectroscopy, including in vivo magnetic resonance spectroscopy (MRS) 
and high-resolution solution-state analysis of tissue extracts, has been widely used 
for several years. Although NMR spectroscopy detects only a relatively small 
number of metabolites, it can be used to monitor the activity of many cellular 
processes. As many metabolic pathways are connected, changes detected in the 
metabolome can be used to follow seemingly unrelated pathways. Despite 
limitations in sensitivity and the ability to measure a broad range of metabolites, 
MRS has been used to analyse tumour types in humans and in animal models of 
cancer (Tate, Crabb et al. 1996; Tate, Griffiths et al. 1998). In vitro NMR metabolomics 
studies have also demonstrated differences between tumour types, in terms of 
various biochemical pathways (Florian, Preece et al. 1995). 
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1.6.4 Leading NMR techniques for cancer metabolomics 
1.6.4.1 Magic Angle Spinning (MAS) 
As mentioned previously, high-resolution magic angle spinning (HRMAS) 1H-
NMR spectroscopy, can produce high-resolution spectra from small pieces of intact 
tissue (Denkert, Bucher et al. 2012). A biopsy or post-mortem sample of tissue is spun 
at an angle of ca. 54.74° (the so-called magic angle) to the applied magnetic field. The 
spinning results in a significant improvement in the resolution of the spectrum 
obtained by eliminating dipolar interactions and magnetic susceptibility effects 
which cause wide lines (Renault, Shintu et al. 2013). This approach has several 
advantages over NMR spectroscopy of tissue extracts. Both aqueous and lipid-
soluble metabolites can be observed simultaneously in situ, whereas solution-state 
NMR would require separate extraction procedures. One of the first applications of 
this technique was to distinguish between healthy and malignant lymph nodes 
(Cheng, Lean et al. 1996). Information about the metabolic environment of the 
tumour can also be obtained using HRMAS 1H-NMR spectroscopy, which can be 
used to identify metabolites with a range of physical properties. These approaches 
have also been used to follow the effects of therapeutics on tumour cells in vitro and 
in vivo (Griffin and Shockcor 2004). 
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1.6.4.2 NMR measurements of cell extracts 
Obtaining cell extracts requires concentrated samples in order to obtain a 
sufficiently good signal-to-noise ration in NMR spectra. If the signal overlap is not 
significant, parameters such as chemical shift and spin multiplicity can be obtained 
using simple one-dimensional spectra (usually one-dimensional nuclear Overhauser 
effect spectroscopy (NOESY) with solvent presaturation). When the spectral overlap 
becomes too extensive, two dimensional NMR experiments can be used to overcome 
this problem by significantly increasing the resolution and dispersing the peaks into 
two-dimensions. 2D 1H-1H TOCSY (TOtal Correlation SpectroscopY), 2D 1H-13C 
HSQC (Heteronuclear Single-Quantum Correlation) and 2D 1H-1H JRES (J-resolved 
spectroscopy) are the three most commonly used 2D NMR methods in metabolomics 
(Gebregiworgis and Powers 2012). These methods not only improve the resolution, 
but also allow various spin correlations to be observed and recorded using the 
natural abundance of isotopes, and may be sufficient to identify and quantify 
metabolites to answer important questions about cell metabolism, tumour 
progression and efficiency of treatment. 
1.6.4.3 Dynamic Nuclear Polarization (DNP)  
It has recently been shown that NMR of hyperpolarised precursors has the 
potential to become a suitable modality for monitoring metabolism and for 
measuring changes in metabolic fluxes (Golman, in 't Zandt et al. 2006; Schroeder, 
Chapter One - Introduction 
 
50 
 
Atherton et al. 2009). In these studies, 13C-labeled metabolites are hyperpolarised 
using stable radicals. 13C chemical shifts can be exploited to distinguish between the 
original molecules and their metabolic products and gradient-based imaging 
techniques can localise the spatial source of these spectral signatures.  
To obtain a thorough understanding of the cellular processes, it was important 
to develop in vitro cell systems in which conditions could be carefully controlled and 
manipulated. So far, a number of studies have monitored the metabolism of 
hyperpolarised molecules in concentrated cell suspensions (Chen, Albers et al. 2007; 
Day, Kettunen et al. 2007). This method has also been used to measure breast cancer 
cells cultivated on beads and maintained by continuous perfusion under 
physiological conditions. This enabled a reliable characterisation of the kinetics and 
mechanism of hyperpolarised pyruvate-to-lactate conversions in T47D cell line 
(Harris, Eliyahu et al. 2009). DNP based approaches are however limited to the short 
time frames in the order of the longitudinal relaxation time of the metabolites that 
were polarised.  
1.6.4.4 Measurement of living cells in NMR 
NMR spectroscopy was developed in the 1960s, and by the early 1970s it had 
already been used for in vivo measurements using intact red blood cell suspensions, 
although in non-viable conditions (Morris 1988). Since then, multiple applications in 
fields such as medicine, toxicology and environmental sciences have been reported 
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and its usage continues to increase (Cohen, Motiei et al. 2004; Palomino-Schatzlein, 
Escrig et al. 2011). The popularity of NMR arises from its non-invasive and non-
destructive nature, as well as its capacity to measure metabolite levels in complex 
mixtures without the need for separation. 
1.6.4.4.1 31P NMR as an indicator of pH in samples 
Tumour pH has long been of interest because it can alter the therapeutic 
efficiency of chemotherapeutic agents, radiation or hyperthermia. Tumour thermal 
sensitivity depends primarily on intracellular pH (pHin) and its lowering has been 
proposed as a target for tumour specific therapies. Therefore, particular methods are 
required to accurately measure pHin in tumours. NMR spectroscopy provides a non-
invasive technique for measuring the pHin of tumour cells in situ by the observation 
of the 31P signal from ionisable intracellular phosphates. Since the 31P chemical shift 
of readily observable inorganic phosphate (Pi) is sensitive to pH changes in the 
physiological range (i.e. pKa= 6.6), it has been used routinely in a wide range of 
tissues as the NMR indicator of pHin measurements performed in vivo (Soto, Zhu et 
al. 1996). This is also feasible in vivo in particular in MRS applications. With new 
technology it is also possible to use dual receiver probes that allow recording spectra 
of the same sample simultaneously, for example 1H and 31P. This may enable 
monitoring changes in metabolic flux together with pH changes.  
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1.6.4.4.2 Challenges of recording real-time metabolic changes 
The development of effective therapies against malignant diseases and 
monitoring their effect in a non-invasive manner is one of the most important 
challenges for biomedical research in the area of personalised medicine. NMR is a 
very useful experimental approach in this context as it enables continuous 
monitoring of biochemical processes. The approach of measuring living, patient 
derived cells and their metabolic changes in real-time is new and therefore 
challenging. Firstly, to record real-time metabolic fluxes in cells, the problem of 
cellular sedimentation needs to be solved, in order to obtain a homogenous sample in 
the NMR tube. To avoid the disruption of metabolic process to be measured, cells 
need to be kept in conditions mimicking their natural environment. Constant 
perfusion can potentially be applied to keep cells in suspension during NMR 
experiments and various flow-systems have been reported (Keshari, Kurhanewicz et 
al. 2010; Khajeh, Bernstein et al. 2010). 
Secondly, in order to record spectra within a short time period, proton spectra 
need to be used as 1H is the most sensitive NMR nucleus. 1H-NMR is intrinsically 14 
times more sensitive than 31P, thus allowing shorter acquisition times to be used. 
Moreover, proton NMR offers the advantage that numerous natural biological 
compounds, as well as drugs and their metabolites, can be detected. However, the 
presence of signals originating from extracellular compounds and the immense water 
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signal, as well as many overlapping proton signals, have limited the application of 
proton NMR in studies of biological samples. Some proton NMR studies have been 
reported in vivo (Garcia-Segura, Sanchez-Chapado et al. 1999); however, these have 
not yet attained translation to routine clinical application. It was also shown that 
Diffusion Weighted Proton Magnetic Resonance Spectroscopy can be used to 
selectively observe only the intracellular metabolites of several cell lines in vitro 
(Mardor, Kaplan et al. 2000). This method is based on differences in motional 
properties of cellular components, as larger molecules (such as proteins) exhibit 
slower rotational tumbling. Interaction with small molecules may also affect their 
motional properties within cells. Owing to such interactions, intracellular 
components have a lower apparent diffusion constant (ADC) than extracellular 
components and free water. Diffusion Weighted Proton Magnetic Resonance 
Spectroscopy can select small molecules that maintain fast rotational diffusion, 
however this requires large concentrations of intracellular metabolites. 
There has been progress in measuring living cells using NMR in recent years 
and techniques are still being improved to obtain the full picture of cellular 
metabolites which could be detected within short time frames. This will eventually 
create the possibility of monitoring real-time metabolic fluxes in living cells, in 
different conditions and responding to various treatments. 
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1.6.4.4.3 Flow systems 
In order to obtain accurate quantitative metabolic data, studies should be 
performed on intact living cells - ex vivo or in vitro as opposed to metabolite 
extraction from cells, which often exhibits low reproducibility. For measurements to 
be conducted on living cells, combinations of small-scale bioreactors with NMR 
spectrometers have been designed to reduce cellular sedimentation and to allow for 
the acquisition of metabolic data, in a defined and controlled environment. However, 
the high cell density required in the NMR tube causes many constraints, especially 
for primary human cells where limited numbers are available.  
For any bioreactor, the maintenance of oxygen levels is important. Low 
solubility of oxygen in media entails that gas diffusion alone will not adequately 
provide for the metabolic needs of cells. Furthermore, mammalian cells respond to 
high oxygen concentrations by changes in their metabolism and it is generally 
recommended that pO2 is maintained between 25 and 50%. Increasing perfusion 
rates would be the simplest solution to ensure that the oxygen consumption rate of 
cells can be satisfied. However, increasing flow rates to suitable levels will most 
definitely cause cell wash-out from the bioreactor, due to the low cell density. In this 
sense, the major challenge is to construct the appropriate configuration that will 
allow for high flow rates, while maintaining freely suspended cells in the NMR 
reading zone. 
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As a part of the presented thesis, a novel approach for measuring the 
metabolism of living primary human cells has been developed. The use of low 
percentage agarose containing embedded suspension cells is an alternative method 
providing both the homogeneity of the NMR sample as well as prevention of cellular 
sedimentation.    
1.7. FUTURE PROSPECTS 
Most of today's anti-cancer drugs are far from specific in attacking tumours. 
Rather, they represent poisons that tend to kill cancer cells more than normal cells. 
As a consequence of this incomplete specificity, they can cause severe side effects. 
Fortunately, cancer researchers are rapidly progressing to more targeted treatments, 
and pioneering new approaches to diagnose and classify cancers more effectively. 
The necessity for tests that can predict or at least monitor the response of an 
individual patient to specific treatment is still increasing.  
Metabolomics can be used in this context in several ways. The most important 
approach is to detect changes on a metabolite level that can be used as a fundamental 
component for new targeted therapeutic strategies. This is particularly promising in 
the context of cancer as the disease involves significant metabolic reprogramming. 
Metabolism is involved directly or indirectly in all functional activities of cells. 
There is mounting evidence for cross-talk between signalling pathways and 
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metabolic control in every multicellular organism studied (Vander Heiden, Cantley 
et al. 2009). However, there is still much to learn about how proliferating cell 
metabolism is regulated. Despite a long and rich history of research, the complex 
connection between metabolism and proliferation is an increasingly exciting area of 
investigation and it is possible that additional pathways have yet to be described. 
Understanding this important aspect of biology is likely to have a major impact on 
our understanding of cell proliferation control and cancer. Based on the findings 
presented above, we can say that the developed metabolomics approach constitutes a 
promising analytical tool for revealing specific metabolic phenotypes in a variety of 
cell types and pathological conditions. 
1.8. AIM OF THIS THESIS 
The overall objective of this thesis was to demonstrate a method of monitoring 
metabolism in living cells using NMR and to follow the kinetic changes of 
metabolites, without disturbing cells.  
The use of cell lines in metabolomics studies has significant limitations for 
studying metabolic adaptations or changes in the rates of cell growth and 
proliferation, as cell lines never represent the phenotype of an individual patient’s 
cancer cells. Therefore, it is important to test patient derived primary cancer cells. 
The choice of CLL cells arises from the realisation that these cells can be grown in 
solution and they can be maintained alive for extended periods of time.   
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Specifically, using primary CLL cells the aims of the study presented were: 
 To develop a method for measuring the metabolism of living CLL cells in real 
time. 
 To compare the metabolism of CLL cells as they transit and cycle from 
oxygenated to hypoxic environments and are subject to pH changes. 
 To investigate factors responsible for the metabolic plasticity of CLL cells.  
 To analyse metabolic mechanisms using metabolic flux analysis on CLL cell 
extracts. 
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All chemicals were purchased from Sigma-Aldrich (Poole, U.K.), unless stated 
otherwise and all FC analyses were conducted using a FACSCalibur and Cell 
QuestPro software (BD, Oxford, U.K.). 
2.1 Cells from patients 
Unselected patients with B-cell CLL attending the outpatient clinic at 
Birmingham Heartlands Hospital and Queen Elizabeth Hospital were recruited for 
this study. The patients had been diagnosed according to standard morphologic, 
immunophenotypic and clinical criteria (Oscier, Dearden et al. 2012) and had 
provided informed written consent for the study which had received local ethical 
approval.  
2.1.1 Purification of primary CLL cells  
The mononuclear cells (MNCs) were isolated from blood using Leucosep 
tubes (Greiner Bio-one, Gloucester) loaded with 15 ml Ficoll-Paque plus (G.E 
Healthcare, Amersham). MNCs were cultured in RPMI 1640 (Invitrogen Gibco, 
Paisley) with 1% ITS+ (culture supplement containing insulin, human transferrin and 
selenous acid) (BD Biosciences), 100 U/ml penicillin and 100 μg/ml streptomycin 
(Invitrogen Gibco). Cells were seeded at the concentration 5x106 cells/ml and 
incubated in a humidified chamber at 37°C and with 5% CO2. When cultured in these 
conditions, CLL cells stay quiescent in the G0/G1 phase of the cell cycle.  
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2.1.2 Isolation of CD19+ve cells 
For experiments using CD19+ve cells isolated from the blood of healthy donors, 
MNCs were isolated as above (section 2.1.1). In cases where the purity was < 70%, 
negative selection was performed using the Dynabeads® Untouched™ human B Cells 
kit (Invitrogen) to purify CD19+ve cells without affecting their metabolism. 
2.2 Analysis of cell phenotype using flow cytometry 
Following positive selection of CD19 cells, a cell purity check was carried out, 
using CD19 marker. Staining was carried out on 3x105 cells made up to a final 
volume of 200 µl in phosphate buffered saline (PBS) (Invitrogen Gibco) and 
incubated with 2 μl of the appropriate antibodies at room temperature (RT) in the 
dark. Cells were subsequently washed in 2 ml PBS by centrifugation at 1500 rpm for 
5 minutes, suspended in 300 μl of PBS and analysed. Data were analysed using BD 
FACSCalibur™, and 10,000 events were collected after manually performed 
compensation, using single colour controls. Flow cytometry analysis representative 
for CLL preparation are shown in Figure 2.1 and purity of all CLL preparations is 
demonstrated in Appendix A2. 
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2.3 Assessment of cell viability and proliferation 
2.3.1 AV/PI staining 
Single Annexin V (AV) and co-Annexin V/Propidium Iodide (PI) positivity 
was assessed by flow cytometry (FC) following staining using an AV FITC kit (BD), 
according to the manufacturer’s instructions. Briefly, 100 μl of cell suspension (5x106 
cells/ml) was transferred to a FACS tube and 1 ml of cold PBS was added. Cells were 
centrifuged for 5 minutes at 1500 rpm. The supernatant was removed and cells were 
resuspended in 100 μl of 1xAV binding buffer. Subsequently 5 μl of AV FITC 
antibody and 5 μl of PI stain was added and mixed. Samples were incubated at RT in 
the dark for 15 minutes. Staining was analysed using the flow cytometer within one 
hour. 
2.3.2 Cell cycle analysis. 
An aliquot of 3x105 cells was removed from the cell culture and filled with PBS 
to obtain a final volume of 1 ml. Following the 5 minute centrifugation at 1500 rpm, 
the supernatant was removed and 500 μl of cell cycle buffer (see buffers and recipes 
in Appendix) was added. Cell suspension was vortexed and stored in the dark at 4°C 
for 24 hours before the analysis. 
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2.4 Cell morphology: Jenner-Giemsa staining 
Aliquots of 100 µl cell suspension was loaded onto slides and spun down at 
500 rpm for 3 minutes using a Cytospin 3 Centrifuge. Slides were air-dried and fixed 
with ethanol for 5 minutes. Using a Coplin jar, slides were immersed in Jenner 
staining solution (diluted 1 in 3 in 1 mM sodium phosphate buffer, pH 5.6) and left 
for 5 minutes, after which they were washed with distilled water. Slides were then 
placed in Giemsa Staining solution (diluted 1 in 20 in 1 mM sodium phosphate buffer 
pH 5.6) and left for 10 minutes, after which they were washed with distilled water 
again. Slides were left to dry followed by mounting onto coverslips using DePex 
(VWR, UK). Cytospins were observed at 40x magnification. 
2.5 Real time NMR experiments with living cells   
2.5.1 Sample preparation 
Cell populations characterised as healthy (> 80% Annexin V negative) were 
selected for NMR experiments. Two concentrations of cells were used: 5x107 cells/ml 
or 1x107 cells/ml. Directly before the start of each experiment, cells were washed 
twice with warm RPMI medium and gently suspended in pre-warmed (37°C) 0.1% 
low melting agarose (Sigma) in RPMI (supplemented with 100 U/ml penicillin, 100 
μg/ml streptomycin (Invitrogen Gibco) and 1% ITS+ (BD Biosciences)) and 1 mM 
sodium 3-(trimethylsilyl) propionate-2,2,3,3-d4 (TMSP, Cambridge Isotope 
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Laboratories) in D2O (GOSS Scientific Instruments Ltd.). After suspending cells in the 
agarose matrix, 550 µl of cell suspension was loaded into 5 mm NMR tubes using 
long, glass NMR pipettes. The Oxygen Sensor connected to a Fiber Optic Oxygen 
Meter (World Precision Instruments) was inserted into the NMR tube and sealed 
together with Parafilm M®. The NMR tube with the immersed oxygen sensor was 
transferred into the 500 MHz NMR magnet after pre-warming to 310 K. 
Measurements were started within 15 minutes of sample injection into the magnet. 
2.5.2 Set up of the NMR experiment 
After injecting the sample into the magnet, the probe was tuned, the 
spectrometer was locked for field frequency stabilisation (H2O + D2O), and finally the 
sample was shimmed using automated shimming. This was facilitated by shimming 
a 0.1% agarose in RPMI sample before the cell sample was prepared. A series of 
automated 3D shims was performed until no changes were seen, followed by a series 
of 1D shims and an adjustment of the Z-shim to compensate for temperature 
gradients across the sample. This adjustment was previously optimised to minimise 
the TMSP line width. When the cell sample was in the magnet, the series of 1D shims 
was usually sufficient to obtain a good line width of TMSP (< 2 Hz). On occasions 
when the line width was higher than 2.5 Hz, additional manual shimming was 
performed. Following this, the pulse calibration was applied and the receiver gain 
determined followed by the acquisition of series of 1D 1H NOESY spectra over 24 
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hours. The oxygen measurement was started together with the acquisition. After the 
measurement, cells can be recovered for further analysis. A scheme of the NMR time 
course is presented in Figure 2.2.  
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Figure 2. 2. Scheme of NMR time course experiment. 
Peripheral blood CLL cells were suspended in RPMI 1640 medium with 1% ITS+, TMSP, 
D2O and 0.1% agarose and transferred to the NMR tube. Spectra are acquired over 24 
hours using a 500 MHz NMR spectrometer with the temperature set to 37°C. 
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2.5.3 Real time NMR measurement 1D 1H NOESY  
1D 1H NOESY spectra were acquired at 37°C, using a 500 MHz Bruker 
spectrometer equipped with a cryogenically cooled probe. The spectral width of the 
acquired spectra was 12 ppm, with 16384 acquired complex data points. The 
transmitter frequency offset was set to 4.696 ppm to suppress the water signal by 
presaturation. For apodisation an exponential multiplication (EM) window function 
with a line broadening of 0.3 Hz was used and the NMR data was zero filled to 32768 
points. Measurements were carried out with deuterium frequency locking after 
shimming. For time course experiments, a series of 144 1D spectra were acquired 
over 24 hours. Each spectrum was acquired over 10 minutes (which included the 
time of shimming between each sample), acquiring 64 transients and a recycle delay 
of 4 s.   
2.5.4 Proton-Carbon 1D spectra 
In order to investigate carbon flux in real time, a set of two 1D-1H13C 
decoupled NMR spectra were acquired. One spectrum contained NMR signals 
originating from all protons in the sample, while the second acquired spectrum 
contained only signals originating from protons bound to 13C (the pulse sequences 
are presented in Figure 2.3). Quantitation of this spectral approach was ascertained 
by scaling the first spectrum down to 1% and then comparing the signal intensity of 
the TMSP signal in both spectra. Due to the 1% natural abundance of 13C, both signals 
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had to have the same intensity after scaling down the first spectrum. Then by 
comparing relative signal intensities in both spectra, the percentage of incorporation 
of the 13C label could be determined from a single sample in real time (see Figure 2.4). 
The time resolution achieved was 5 minutes per spectrum or 10 minutes per data 
point. 
As an alternative, in principle the first increment of an HSQC spectrum could 
also be used, but due to non-adiabatic 90° pulses, magnetisation is not quantitatively 
recovered at chemical shifts far away from the carrier frequencies. The sequence 
presented here does not edit through 13C, but rather filters out 12C bound 1H signals 
and only uses adiabatic 180° pulses on the carbon channel and therefore omits these 
artefacts.  
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2.5.5 NMR time course data processing  
The NMR data was processed using the MATLAB based NMRLab/MetaboLab 
software (Gunther, Ludwig et al. 2000; Ludwig and Gunther 2011). A script for 
automated data processing of all the spectra was created using the ScriptBuilder 
module of MetaboLab. To further suppress the residual solvent resonance, a 
convolution filter using a gauss function was applied. Zero filling was set to 131072 
data points and phase correction was performed using the automatic phase 
correction of MetaboLab. Exponential like broadening of 0.3 Hz was applied prior to 
Fourier transformation of the data. Subsequently a spline based baseline correction 
(Gunther, Ludwig et al. 2000) was applied simultaneously to all acquired spectra. 
The chemical shift of TMSP changes with pH, but in order to compare the linewidths 
and ensure that they did not change throughout the timecourse, all spectra were 
aligned to the TMSP signal which was set to 0 ppm. As the change in chemical shift 
for TMSP was very small from spectrum to spectrum, the automatic peak picking 
algorithm for shifting peaks for other metabolites was able to cope with 
automatically determining the correct signal and therefore did not compromise any 
results. Also, pH measurement (described in chapter 5.2.7) which only depends on 
the difference between the two shifts of histidine, was not affected by the TMSP 
alignment to 0 ppm. 
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2.5.6 NMR time course data analysis 
NMR resonances of metabolites were assigned using the Chenomx software 
and HMBD (Human Metabolite Database). In cases of uncertain peaks, samples were 
spiked with the known metabolite at the concentration similar to that predicted from 
the obtained NMR spectrum. In order to distinguish peaks which changed their 
intensity or chemical shift during the time course, spectra were coloured using a 
rainbow gradient starting from red for the first spectrum, going through yellow and 
green and finishing with blue for the final spectrum (see Figure 2.5).  
For peaks exhibiting intensity changes over time, kinetic modelling was 
performed using the time series analysis tool (TSATool) from the Metabolab 
software. Peaks of interest were selected from the first or last spectrum, depending 
on whether the associated metabolite concentration increased or decreased over time. 
Selected peaks were then propagated automatically to the rest of the spectra in the 
time course. For the analysis, the time axis was obtained automatically from the 
Bruker acquisition data files. First order mono or bi-exponential kinetics were 
assumed to compare metabolic turnover between cells from different patients or 
from different treatments. 
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Figure 2. 5. Colour time gradient of the 1D 1H noesy spectra. 
Spectra were recorded every 10 minutes over the course of 24 hours. Then data was 
processed in NMRLab, spectra were superimposed and coloured. The first spectrum is 
coloured red, with the colour scheme proceeding through yellow and green to blue for 
the final spectra of the series. This fragment of spectra shows peaks of lactate increasing 
(quartet at 4.125; 4.111; 4.098; 4.084 ppm) and peaks of glucose decreasing (doublets at 
3.877; 3.881; 3.897; 3.901 ppm*). Glucose peaks are shifting to the right as the pH becomes 
more acidic. 
 
* Peaks were assigned using the HMDB database (The Human Metabolome Database), due to the 
different temperature and pH, the actual chemical shift values may differ.   
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𝑝𝐻 = 𝑝𝐾𝑎 + 𝑙𝑜𝑔10
𝛥𝛿 − 𝛿𝐵𝐻
𝛿𝐵 − 𝛥𝛿
 
2.5.7 Determination of the intracellular pH inside the NMR tube   
The extracellular pH inside the NMR tube was determined using the pH 
sensitivity of the chemical shift of the 2 side chain resonances from histidine (see 
figure 2.6). In order to obtain the pH curve, 23 media samples with increasing pH 
were measured (ranging from pH=3 to pH=8.5) in triplicate. Using the chemical shift 
difference Δδ between the peaks corresponding to imidazole ring protons H2 and 
H5, attached to C2 and C5 and C5-H peaks (Kintner, Anderson et al. 2000; Cohen, 
Motiei et al. 2004), we were able to measure the pH of the NMR sample at each 
particular time point. A calibration curve for the H2 and H5 histidine protons was 
determined in a solution of RPMI medium adjusted to pH 3-8.5. Curve fitting was 
carried out in MATLAB using a custom made script with the equation (Schechter, 
Sachs et al. 1972):  
 
 
where pKa is the acid dissociation constant reflecting the inflection point of the 
titration curve, Δδ represents the difference between the chemical shift of the 
histidine protons in solution, δBH is the limiting chemical shift value at acid pH and 
δB is the limiting chemical shift value at basic pH. 
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Figure 2. 6. Changes of pH in the NMR tube. 
A) Picture of the NMR tube with CLL cells suspended in 0.1% agarose RPMI at 5x107 
cells/ml before and after the 24 h time course experiment. B) Chemical structure of 
histidine with C2 and C5 marked and histidine region of 144 overlaid 24 h time course 
1H spectra (sample contained 5x107/ml CLL cells in 0.1% agarose RPMI with 1% ITS+). 
Spectra are coloured starting from the first data point in red, and the last data point in 
blue. Peaks of protons connected to C2 (H2) and connected to C5 (H5) of histidine are 
shifting to the left. C) Histidine pH curve with the equation of fitted line. Samples of 
RPMI medium with different pH (x axes) were measured and the difference in chemical 
shift between frequency [ppm] of two histidine peaks was calculated (y axes). The pH 
value was calculated using the equation: pH= 5,49 + log10 ((δ−1,272)/(0.7004−δ)).  
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2.6 CLL cell extraction 
2.6.1 Incubation with the 13C labelled precursor 
For the extracts analysis ≥180x106 cells were required per sample. Media for 
particular samples were prepared according to Table 2.1. Cells were washed once 
with the appropriate medium, seeded at 5x106/ml and incubated for 24 hours in an 
incubator under normoxic (22% O2) or hypoxic (1% O2) conditions before quenching. 
  
Table 2. 1. Media with the 13C labelled precursors 
Sample 
RPMI 1640 medium (Invitrogen, 
catalogue number) 
Added precursors 
Control No glutamine (31870-082) 300 mg/l, 2 mM Glutamine (Sigma) 
13C-1,2-
Glucose 
No glucose (11879-020) 
2000 mg/l, 11.11 mM of 13C-1,2-Glucose 
(Sigma Isotopes) 
13C-3-
Glutamine 
No glutamine (31870-082) 
300 mg/L, 2 mM 13C-3-Glutamine (Sigma 
Isotopes) 
 
2.6.2 Quenching 
The centrifuge was pre-chilled to -9°C and the fixed angle centrifuge rotor was 
pre-chilled in the -20°C freezer for 1 hour. The 2 ml Eppendorf tubes were labelled 
and weighed (for the estimation of the cell pellet biomass). HPLC grade methanol 
(1.6 ml, 60%, prepared using HPLC grade water) was added to each Eppendorf and 
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put on dry ice for a minimum of 15 minutes to cool the quenching solution to -40°C. 
The cell suspension from the sample to be quenched was poured into a 50 ml Falcon 
tube and centrifuged at room temp (1500 rpm, 5 min). Supernatant (1 ml) was 
transferred into an Eppendorf and snap frozen in liquid nitrogen. The remainder of 
the supernatant was discarded. The cell pellet was resuspended in the residual media 
in the Falcon tube and 200 μl of this suspension was ejected directly into the 2 ml 
Eppendorf containing quenching solution, mixed and returned to dry ice. Next, all 
samples were placed in the pre-chilled rotor and centrifuged at -9°C, 2500 g for 5 
min. The quenching solution was removed with a glass Pasteur pipette. Tubes with 
pellet were weighed to estimate the pellet mass. Pellets were frozen in -80°C until 
extraction. 
2.6.3 Extraction 
Quenched cell pellets were kept on dry ice. Pre-chilled HPLC grade methanol 
was added to each pellet 8 μl/mg (of pellet) and vortexed for 30 seconds. Then pre-
chilled HPLC grade chloroform was added (8 μl/mg) to each Eppendorf and pulse 
vortexed. Following this, 7.2 μl/mg of HPLC grade water was added and samples 
were vortexed for 30 seconds and left on ice for 10 min. Next, samples were 
centrifuged at 1500 g (4000 rpm) for 10 min at 4°C. Subsequently, samples were left 
on the bench for 5 min. After the centrifugation samples were bi-phasic: the upper 
layer contained polar metabolites and the lower layer contained lipids. The same 
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volume from the upper layer was transferred to the new Eppendorf vials and 
aliquots were dried in the vacuum concentrator (SpeedVac) for 3-6 hours. Dry pellets 
were stored at -80°C until required. The non-polar fraction was also collected (in 
glass vials) and stored in -80°C for potential future lipid analysis. 
2.7 NMR Metabolic Flux experiments using cell extracts 
2.7.1 Sample preparation 
The dried polar extracts were dissolved in 90% H2O/10% D2O (GOSS Scientific 
Instruments Ltd, Essex UK) prepared as 100 mM phosphate buffer (pH 7.0), 
containing 0.5 mM sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4 (TMSP, Cambridge 
Isotope Laboratories) as an internal reference. 
2.7.2 HSQC acquisition 
The 2D 1H 13C- HSQC spectra were acquired on a 600 MHz UltraShield plus 
Bruker magnet with a 4-channel Bruker Avance III console using a low volume 1.7 
mm CryoProbe™ with a 35 μl sample volume. This spectrometer was also equipped 
with a SampleJet automated sample changer with sample cooling at 6°C. After the 
sample was inserted into the magnet, it was temperature equilibrated for 30 s at 300 
K (27°C). The probe was then automatically tuned and matched for each sample, 
followed by sample locking to the D2O resonance, automatic shimming (shimming is 
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a procedure which makes the magnetic field as homogenous as possible across the 
sample) and automated pulse calibration (Wu and Otting 2005) which included: 
spectral widths (13 ppm & 160 ppm), number of acquired data points (TD), interscan 
relaxation delay (d1), acquisition time (aq), number of scans (NS) and quadrature 
detection (Echo/Antiecho). 
2.7.3 HSQC data processing 
All data processing and analysis was performed using the MATLAB based 
NMRLab/MetaboLab software package (Gunther, Ludwig et al. 2000; Ludwig and 
Gunther 2011). Prior to Fourier transformation, the NMR data was apodized using a 
90° phase shifted quadratic sine function, then zero filled to 1024 and 4096 data 
points for 1H and 13C dimension respectively. The NMR spectra were manually phase 
corrected to obtain pure absorption line shapes and referenced to the methyl signal 
of alanine using the HMDB based library shifts of the MetaboLab software. To 
further suppress the residual solvent resonance, a convolution filter using a gauss 
function was applied to the fids in the 1H dimension (Marion, Ikura et al. 1989).  
2.7.4 HSQC data analysis 
Assignment and analysis were all carried out in MetaboLab using the HMDB 
based chemical shift library. A combination of various analyses were used, including 
an approach using an unlabelled reference sample, multiplet analysis (quantum 
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mechanical reconstruction of the NMR spectrum using pygamma (Smith, Levante et 
al. 1994)), as well as the absolute label incorporation into C3 of lactate via 1D spectra. 
2.8 Quantitative real-time polymerase chain reaction (QRT-
PCR) 
2.8.1 RNA extraction 
RNA was extracted from a pellet of 1x106 cells using a Qiagen RNeasy mini kit 
(Qiagen, Crawley, U.K.) according to the manufacturer’s instructions. Briefly, cells 
were resuspended in 350 μl buffer RLT (plus β-mercaptoethanol; Sigma). The sample 
was then homogenised using a QIAshredder spin column. One volume of 70% 
ethanol (Fischer Loughborough, U.K.) was added to the homogenised sample and 
700 μl of this mixture added to an RNeasy mini column. The column was centrifuged 
for 15 seconds at 14000 rpm in a microfuge. Further DNA removal was carried out 
using the RNase-free DNase set. 350 μl buffer RW1 was added to the column and the 
column centrifuged for 15 seconds at 14000 rpm in a microfuge. The DNase I stock 
solution was added to buffer RDD according to manufacturer’s instructions and 80 
μl of this mix was added to the column and incubated for 15 minutes at room 
temperature. Buffer RW1 (350 μl) was added to the column and the column was 
centrifuged for 15 seconds at 14000 rpm in a microfuge. Buffer RPE (500 μl) was 
added to the column and centrifuged for 15 seconds at 14000 rpm in a microfuge. 
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Another 500 μl RPE was applied to the column prior to centrifugation for 2 minutes 
at 14000 rpm in a microfuge. The RNeasy column was transferred to a 1.5 ml 
collection tube, RNA was eluted with the addition of 30 μl RNase-free water and was 
isolated by centrifugation for 1 minute at 14000 rpm in a microfuge, and stored at – 
20°C. 
2.8.2 RNA quantification 
RNA samples were diluted 1 in 50 with RNase-free water (Invitrogen Gibco) 
in a total volume of 100 μl. The absorbance at 260 nm was measured at OD 260 and 
the RNA concentration was calculated using the following equation:  
RNA concentration (μg/μl) = (OD260 x 40 x dilution factor)/1000. 
2.8.3 Reverse transcription 
cDNA was produced from 100 ng RNA using reverse transcription. Unless 
stated otherwise, all constituents were obtained from Invitrogen (Paisley, U.K.) and 
the procedure carried out as follows: 1 μl of both random primers (Promega) and 
deoxynucleotide triphosphates (dNTPs) (Bioline, London, U.K.) were added to 100 
ng RNA, the volume made up to 12 μl with DNase RNase-free water (Invitrogen 
Gibco), and the mix heated to 65°C for 5 minutes, transferred to ice and centrifuged 
for 15 seconds at 14000 rpm in a microfuge. A solution comprising the following 
components was prepared: 1x buffer, 0.1 M DTT, RNase Out (Promega) and 
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Superscript. After centrifugation, 8 μl of this solution was added to the RNA, primer 
and dNTPs. The mix was incubated at 25°C for 10 minutes, 42°C for 90 minutes and 
70°C for 15 minutes in a thermocycler. 
2.8.4 β-actin PCR 
To confirm that the reverse transcriptase reaction had worked, PCR reactions 
for β-actin were performed. The sequences of these primers were as follows: 
Forward 5’ GTCACCAACTGGGACGACA 3' 
Reverse 5’ TGGCCATCTCTTGCTCGAA 3' 
The 1x reaction mix was prepared as follows: Taq buffer, primers (33 μM), dNTP's 
(10 mM), MgCl2 (50 mM), Taq polymerase, cDNA and DNase RNase-free water to 50 
μl. The PCR cycle included an initial denaturation step (95°C for 2 minutes), followed 
by 38 cycles of 94°C for 20 seconds, 55°C for 30 seconds and 72°C for 60 seconds and 
a final incubation at 72°C for 5 minutes. Subsequently, 6 μl of a product was mixed 
with 2 μl 10x DNA gel loading buffer (Bioline), loaded onto a 1% agarose gel and 
electrophoresed in 1x Tris-borate-EDTA buffer (TBE) (see Appendix) at 60 V, for 45 
minutes.  
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2.8.5 Agarose gel electrophoresis 
Gel electrophoresis was used to analyse β-actin products. Powdered agarose 
(Bioline, London, UK) was dissolved by heating in 50 ml 1x TBE buffer 
supplemented with a fluorescent dye used for staining nucleic acids - ethidium 
bromide (0.5 μg/ml). The gel was set in the tank at RT and submerged in 1x TBE 
buffer containing ethidium bromide (0.5 μg/ml). Nucleic acid samples were 
combined with 1 μl of 6x gel loading dye (New England Biolabs, UK) and loaded 
into sample wells alongside the DNA molecular weight ladder (New England 
Biolabs, UK). Samples were subjected to electrophoresis at 80 V for 40 minutes and 
the gel visualised by UV illumination using bio imaging unit (Geneflow, UK). 
2.8.6 Real-time PCR 
2.8.6.1 Measurement of gene expression. 
Reactions were performed using an ABI Prism 7700 sequence detector 
(Applied Biosystems) using the SensiFast SYBR Hi-Rox kit (Bioline, UK). 
Thermocycler conditions were 50°C for 2 minutes, 95°C for 10 minutes, followed by 
44 cycles of 95°C for 15 seconds and 60°C for 1 minute. Each PCR reaction contained 
900 nM gene specific 5’ and 3’ primers: VEGF (Hs_VEGFA_1_SG), GLUT1 
(Hs_SLC2A1_1_SG), LDHA (Hs_LDHA_1_SG) (all from Qiagen), 1x SensiMixTM 
SYBR Low-ROX MasterMix (Bioline) (containing pre-optimized dNTPs, MgCl2, 
molecular probe and ROX dye), and cDNA (1 μl) in a total volume of 20 μl with 
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dH2O. Three biological replicates were used for each of the target genes, with each 
individual assessed in triplicate. Results were normalised to the internal reference 
gene 18S rRNA. Control 18S reactions contained 50 nM 18S 5’ and 3’ primers (Sigma), 
SensiMix™ (Biolone) and cDNA in a total volume of 20 μl.  
2.8.6.2 Q-PCR data analysis. 
Q-PCR data was first analysed using ABI Prism 7000 software (Applied 
Biosystems) according to manufacturer’s guidelines. Briefly, cycle threshold (CT) 
values were determined for both 18S internal control and genes of interest in each 
sample by placing a threshold line over the exponential phase of the PCR cycle 
profiles. The average CT values were calculated from the duplicates. The 18S internal 
control value was then subtracted from the value for the gene of interest to give ΔCT 
values. This value was converted to fold change in gene expression relative to control 
using the equation:  
Fold change = 2-ΔΔCT 
and fold change was converted to percentage expression relative to control via 
multiplication by 100. The average and standard error of the mean of samples were 
calculated. 
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2.9 Protein analysis: western blotting 
2.9.1 Protein extraction and quantification. 
For protein extraction, 2.5x107 cells were resuspended in 150 μl RIPA buffer 
(see Appendix), supplemented with 1x protease inhibitor (Sigma), and incubated for 
30 minutes on ice prior to centrifugation at 14000 rpm at 4°C for 10 minutes in a 
microfuge. The supernatant was transferred to a 1.5 ml centrifuge tube and frozen at 
-20°C.  
For protein quantification, the Dc protein assay protocol (Bio-Rad, Hemel 
Hempstead, U.K.) was followed according to manufacturer’s instructions. Briefly, 5 
μl BSA standards (0, 0.625, 1.25, 2.5, 5 and 10 mg/ml) were added to duplicate wells 
of a 96 well plate and 2 μl of each protein sample were added to 3 μl distilled water 
in replicate wells. 20 μl reagent S was added to each ml of reagent A required to 
make solution ‘A’, and 25 μl A’ added to each well. Reagent B (200 μl) was then 
added to each well, wells were mixed and the reaction allowed to develop for 15 
minutes before the optical density was measured at 645 nm, using a plate reader. 
2.9.2 Sample preparation and protein separation by sodium dodecyl 
sulphate – polyacrylamide gel electrophoresis (SDS PAGE). 
Protein samples (20-40 μg) were mixed in a 3:1 ratio with 4x SDS gel loading 
buffer (see buffer and recipes in Appendix), heated to 100°C for 10 minutes in boiling 
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water. A 10% resolving gel mix was prepared (see Appendix) and allowed to fully 
polymerise at RT for 40 minutes prior to the addition of the stacking gel; prepared as 
described in Appendix. Protein samples, and 5 μl pre-stained precision dual stained 
markers (Bio-Rad) were loaded onto the gel and electrophoresed at 150 V with 1x 
SDS gel running buffer for 90-100 minutes. 
2.9.3 Protein transfer 
The polyvinylidene difluoride (PVDF) membrane (Millipore, Watford, U.K.) 
was soaked in methanol (Fischer) for 2 seconds, dH2O for 2 minutes and equilibrated 
in transfer buffer (see Appendix) for 10 minutes. Semi-dry transfer was carried out 
using four layers of pre-transfer buffer-soaked 3 mm paper (Fischer) on the cathode 
and anode and the transfer was carried out using a Mini-Protean transfer tank (Bio-
Rad) at 25 V for 1 hour. 
2.9.4 Immunodetection of proteins 
The membrane was rinsed in TBS-T (see buffer and recipes in Appendix) and 
then blocked for 45 minutes in 5% blocking solution (see Appendix). Primary 
antibody was diluted (according to table 2.2) in 5% blocking solution and the 
membrane was incubated overnight at 4°C with rocking. On the following day, the 
membrane was washed three times for 5 minutes in TBS-T and incubated for 45 
minutes at RT, with rocking in the 5% blocking solution with the secondary antibody 
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(horseradish peroxidase (HRP)) diluted according to Table 2.2. Then the membrane 
was washed as above and signal developed using Supersignal West Pico 
Chemiluminescent substrate (Pierce, Northumberland, U.K.) and signal detected by 
exposure to Xomat scientific imaging film (Kodak, Sigma) for 5 minutes. Films were 
developed using an AGFA CURIX 60 (Agfa, Mortsel, Belgium). Equal loading was 
checked using mouse anti-human β-actin antibody (Sigma) and secondary rabbit 
anti-mouse following the same protocol (dilutions 1 in 10000 for each).  
Table 2. 2. Antibodies used for the western blot analysis 
Antibody Source Company Cat no. Dilution 
Anti-HIF-1α mouse BD Biosciences 610959 1:500 
Anti-VEGF rabbit Abcam ab46154 1:1000 
Anti-GLUT1 
(H-43) 
rabbit 
SantaCruz 
Biotechnology 
sc-7903 
1:1000 
Anti-β-actin mouse Sigma 
A2228-
100UL 
1:10000 
Anti-rabbit goat Sigma A6154-1ML 1:1000 
Anti-mouse goat Sigma A2554-1ML 1:1000 
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2.10 Investigation of oxidative stress 
2.10.1 Assessment of accumulation of Reactive Oxygen Species (ROS) 
Carboxy-H2DCFDA (H2DCFDA) (Invitrogen Molecular Probes, Paisley, U.K) 
binds to all ROS and was dissolved in dimethyl sulfoxide (DMSO) to yield a 2000x 
stock, of 10 μM. This was aliquoted into 10 μl volumes and was stored at -20°C. 
Immediately prior to use, a 1 μM working dilution was made in warm RPMI 
medium. 500 μl of cell suspension was placed in the FACS tube and 5 μl of medium 
with H2DCFDA was added, mixed and incubated at 37°C, for 40 minutes. 
Immediately after the incubation, FACS tubes were analysed. 
2.10.2 Assessment of accumulation of Mitochondrial Superoxide 
MitoSOX Red (Invitrogen Molecular Probes, Paisley, U.K) was used to assess 
the presence of mitochondrial superoxide (mitosox) in cells, according to the 
manufacturer’s instructions. Briefly, 1 ml of warm PBS was added to 200 μl of cell 
suspension and centrifuged at 1500 rpm for 5 minutes. The supernatant was removed 
and a vial of MitoSOX Red was diluted in 13 μl of DMSO to yield a 10 mM stock. A 
working stock of 10 μl MitoSOX Red was prepared in warm PBS (Invitrogen Gibco) 
and this was added to the cells, prior to incubation at 37°C for 10 minutes. 
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2.11 Treatments of CLL cells with inhibitors 
Stock solutions of inhibitors in DMSO were aliquoted and stored at −80°C 
prior to use. For cell treatment, these stock solutions were diluted 1:1000 in medium 
to a final DMSO concentration of 0.1%. 
2.11.1 HIF-1α inhibition with Chetomin 
Cells were pre-treated for 3 hours with 0.1 μM, 1 μM and 5 μM chetomin 
(CTM) dissolved in DMSO. In order to obtain hypoxic conditions, cells were 
incubated in the hypoxic incubator (Mini Galaxy A, O2 control) with 1% O2 and 5% 
CO2 at 37°C for 24 hours. 
2.11.2 Alanine aminotransferase inhibition with cycloserine and β-
chloro-l-alanine. 
Cells were treated with two concentrations of cycloserine and β-chloro-l-
alanine: 10 μM and 250 μM for 24 hours in normoxia and hypoxia. 
2.11.3 Pyruvate cellular transporter (MCT1) inhibition with CHC  
Alpha-cyano-4-hydroxycinnamate (CHC) (Sigma) was dissolved in DMSO 
and used at 2 mM and 5 mM concentrations. Cells were pre-treated for 3 hours 
before transfefrring into hypoxic conditions. 
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2.12 HRP chromogenic staining of cytospins 
2.12.1 Staining 
After spinning and drying, of the cytospins, they were fixed for 10 minutes in 
cold acetone and air dried. Then the spot of cells was circled with a hydrophobic pen 
to create a barrier and 80 μl of peroxidase block was added and incubated at RT 
protected from light for 10 minutes. Following this, the cytospins were rinsed twice 
in fresh wash buffer for 3 minutes each time followed by incubation with 80 μl of FcR 
block at RT protected from light for 10 minutes. Next, cytospins were rinsed twice in 
fresh wash buffer for 3 minutes each time.  
Primary HIF-1α antibody (Sigma) was diluted 1:100 in Dako Antibody Diluent, 
applied on the slides and incubated for 30 minutes at RT, protected from light. Then 
cytospins were rinsed as previously. Secondary Antibody – Anti rabbit/mouse HRP 
Dako premade solution, was applied on the slides, incubated for 30 minutes at RT 
protected from light and rinsed as previously. Chromogenic developer was then 
prepared using 20 μl of stock added to 1 ml of diluent and added to each slide 
separately and incubated at RT for up to 10 minutes while monitoring under a 
microscope. Once clear staining was seen or high background developed, the 
solution was rinsed off by dropping slides into fresh buffer. 
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2.12.2 Counterstain 
Slides were immersed in haematoxylin for 15 seconds, then rinsed in Scotts 
water, freshened and rinsed again. Subsequently, slides were dipped in acid alcohol 
wash for less than 5 seconds and rinsed well in Scotts water, then rinsed with 
running tap water for 30 seconds-1 min.   
2.12.3 Dehydration and Mounting 
Cytospins were immersed twice in 50% ethanol, twice in 70% ethanol, once in 
96% ethanol for 3 minutes, once in 96% ethanol for 2 minutes, twice in 98% ethanol 
for 2 minutes each and once in 100% ethanol for 2 minutes. Then cytospins were air 
dried and mounted with the coverslip using mounting medium (Dako). 
2.13 Fluorescent staining of cytospins  
After spinning and drying, the cytospins were fixed for 10 minutes in cold 
acetone and air dried. Then the cells spot was circled with a hydrophobic pen to 
create a barrier and 80 μl of donkey serum (Jackson ImmunoResearch) was added 
and incubated at RT protected from light for 10 minutes. Then the cytospins were 
rinsed twice in fresh wash buffer for 3 minutes each time followed by 30 minute 
incubation at RT protected from light with first primary antibodies: rabbit anti HIF-
1α (Sigma) diluted 1:100 (see table 2.3). Next, cytospins were rinsed twice in fresh 
wash buffer for 3 minutes each time. Secondary antibody – donkey anti rabbit 
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(Jackson ImmunoResearch) was applied on the slides, incubated for 30 minutes at RT 
protected from light and rinsed as previously. Cytospins were then stained with 
PAX-5 which is a B cell marker. The procedure was the same as previously, IgG 
control was stained with anti-goat antibody. All the antibody dilutions are presented 
in table 2.3. After the last wash, cytospins were mounted to the coverslips using the 
ProLong® Gold anti fade reagent with DAPI dye, staining the nuclei of cells (Life 
Technologies).  
 
Table 2. 3. Antibodies used for cytospin staining 
Antibody Source Company Cat no. Dilution 
Anti-HIF-1α rabbit Sigma HPA001275 1:100 
Human Pax5/BSAP goat R&D systems AF3487 1:10 
Normal rabbit IgG rabbit R&D systems AB-105-C 1:100 
Normal Goat IgG goat R&D systems AB-108-C 1:10 
Anti-Rabbit HRP goat Dako P 0448 
premade 
solution 
Anti-Rabbit donkey 
Jackson 
ImmunoResearch 
711-001-003-
JIR 
1:100 
Alexa Fluor® 568 
Donkey Anti-Goat 
donkey Life Technologies P36930 1:100 
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2.14 Statistical analysis of experiments 
Normal distribution and homogeneity of variance of all data sets was assessed 
by Shapiro-Wilk and Levene’s tests respectively using SPSS version 16 software. All 
the data were normally distributed and displayed homogeneity of variance. 
Statistical significance was assessed using the student’s t-test for paired data, 
calculated using the statistics package within Microsoft Excel™. p values below 0.05 
are indicated by * as described in the legends of figures. 
2.15 MetaboLab routines used for data analysis 
Together with the progress of the project, development of MetaboLab was 
carried out. The HSQC library of chosen metabolites was built, based on the HMDB 
data. 
2.15.1 MATLAB scripts 
In order to perform the analysis of the time course NMR spectra, specific 
MATLAB scripts were created. 
2.15.1.1 Scale TMSP 
Scale TMSP height script has been used to scale all of the TMSP signal heights 
from the time course experiment to 1. This enabled us to compare peak heights in the 
different experiments as well as overcome the line width instability between spectra 
of the same time course. TMSP is the reference point for 0 ppm. 
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function scale_tmsp_height(stepsize) 
 
if(nargin<1) 
    stepsize = 1; 
end 
 
global NMRDAT 
global NMRPAR 
 
s = NMRPAR.CURSET(1); 
e = NMRPAR.CURSET(2); 
 
ref  = NMRDAT(s,1).PROC(1).REF; 
nexp = NMRDAT(s,1).ACQUS(1).NE; 
 
for k = 1:nexp 
    NMRDAT(1,k).MAT       = NMRDAT(1,k).MAT/NMRDAT(1,k).MAT(ref(2)); 
    NMRDAT(1,k).DISP.PLOT = 0; 
end 
 
for k=1:stepsize:nexp 
    NMRDAT(1,k).DISP.PLOT=1; 
end 
 
 
 
2.15.1.2 Peaking shifting peaks 
This script was built in order to pick all of the peaks from the time course 
dataset, including shifting peaks (like histidine), crossing through other peaks.   
% pick the first spectrum and transfer, then 
 
 
nspc = 147; 
 
pp = {}; 
 
for k = 1:147 
    pp{k} = NMRDAT(1,k).MANINT; 
end 
 
% then pick last spectrum and transfer, then 
% determine until which spectrum it's fine (83) 
 
 
for k = 1:100 
    NMRDAT(1,k).MANINT = pp{k}; 
end 
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2.15.1.3 Fit pH curve 
The ‚fit pH curve‛ script was built in order to create pH curves from the 
differences of the chemical shifts of histidine peaks from 21 spectra, acquired on the 
medium samples with differing pH (3.5-8.5). 
 
nPeaks = 2; 
nSpc   = 21; 
pH     = [8.5, 8.25, 8, 7.75, 7.5, 7.25, 7, 6.75, 6.5, 6.25, 6, 
5.75, 5.5, 5.25, 5, 4.75, 4.5, 4.25, 4, 3.75, 3.5]; 
fitfun = '(10.^(t-pk)*DB+DA))./(1+10.^(t-pk))'; 
 
 
 
%-------------------------------------------- 
 
ppm    = zeros(nSpc,nPeaks); 
for k = 1:nSpc 
    ppm(k,:) = NMRDAT(1,k).MANINT.peakMaxPPM; 
end 
 
diffData = abs(diff(ppm')'); 
pars    = parse_command_string(fitfun,1); 
 
fitpars = zeros(1,length(pars)); 
for k = 1:length(pars) 
    fitpars(k) = pars(k).value; 
end 
     
opts                     = optimset(); 
opts.MaxFunEvals          = 1e7; 
opts.MaxIter              = 1e7; 
opts.TolFun               = 1e-7; 
opts.TolX                 = 1e-7; 
 
 
[par_eval, fval, status] = 
fminsearch(@gen_fit,fitpars,opts,pH,diffData,fitfun,pars); 
[chi2,simFct]            = gen_fit(par_eval,t,data,fitfun,pars); 
 
 
figure 
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2.15.1.4 Calculate pH 
In order to get the value of the chemical shift differences (Δδ) between two 
histidine peaks for each spectrum automatically, the following script was used. 
nspc = 144 
; 
 
 
 
shifts = zeros(nspc,2); 
for k = 1:nspc 
    shifts(k,:) = NMRDAT(1,k).MANINT.peakMaxPPM; 
end 
difference = diff(shifts')'; 
 
Subsequently the series of Δδ was inserted in the pH curve equation to obtain the pH 
value for each NMR spectrum. 
2.15.1.5 Calculate percentage of keto and enol form of pyruvate 
In order to calculate percentage of keto and enol form of pyruvate at any 
particular time point of the time course, the following script was used. This script 
combines the information about the pyruvate tautomers together with the pH values.   
% Pick 4 peaks (Keto/Enol-Pyruvate and the 2 Histidine signals) 
 
global NMRPAR 
global NMRDAT 
global extractPeaks 
 
 
s = NMRPAR.CURSET(1); 
e = NMRPAR.CURSET(2); 
 
nspc = NMRDAT(s,1).ACQUS(1).NE; 
t    = extractPeaks(1).t; 
t    = t(:); 
 
 
shifts = zeros(nspc,4); 
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for k = 1:nspc 
    shifts(k,:) = NMRDAT(s,k).MANINT.peakMaxPPM;  
end 
 
 
pHshifts = shifts(:,3:4); 
deltaCS  = diff(pHshifts')'; 
 
 
ph = 5.49 + log10((deltaCS - 1.272)./(0.7004-deltaCS)); 
 
pyr1 = extractPeaks(2).peak(1).expInt; 
pyr2 = extractPeaks(2).peak(2).expInt; 
     
enolPyruvate = 100*pyr2./(pyr1+pyr2); 
enolPyruvate = enolPyruvate(:); 
ketoPyruvate = 100*pyr1./(pyr1+pyr2); 
ketoPyruvate = ketoPyruvate(:); 
 
 
%figure; plot(ph,enolPyruvate); 
%title('pH vs enol %') 
%print -dpdf pyruvate_ph_vs_enol.pdf 
%plot(t,ph); 
%title('pH over time') 
%print -dpdf pyruvate_ph_over_time.pdf 
plot(t,enolPyruvate,'b-',t,ketoPyruvate,'r-'); 
title('Keto-r-/Enol-b- % over time') 
%print -dpdf pyruvate_enol_over_time.pdf 
 
data = [t'; ph'; enolPyruvate'; ketoPyruvate']; 
 
csvwrite('pyruvate_ph_data.csv',data); 
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3.1 INTRODUCTION 
Metabolomics has been widely used to examine the metabolic phenotype of 
cells, usually exploiting either hydrophilic or lipophilic extracts (Gromova and Roby 
2010; Fernando, Bhopale et al. 2011). Performing time course analyses in this way 
requires large amounts of biological material, which is a limiting factor for studies 
using primary human cells. However, NMR represents a non-invasive analytical 
method that is, in principle, able to analyse the metabolism of living cells, and 
monitor its dynamics over extended periods of time in a single batch of cells.  
NMR is a powerful tool that can be used to monitor labelling patterns in key 
metabolic intermediates, which can be used to calculate fluxes in mammalian tissues 
(Griffin and Corcoran 2005). While metabolomics measures static metabolite 
concentrations, metabolic flux analysis observes the flux of individual atoms across 
metabolic networks employing isotopically labelled metabolic precursors such as 
glucose and glutamine as tracers. However, because of the limited sensitivity of 13C 
NMR, it has not been widely applied to the study of isolated cells in culture. Such 
studies require a very large number of cells to fill the sample volume of an NMR 
tube. A number of different methods have been used to immobilise dense cultures of 
cells inside an NMR tube. A key parameter that must be considered with any cell 
immobilisation technique is the transport of metabolites and nutrients. Oxygen can 
be particularly problematic, because it is poorly soluble in aqueous media. In dense 
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masses of cells, metabolic rates are often limited by the rate of oxygen diffusion. Such 
limitations can hinder the determination of the true intrinsic metabolic characteristics 
of a population of cells. To avoid such limitations either the diffusion distance in the 
cell mass must be short, or the density of the cell mass must be relatively low. It has 
previously been shown that the metabolism of human cancer cells can be monitored 
using NMR perfusion systems with various adherent cell lines grown on 
microcarrier beads. Methods involving microcarriers can be used with cell lines, 
where the amount of biological material can easily be multiplied. In published 
experiments, 3-8x108 cells grown on beads were used, filling a 20 mm NMR tube 
(Pianet, Canioni et al. 1992). Similar methods have been used for the metabolic flux 
analyses in glioma cells after enriching the metabolic substrates with 13C labels. 
Microbeads were mixed with SF188 cells at a ratio of 107 cells per gram 
(DeBerardinis, Mancuso et al. 2007). As the cells usually need to grow in the 
microcarriers for 8-9 days, this method can be effectively used solely with cells that 
proliferate and adhere to microbeads (Mancuso, Beardsley et al. 2004; Mancuso, Zhu 
et al. 2005).  
As a result of the non-invasiveness of NMR, in-cell NMR is widely used for 
protein investigation. This method allows for the determination of the conformation 
and functional properties of proteins inside living cells (for example Xenopus laevis 
oocytes) (Selenko and Wagner 2007).  
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Despite well-developed systems for measuring metabolites using 
proliferating, adherent cells, little has been reported on NMR metabolomics using 
quiescent, suspension cells. A ‚continuous cell cultivator‛ providing convective 
oxygen and nutrient transport was constructed for 31P NMR experiments using 
Saccharomyces cerevisiae where large amounts of cells can easily be grown (Meehan, 
Eskey et al. 1992). More recently, a perfusion small-scale bioreactor for on-line 
monitoring of the cell energetic state was developed for free-suspension mammalian 
cells (Chinese hamster ovary cell line) (Ben-Tchavtchavadze, Chen et al. 2010), 
however, no metabolomics work on human suspension cells has been published to 
date.  
In order to investigate the metabolism of primary CLL cells which are non-
dividing, an NMR system for cells in suspension that does not require microcarriers, 
perfusion systems or large amounts of cells, was developed. In order to suspend cells 
evenly in the NMR tube and for the duration of the experiment, cells were embedded 
in a medium-agarose matrix. To monitor the oxygen concentration in the tube, an 
oxygen sensor was used and the pH was calculated using the histidine resonances 
(as described in materials and methods).  
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3.2 RESULTS 
3.2.1 1D 1H NMR spectrum of living CLL cells 
A typical 1D 1H-NMR spectrum obtained from 5x107 CLL cells is shown in 
Figure 3.1. NMR spectra were obtained with a time resolution of 7-10 minutes over 
24 hours permitting a well-resolved time course of metabolic activity. The spectrum 
contains signals of > 30 metabolites, of which alanine, glutamate, formate, 
hypoxanthine, uridine, pyroglutamate, phosphocholine, pyruvate, succinate, lactate 
and 3-hydroxybutyrate (3-HB) arise from the cells. Some peaks such as hypoxanthine 
or 3-HB were visible only after a few hours of running the experiment. The rest of the 
assigned peaks were the ingredients of the RPMI medium or their derivatives. 
Around 10 resonances were not assigned owing to the lack of corresponding signal 
assignments in existing metabolomics spectral libraries. Signals which were difficult 
to distinguish due to signal overlap were not assigned (with the exception of 
pyruvate). Some metabolites were pH sensitive (such as histidine), resulting in 
changing chemical shifts during the time course, as the extracellular pH was 
changing, which made them difficult to categorise. One of the unassigned peaks 
placed at 5.06 ppm was increasing over time in all the samples.  
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Figure 3. 1. 1D 1H NMR spectrum of CLL cells. 
Metabolites assigned: 1-formate, 2-hypoxanthine*, 3-histidine, 4-phenylalanine, 5-tyrosine, 
6-glucose, 7-trans-4-hydroxyl-L-proline, 8-uridine, 9-pyroglutamate, 10-serine, 11-myo-
inositol, 12-glycine, 13-phosphocholine, 14-choline, 15-lysine, 16-asparagine, 17-aspartate, 
18-methionine, 19-glutamine, 20-succinate, 21-pyruvate, 22-glutamate, 23-arginine, 24-
alanine, 25-lactate, 26-3-hydroxybutyrate, 27-ethanol, 28-valine, 29-isoleucine and 30-
leucine.  
 
* hypoxanthine was detectable after a few hours of the time course. 
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In order to confirm the assignment of the most abundant peaks, the agarose 
matrix and cells were removed by centrifugation, the pH of the medium was re-
adjusted to 7.0 and placed back in the NMR tube to acquire another 1D NOESY, 2D 
1H1H J-resolved (J-res) and 2D 1H13C HSQC spectrum (Figure 3.2). J-res spectra were 
analysed using automatic metabolic quantification – FIMA (Field Independent 
Metabolic Analysis) through the online service at http://www.bml-nmr.org/. The 
major advantage of using two-dimensional NMR spectra is the reduction of signals 
overlap due to the introduction of a second independent chemical shift axis. In J-res 
spectra reduction of overlap is achieved by the ability to create a proton decoupled 
1D spectrum, which has less overlap compared to a normal 1D proton spectrum.  
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3.2.2 Viability of CLL cells was not affected by the NMR experiment   
High cell viability was maintained during NMR measurements, as proven by 
flow cytometric Annexin V / Propidium Iodide analyses of cell death and apoptosis, 
and confirmed by cell morphology (Figure 3.3). The ability to recover viable cells 
after the time course experiment allowed cells to be used for parallel analyses such as 
Western Blotting and PCR. 
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Figure 3. 3. CLL cells can tolerate NMR analyses. 
A) Representative image of CLL cells before and after the NMR experiment, stained using 
Jenner-Giemsa stain and representative scatter plot for Annexin V/PI staining of CLL cells 
before and after NMR measurement. Lower left corner: healthy cells which are both 
propidium iodide and annexin V negative. B) Viability data for 10 primary CLL samples. 
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3.2.3 Changes can be seen in the intensity of metabolites  
NMR time course analyses showed changes of the intensity of some 
metabolites. The most profound increase was exhibited by lactate peaks (δ: 1.31; 1.324 
ppm) visible as an orange peak on the Figure 3.4 A. The most visible decrease of 
intensity was observed by the signals of glucose (the majority of peaks between 3.2-4 
ppm) clearly visible in the 2D spectrum in Figure 3.4 A. In order to investigate 
whether the changes seen were the result of the metabolism of CLL cells, a control 
time course was recorded on the sample containing RPMI medium and agarose only 
(Figure 3.4 B). Looking at both, the 3D projection and the overlaid first (red) and last 
(blue) spectra, it appeared that there were no changes in metabolite concentrations 
and the signals were stable over the 24 hours. Moreover, the lactate peak was not 
detected in the control sample. Results from control spectra recorded without cells 
confirmed that the observed changes in intensities arose from the metabolic activity 
of the CLL cells.  
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Figure 3. 4. Changes in the NMR spectrum are the result of metabolic activity of 
CLL cells. 
3D view of the NMR time course experiment. The sample contains A) 5x107 CLL cells/ml 
suspended in RPMI medium with ITS+ and 0.1% low melting agarose; B) control sample 
without CLL cells. The largest signal coloured orange corresponds to lactate which is 
increasing over time. Superimposed first (red) and last (blue) 1H spectra of the 24 hour 
time course show the most profound decrease for glucose in the CLL sample. 
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In order to find out if any of the metabolites observed arose from the 
intracellular environment the spectrum of medium with CLL cells in agarose was 
compared with spectrum of medium alone retrieved from the supernatant after 
spinning down the agarose and cells. Figure 3.5 shows that the superimposed spectra 
are overlapping, suggesting that all the metabolites seen in the sample with cells are 
largely extracellular. Slight differences between some peaks are the consequence of 
pH dependent shift. The fact that we were not able to see signals of metabolites 
inside cells may be due to the small volume of cells (3-5 μl) compared to the total 
sample volume (550 μl). Because the biomass is so small, we also do not see lipids 
which would not be secreted from cells in large amounts. 
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Figure 3. 5. Spectrum of CLL cells in medium with agarose overlaid with spectrum 
of medium alone. 
The black spectrum is the last spectrum of 1x107 CLL cells embedded in RPMI medium 
supplemented with 1% ITS+ and 0.1% low melting agarose. After acquiring the spectrum, 
sample was spun down so that pellet contained agarose and cells. Medium supernatant 
was transferred back to the NMR tube and spectrum (shown in teal colour) was 
obtained. The line width of the black spectrum was broadened for the better visibility. 
Fragment from 0.5- 3.5 ppm was enlarged and presented in the top rectangle. 
1H [ppm] 
Medium  
Medium + CLL cells 
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3.2.4 Changes of intensities of metabolite signals 
In order to distinguish between signals which changes intensity and those that 
are stable over time course of 24 hours, sections from spectra representing several 
metabolites were compared (Figure 3.6). Colours move from red to blue over the 
time course. Signals of metabolites that were consumed by cells (such as glucose or 
glutamine) decreased over time, while those of metabolites secreted by cells (such as 
lactate, alanine, glutamate, hypoxanthine and 3-hydroxybutyrate) increased. Some 
metabolites showed up or downfield changes in their chemical shift caused by pH 
changes (such as histidine, glutamine and arginine). To allow for scaling of the 
spectrum to its frequency as well as to its intensity, for the comparison of different 
samples, it was crucial that the internal reference compound - TMSP, stayed stable 
throughout time course experiments. The stability of TMSP peak was achieved by 
shimming between the acquisition of subsequent spectra of the time course. 
3.2.5 Apparently quiescent CLL cells show high metabolic activity 
Peripheral blood CLL cells are out of cell cycle (Messmer, Messmer et al. 2005), 
have relatively scant cytoplasms (see Fig 3.3.A), and are generally considered to be 
quiescent (Calissano, Damle et al. 2011). Cell cycle analysis confirmed that all CLL 
cells were in the G0 phase (Figure 3.7). Despite this, marked metabolic activity in 
these cells was observed, notably evidenced by increases in signals for lactate, 
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glutamate, alanine, 3-hydroxybutyrate and histidine (Figure 3.6) as well as 
consumption of glucose and glutamine. 
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Figure 3. 6. Representative peaks for chosen metabolites, changes over time. 
144 superimposed 
1
H spectra recorded over 24 hours. Spectra are colour coded for the 
time course: the first spectrum is red, and the last one is blue. The equation under each 
spectral section indicates which formula was used for fitting kinetics for experimental 
data points. The equation below the pyruvate could only be used for the first phase 
where the signal grows. A) Metabolites the intensity of which changed over time; B) 
Metabolites the intensity of which reminded stable during 24 hour experiment. Some of 
the signals which are pH sensitive are shifting to the left or right. TMSP - internal 
standard. 
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3.2.6 Metabolic changes were not affected by the stabilisation of 
extracellular pH  
As it would be expected, lactate production was associated with a progressive 
acidification of the medium. We used the chemical shift of histidine signals (Cohen, 
Motiei et al. 2004), which is a component of RPMI medium, to determine the in situ 
changes in pH during each acquisition. As shown in Figure 3.8, pH changed from 
~7.8 to 6.5 over a 24 h time course and displayed a pattern which correlated with the 
accumulation of lactate (Figure 3.8 B). In order to stabilise the pH, medium with 
additional HEPES buffer was used. Experiments performed using RPMI medium 
with 25 mM HEPES demonstrated that lactate production was unaffected by the 
stabilisation of the extracellular pH (Figure 3.8). RPMI medium with HEPES buffer 
was not used routinely as HEPES signals obscured a large part of the spectrum 
(Figure 3.9). 
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Figure 3. 9. Spectrum of RPMI with HEPES vs spectrum of standard RPMI. 
The green spectrum was recorded using 1x107 CLL cells in RPMI medium with 25 mM 
HEPES and the black one using 1x107 CLL cells in the standard RPMI medium. The 
intense multiple peaks around 2.9, 3.2 and 3.75 ppm correspond to protons of HEPES.  
 
 
 
 
 
 
 
           5                                         4                                         3                                         2                                         1                                          0 
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3.2.7 Primary CLL cells survive extreme hypoxia 
The external diameter of the glass tubes used for NMR analyses was 5 mm, 
with an inner diameter of approximately 4.2 mm, whereas the volume of the semi-
solid culture was 550 μl. This large ratio of volume to surface area, in combination 
with the previously unrecognised high metabolic activity of CLL cells, suggested that 
oxygen within the cultures would be rapidly depleted. In order to investigate 
changes of oxygen levels over time a fibre optic oxygen sensor was placed in the 
agarose matrix during the spectra acquisition (see Figure 3.10 A). Oxygen 
measurements were recorded every 10 minutes parallel to each 1D NMR spectrum. 
These measurements indeed confirmed that oxygen was progressively and rapidly 
depleted and that CLL cells experienced profound hypoxia for the majority of each 
24 hour exposure. The level of oxygen stabilised after reaching a value between 0.1-
0.8%. The rate of oxygen consumption was cell number dependent, indicating that it 
was driven by cellular consumption (Figure 3.10 B). In experiments using 5x107 
cells/ml, oxygen was consumed within ≈70 minutes (Figure 3.10 B).  
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Figure 3. 10.  Change of oxygen concentration over the time course experiment. 
A) Fibre optic oxygen probe immersed in the NMR tube with CLL cells. B) Oxygen 
consumption for the samples containing 10x106 cells/ml and 50x106 cells/ml. 
 
 
3.2.8 Kinetics of the metabolic changes 
Real-time measurements of metabolites over 24 hours showed that production 
of lactate was associated with glucose consumption, as expected (Figure 3.11). Some 
CLL samples consumed glucose more rapidly than others. Concordantly, the 
production of lactate showed the greatest correlation with those samples that 
consumed the most glucose. The production of alanine also mirrored the extent of 
glucose consumption and lactate production. Similarly, the consumption of 
glutamine reflected glucose consumption and lactate production. Overall these 
observations appear to indicate that CLL may be divided into tumours with higher 
and lower metabolic states (Figure 3.11.A). Interestingly all the CLL samples 
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exhibiting lower metabolic activity came from patients diagnosed with the A0 stage 
of the disease whereas the rest of the patients were at more advanced stage at the 
time of sampling (See Table 3.1). However, there were too few patients to draw any 
statistically relevant conclusion about correlations between CLL cellular behaviour 
and clinical or prognostic markers. 
Glutamate variably accumulated across all the samples with one sample 
displaying particularly marked accumulation. 3-Hydroxybutarate peaks were very 
close to the ethanol peaks (see Figure 3.6). In order to obtain the intensity values 
corresponding to 3-hydroxybutyrate only, the ethanol peak intensity values were 
subtracted from the overlapping peaks. Hypoxanthine, another increasing 
metabolite, was observed to be secreted only after a few hours of hypoxic conditions. 
Although the peak intensity was not very high, the increase was consistent for all the 
samples containing 5x107 cells/ml and for some samples containing 1x107 cells/ml. 
Other metabolites including lysine, arginine and valine were remarkably stable 
during the acquisition of spectra (Figure 3.11.B). Table 3.1 shows the patient 
characteristics for all of the primary CLL cell donors, compared in Figure 3.11. 
As some metabolites are represented by multiple peaks seen in different parts 
of spectrum, it was crucial to show that individual peaks of the same metabolite 
exhibit identical kinetics. Figure 3.12 presents an example of lactate and glucose 
representative peaks, together with fitted kinetics.     
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Table 3. 1. Clinical characteristics of CLL patients. 
CLL samples used to obtain data presented in Figure 3.11. Patients were attending the 
outpatient clinic at Birmingham Heartlands Hospital or Queen Elizabeth Hospital in 
Birmingham, UK. 
Patient Sex Age 
(Y) Stage 
Additional 
clinical  
features 
Leukocyte 
count 
CD19+ at the 
time of 
sampling 
[%] 
Length of 
time with 
disease 
Treatment 
when 
sampled 
Previous treatment 
1 M 85 C 
CD38 neg, 
Zap70 pos, 
Normal 
cytogenetics. 
 150 91 14y 3m Observation 
First treated with 
chlorambucil in 1998 
then in 2012.  
2 M 71 A0 CD38 neg 150 90 2y 11m Observation none 
3 M 58 A0 CD38 neg 58 74 1y 9m Observation None 
4 F 92  C 
ATM, p53 
WT. CD38 
unknown 
191 88 18y 2m Chlorambucil 24/9/02 then 04/07/08 
and 2012 
5 F 76 B ATM and p53 
WT - 170 85 6y 1m Observation 
None. Progressive 
on that date though 
with sweats, LN and 
high WCC. No 
cytopenia 
6 M 58 A CD38 neg 58 80 1y 9m Observation None 
7 F 77 A nil 76 89 8y 9m Observation 
None. Had eyelid 
swelling but RT 
given locally after 
this date. 
8 M 82 A0 nil 132 75 7y 9m Observation none 
9 M 65 A CD38 neg 147 59 2y 3m Observation none 
10 F 92 A0 CD38 neg 60 76 18y 2m Chlorambucil none 
11 M 83 A0 
Additional 1q 
on karyotype. 
ATM, p53 
WT 
177 92.5 6y 11m Observation 
Previous FC in 2009 
x 2 courses, BaP 
started week after 
this sample 
LN; lymph node, RT; Rituximab, FC; Fludarabine and Cyclophosphamide, WCC; white cell count, BaP; The 
redeployed drug combination of bezafibrate and medroxyprogesterone acetate (Murray, Khanim et al. 2010) 
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Figure 3. 13. Kinetics of different peaks corresponding to the same metabolite were 
similar. 
Data points and fitted kinetics for two lactate and glucose signals. Kinetic parameters (L- 
low field signal, H- high field signal) are similar. Lactate: low field signal at 1.324 ppm 
and high field signal at 1.310 ppm; Glucose: low field signal at 5.226 ppm and high field 
signal at 5.220 ppm. 
 
    Lactate                                                         Glucose                      
L: I(t) = 0.068357 – 0.74136 *e-0.044119*t 
H: I(t) = 0.067544 – 0.72497 *e-0.039716*t 
L: I(t) = 0.023*e-0.16*t + 0.08- 0.00062*t 
H: I(t) = 0.022*e-0.17*t + 0.08- 0.00063*t 
                     Low field signal      High field signal             Kinetics        
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3.3 DISCUSSION 
In order to measure changes in metabolism in living cells by NMR 
spectroscopy required to overcome two challenges. First, the NMR experiment 
needed to be designed in a way that does not affect the metabolism of cells. This is 
challenging for an experimental procedure, which is carried out away from the 
standard, sterile tissue culture conditions. Presented data confirm that CLL cells 
remained viable throughout a 24 h time course, and showed comparable viability to 
control cells incubated in the tissue culture incubator. Maintenance of cell viability 
allows to use cells for further analyses (here they were used for gene and protein 
expression assays). Secondly, to obtain good quality and informative NMR spectra 
two key requirements had to be fulfilled: a sufficiently high concentration of 
metabolites and good sample homogeneity. A lack of homogeneity causes broad 
lines in NMR spectra and therefore low spectral resolution. Broad lines would also be 
expected if the mobility was significantly reduced by embedding the sample in a gel 
matrix that significantly affects rotational diffusion of small molecules. Optimal 
spectra were obtained for 1-5x107 CLL cells/ml. While the concentration of cells does 
not directly affect metabolite concentrations, it does affect the rate of changes. 
Moreover, using the 0.1% low melting agarose matrix, with carefully suspended CLL 
cells yields good sample homogeneity over 24 h without causing any significant line 
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broadening. The low concentration of agarose gel does not disturb the free 
movements of metabolites in the suspension.  
Comparison of spectra obtained from samples containing cells and medium 
without cells indicated that the observed metabolic changes were solely caused by 
the metabolic activity of CLL cells. A high similarity between the last spectrum of a 
time course and the spectrum of medium after removing cells indicates that the 
observed signals represent metabolites present in the medium and not inside cells. 
This may be a consequence of the small proportion of cell biomass in comparison to 
the total sample volume. It is also possible that metabolite signals inside cells are too 
broad to be observed. The sensitivity obtained from this method was sufficient to 
investigate metabolic kinetics of 30 of the most abundant metabolites.  
The assignment of 30 metabolites was confirmed using 2D 1H-1H J-resolved 
(Ludwig and Viant 2010) and 13C-1H HSQC spectra. These spectra were recorded on 
medium obtained from the sample with CLL cells after the time course experiment. 
Because both J-res and HSQC libraries were acquired at 25°C and at pH=7.0, it is 
difficult to assign the spectra recorded with living cells as the pH changes during the 
experiment causing significant chemical shift changes. 
The observed metabolic changes indicate that CLL cells consume both glucose 
and glutamine and produce large amounts of lactate as well as alanine and 
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glutamate. The metabolism of these compounds will be investigated and discussed in 
the next chapters.  
Another metabolite secreted by CLL cells, 3-hydroxybutyrate represents a 
ketone body (together with acetone and aceto-acetate), an end product of fatty acid 
beta-oxidation. It allows the production of acetyl-CoA and provides a route whereby 
fatty acids can be utilised to provide energy via the TCA cycle. Ketone bodies can 
also be produced from excess acetyl-CoA which cannot be used by the citric acid 
cycle. This state is referred to as the fasted state in humans. Ketone bodies can also be 
produced from certain amino acids (leucine, isoleucine, lysine, phenylalanine, 
tyrosine and tryptophan). Ketone bodies have previously been reported to be 
implicated in carcinogenesis and can be seen as indicators of mitochondrial 
dysfunction (Kennaway, Buist et al. 1984; Robinson, McKay et al. 1985). Increased 
levels of 3-HB have been detected in the serum of patients with colorectal 
malignancy (Ludwig, Ward et al. 2009; Ma, Liu et al. 2009) as well as in patients with 
late stage head and neck cancer compared to early stage diseases (Tiziani, Lopes et al. 
2009). On the other hand, lower levels of 3-hydroxybutyrate have been found in the 
serum of patients with pancreatic cancer compared to healthy controls (OuYang, Xu 
et al. 2011). It has recently been shown that administration of 3-HB in a xenograft 
model of breast cancer increased tumour growth 2.5-fold, and has been suggested 
that this finding may explain the increased incidence of cancer in diabetic patients, 
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due to increased ketone production (Bonuccelli, Tsirigos et al. 2010). Moreover 3-HB 
has been shown to act as a chemo-attractant, stimulating the migration of epithelial 
cancer cells (Bonuccelli, Tsirigos et al. 2010). It has been suggested that 3-HB detected 
in patient serum/plasma, or homogenates of fresh tumour tissue, might be useful as a 
marker to identify high-risk cancer patients at diagnosis, for treatment stratification 
and/or for evaluating therapeutic efficacy during anticancer therapy (Pavlides, 
Tsirigos et al. 2010). Elevated levels of ketone bodies in plasma can also be a result of 
accelerated catabolism of fatty acids (Laffel 1999), therefore 3-HB may be seen in 
samples of CLL cells, both as a product of starvation and as a fuel for the growth of 
the cancer. 
Another increasing metabolite detected during time course experiments was 
the purine derivative hypoxanthine. Purine nucleotides are essential components of 
any cell, not only as the raw material for the synthesis of DNA but also being vital 
cofactors for many enzymatic reactions responsible for cell proliferation. Purine 
biosynthesis proceeds along two known routes. These include de novo synthesis and 
recycling of endogenous or exogenous purines through a salvage pathway.  
The de novo pathway for purine nucleotide synthesis leads to the formation of 
inosine 5’-monophosphate (IMP) in ten metabolic steps and requires hydrolysis of 
ATP to drive several reactions along this pathway.  
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The salvage pathway involves the housekeeping protein hypoxanthine-
guanine phosphoribosyl transferase (Hx-PRTase) which catalyses the addition of 
phosphoribosyl pyrophosphate to guanine or hypoxanthine to form guanosine 
monophosphate and inosine monophate respectively. In the absence of this pathway, 
hypoxanthine would proceed to form the waste product uric acid, through the 
formation of xanthine (Harrison 2002).  
The salvage pathways are used to recover bases and nucleosides that are 
formed during degradation of RNA and DNA, offsetting the potential waste into a 
vital resource. Purine salvage enables ingested purines or those synthesised in one 
tissue to be available to other tissues (Murray 1971). Given its importance, it is not 
surprising that the purine salvage pathway has been implicated in human cancer 
development (Sanfilippo, Camici et al. 1994). In order to cope with rapid cell 
replication, tumour cells use the more efficient purine salvage pathway for energy 
production and nucleic acid synthesis (Ong, Zou et al. 2010).  
An increased level of hypoxanthine in plasma and a reduced level in urine has 
been previously demonstrated in patients with gastric and colonic carcinomas 
(Vannoni, Porcelli et al. 1989). In plasma from children with acute lymphoblastic 
leukaemia or non- Hodgkin lymphoma, hypoxanthine levels have been reported to 
be higher than in healthy controls and these levels decreased after methotrexate 
administration (Hashimoto, Kubota et al. 1992). An increased level of hypoxanthine 
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in the urine has been noticed in mesothelioma transplanted nude mice. Moreover, 
the level of this metabolite was reduced in response to chemotherapy (Buhl, 
Dragsholt et al. 1985). On the other hand, a reduced level of urinary hypoxanthine 
was reported by Yoo et al. in patients with non-Hodgkin lymphoma. They reasoned 
that the level of hypoxanthine might be decreased due to consumption by tumour 
cells (Yoo, Kong et al. 2010). To my knowledge the hypoxanthine levels have never 
been reported in Chronic Lymphocytic Leukaemia, however an indication of an 
imbalance in purine metabolism in CLL has been published (Carlucci, Rosi et al. 
1997). There it was shown that enzymes of the salvage pathway, including 
hypoxanthine-guanine phosphoribosyltransferase-HGPRT were greatly reduced in 
lymphocytes from leukaemia patients.  
Beside the observation that primary CLL cells used in presented study 
produced hypoxanthine, especially in hypoxia, this phenomenon was not further 
investigated. Nevertheless, as there is not a lot of recent literature about 
hypoxanthine in leukaemic cells, it would be interesting to further investigate this 
abnormality, and to compare it with hypoxanthine levels in healthy B-cells.  
All of the metabolites detected in samples containing primary CLL cells are 
presented in Figure 3.13 in the form of a metabolic map. 
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Figure 3. 14. Metabolic map presenting all of the metabolites assigned in the 1H 
NOESY spectra recorded on samples with primary CLL cells. 
Metabolites presented on this map are part of the formulation of RPMI medium except 
for: lactate, pyruvate, β-hydroxybutyrate, hypoxanthine, pyroglutamate, formate, 
succinate, uridine, 2-oxobutanoate, choline and phosphocholine. 
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After the time course, it was observed that the medium changed colour to 
yellow which indicates the acidification of pH. Histidine-based pH analysis, showed 
that extracellular pH changed from ~7.8 to 6.5, with slight variations between 
different CLL samples. As the pH changes strongly correlated with lactate 
production, it indicates that lactate was the main contributor to the acidification of 
pH. Time courses performed using RPMI with extra HEPES buffer, showed that 
controlling the extracellular pH did not affect the metabolic changes of glucose 
consumption and lactate production. It has been reported that the acidification of 
intracellular pH may drive the metabolic switch from aerobic glycolysis to oxidative 
phosphorylation, however evidence indicates that tumour cells prevent cytosolic 
acidification by activating a number of transporters that export excess protons 
produced during glycolysis (Huber, De Milito et al. 2010). This active proton 
transport across the cellular membrane suggests that the intracellular pH is 
controlled and not affected by the extracellular pH changes. It has been shown that 
tumour cells have alkaline intracellular pH values (7.12–7.65 compared with 6.99–
7.20 in normal tissues) and acidic interstitial extracellular pH values (6.2–6.9 
compared with 7.3–7.4) (Gillies, Raghunand et al. 2002; Cardone, Casavola et al. 
2005). This indicates that the pH values in the NMR tube represent the natural 
tumour microenvironment conditions. The crucial role of intracellular pH for cancer 
cells is supported by the fact that the inhibition of H+ transporters has been proposed 
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as an attractive anticancer strategy that could potentially be used in a wide range of 
cancer types (Harguindey, Arranz et al. 2009) . 
Another important component of the microenvironment of cells is oxygen. 
Using the NMR based method for monitoring metabolism, determination of the 
oxygen level and regulation of its consumption rate was possible, however it was not 
feasible to keep the percentage stable during data acquisition. The aim of our study 
was to investigate metabolic changes during the transition of CLL cells from 
normoxic to hypoxic conditions, therefore stabilisation of the oxygen on the set level 
was not required. Use of the fibre optic oxygen sensor, which fitted inside the narrow 
NMR tube allowed us to monitor oxygen consumption very precisely. In order to 
slow down the rate of oxygen depletion and prolong the normoxic period, lower 
concentrations of CLL cells (1x107/ml) were used. This allowed very accurate 
identification of the time of the transition to hypoxia and to correlate it with the 
corresponding NMR spectra. The following chapters will present data obtained using 
our method together with other biochemical methods, used to better understand the 
adaptation of CLL cells to different oxygen environments. 
Importantly, real-time NMR time-courses of glucose, lactate, alanine, 
glutamate and glutamine (Figure 3.11.A) revealed potential metabolic subtypes 
amongst the CLLs. In A0 CLL samples, the least aggressive subtype of CLL 
associated with lymphocytosis but no lymphadenopathy, glucose consumption was 
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low, glutamine consumption was equally low, and lactate/alanine as well as 
glutamate production showed also decreased metabolic activity. For one patient 
sample we observed exceedingly high glutamate production. Although not the aim 
of the study, these data suggest that metabolic subtypes exist which may correlate 
with clinical phenotype and may provide information regarding biomarkers. 
However patient numbers are still too small in this study to demonstrate this 
unequivocally. 
Another metabolomics study conducted with CLL patient-derived samples 
was presented by MacIntyre et al. They compared metabolic profiles of serum from 
untreated CLL patients (Binet stage A) and healthy controls (MacIntyre, Jimenez et 
al. 2010). The main differences showed elevated levels of pyruvate and glutamate in 
the CLL samples. MacIntyre et al. did not investigate more advanced stages of CLL 
therefore it would be difficult to compare their results to data presented in this thesis, 
however the common increase of glutamate production by CLL cells can be observed 
for both studies. Additionally MacIntyre et al. have compared serum of patients with 
or without Immunoglobulin variable region heavy chain (IgVH) mutation. They 
observed decreased levels of cholesterol derived from VLDL, lactate, uridine as well 
as increased glycerol, 3-hydroxybutyrate and methionine in serum from patients 
with IgVH mutation, associated with poor prognosis. 
In our study comparisons of the metabolic profiles of 11 primary CLL samples 
allowed us to distinguish two groups of cells with higher or lower metabolic activity. 
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Interestingly, all of the patients exhibiting the slower rates were characterised in the 
A0 stage of the disease (see Table 3.1). The stage A0 is often described as the ‚watch 
and wait‛ stage, in which patients do not receive any treatment, however remain 
under observation. More advanced stages, starting from A1 indicate progression of 
the disease. Therefore although the number of compared CLL samples was only 
small, the correlation between the stage of the disease and the metabolic activity was 
observed, suggesting the potential of this method in diagnostics or investigations of 
clinical and prognostic markers. A clinical test could involve short term kinetic 
analysis, possibly taking a series of time points for 2 metabolites in the growth 
medium, to characterise the ‘stage’ in which the cancer cells exist. 
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4.1. INTRODUCTION 
Metastatic cancer leads to the majority of cancer deaths, creates profound 
economic burden and remains poorly understood (Bocker 2002; Weigelt, Peterse et 
al. 2005; Mehlen and Puisieux 2006). It remains to be determined how metastatic 
cancer cells, having become adapted to the hypoxic tumour environment, survive 
transit in the peripheral normoxic circulation and then re-populate and survive in, de 
novo hypoxic sites. A major challenge in the study of these processes in most cancers 
is the rarity and transient nature of metastatic cells. In order to successfully analyse 
their metabolism, it would be necessary to experimentally isolate the migratory cells.  
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia 
in Western countries (D'Arena, Di Renzo et al. 2003; Chiorazzi, Rai et al. 2005; Parker 
and Strout 2011) and despite recent improvements in prolonging survival, remains 
incurable (Chiorazzi, Rai et al. 2005; Hayden, Pratt et al. 2012). CLL patients present 
elevated lymphocyte counts in the peripheral blood. In most cases these lymphocyte 
numbers increase progressively over months and years. However, these cancer cells 
are out of the cell cycle and superficially highly quiescent (Dameshek 1967). Despite 
this, isotopic labelling studies have determined that peripheral blood CLL cells 
include those that have undergone a number of divisions and also that rates of cell 
death within the tumour are high (Messmer, Messmer et al. 2005). The picture that 
emerges is that circulating CLL cells represent a large pool of non-dividing cancer 
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cells that are able to enter and exit tissue sites, predominantly lymph nodes, spleen 
and bone marrow, wherein they proliferate and drive the progressive expansion of 
the tumour (Messmer, Messmer et al. 2005; Calissano, Damle et al. 2011). The 
microenvironments of the lymph nodes, spleen and bone marrow differ from that of 
the blood, and entry into tissue sites provides important survival signals that protect 
against chemotherapeutics and thus lead to relapsed disease (Burger 2011). 
Moreover, tissues where CLL cells have their proliferation centres are often hypoxic 
(Star-Lack, Adalsteinsson et al. 2000; Sison and Brown 2011) with a pH much less 
controlled than in the blood. Accordingly, CLL cells must be able to quickly alter 
their metabolism to adapt to these different conditions. Therefore, understanding 
how peripheral blood CLL cells can survive transitions between normoxia and 
hypoxia is likely to identify novel strategies to tackle this disease.  
Figure 1.4 presents a model of the lifecycle of CLL B cells including their 
migration between tissues and the factors regulating it. CLL is an unusual cancer 
where a large proportion of cells within the tumour exhibit metastatic capacity, 
therefore the study of its metabolic adaptations permits the potential discovery of 
mechanisms applicable to cancers in general. Currently however, very few studies 
have been conducted to investigate the potential of cell metabolism as a therapeutic 
target in CLL (Tura, Cavo et al. 1984; Samudio, Fiegl et al. 2008; MacIntyre, Jimenez 
et al. 2010). CLL cells were shown to survive considerably longer in circulation than 
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normal B cells (Defoiche, Debacq et al. 2008). This increases their chances of re-entry 
into solid tissues where they receive proliferation stimuli, enhancing their survival. 
Both apoptosis resistance mechanisms and metabolic adaptations that increase cell 
viability are likely to be responsible for the prolonged lifespan of CLL cells in the 
circulation. 
One of the metabolic adaptations could be the increased expression of HIF-1α 
which may maintain CLL cells in a quiescent state through the inhibition of the 
mammalian target of rapamycin (mTOR) (Cam, Easton et al. 2010; Forristal, Winkler 
et al. 2013). HIF-1α is known as the main factor responsible for adaptation of various 
cells to low oxygen conditions. It was reported that CLL B cells express constitutive 
levels of HIF-1α under normoxia as a result of the low level of the von Hippel-
Lindau gene product (pVHL) required for HIF-1α degradation (Ghosh, Shanafelt et 
al. 2009). Figure 1.2 shows the regulation of the HIF-1α degradation mechanism, as 
well as a possible effect on the quiescence of CLL cells via inhibition of the mTOR 
pathway. In this chapter, investigations into the role of HIF-1α in the plasticity of 
CLL cells and metabolic adaptation to transition between different oxygen 
environments are presented.  
Using a novel nuclear magnetic resonance spectroscopy (NMR) based method 
to monitor real time metabolism in living primary CLL cells described in the 
previous chapter, rapid changes of metabolism over extended periods of time were 
Chapter Four – Metabolic plasticity of CLL cells 
140 
 
detected. Using this system, changes in CLL cell metabolism in response to 
oxygenation levels were studied. This chapter presents observations of a remarkable 
plasticity of metabolic adaptations displayed by ‘quiescent’ CLL cells. 
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4.2 RESULTS 
4.2.1 Primary CLL cells adapt their metabolism to hypoxic conditions 
Western blot analyses were performed in order to investigate changes in levels 
of key proteins during the transition from normoxia to hypoxia. Consistent with the 
oxygen consumption and depletion during the NMR time course experiment 
(described in Chapter Three), western blot analysis of CLL cells incubated in the 
agarose matrix in the NMR tube for different time periods, showed that levels of 
stabilised HIF-1α rose after one hour (Figure 4.1) and increased further over the 
following 4 hours. The time at which hypoxia was detected varied slightly between 
samples but it consistently correlated with the HIF-1α increase.  
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Figure 4. 1. HIF-1α level increases immediately after CLL cells reach hypoxia. 
A) Oxygen measurement carried out during the NMR time course experiment, inside the 
NMR tube with 5x107cells/ml. Readings were taken every 10 minutes. After 70 minutes 
the oxygen level reached 0.2% and stabilised. B) Level of HIF-1α increase after the 
oxygen depletion. Cells were incubated in the agarose matrix in the NMR tube, at 36°C 
and the Laemmli buffer was used after different time points in order to lyse cells. 
Western blot was performed using the anti HIF-1α antibodies.  
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PCR analysis showed that selected HIF-1α target genes were expressed in CLL 
cells in both oxygenated and hypoxic conditions but their levels were elevated in 
hypoxia (Figure 4.2.A). In order to confirm that HIF-1α was responsible for the 
expression of the genes of interest, a commonly used inhibitor of HIF-1α 
transcriptional activity – chetomin (CTM) was used. CTM binds to HIF-1α 
transcriptional co-activator p300, disrupting its interaction with HIF-1α and 
attenuating hypoxia-inducible transcription (see Figure 1.2). A range of CTM 
concentrations were used in order to determine the dose inhibiting the expression of 
the chosen HIF-1α target genes. The expression of the glucose transporter GLUT1 
and lactate dehydrogenase A (LDHA) in oxygenated conditions was sensitive to 
chetomin, whereas the expression of vascular endothelial growth factor (VEGF) was 
not affected (Figure 4.2.C). High levels of VEGF in CLL cells in normoxia have 
previously been reported (Frater, Kay et al. 2008). However, in hypoxia, the elevated 
expression of all three genes (including VEGF) was sensitive to inhibition by CTM 
(Figure 4.2.D). This was confirmed by reduced protein levels of all three HIF-1α 
targets after 24 hour treatment with 100 nM CTM (Figure 4.2.B). Surprisingly, levels 
of HIF-1α target proteins detected by western blot were similar in normoxia and 
hypoxia (Figure 4.2.B). 
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Figure 4. 2. Level of HIF-1α increases in hypoxia together with the expression of its 
target genes, which can be blocked by chetomin. 
A) Real-time PCR analysis of VEGF, GLUT1 and LDHA expression in CLL cells 
incubated in normoxia or hypoxia (in the NMR tube) for 24 hours. Values are normalised 
to the normoxia control =1. Data are mean ± SEM n=4; *p < 0.05 by student’s t-test for 
paired data. B) Western blot analysis of levels of VEGF, GLUT1 and LDHA in cells 
treated with CTM in normoxia or hypoxia.  Cells were pre-treated with CTM 3 hours 
before placing in hypoxia, images are representative of 3 experiments. C&D) Real-time 
PCR analysis of VEGF, GLUT1 and LDHA expression in CLL cells incubated for 24 
hours in normoxia (C) or hypoxia (D) with or without chetomin (CTM). Cells were pre-
treated with CTM 3 hours before placing in hypoxia. Values are normalised to the 
normoxia control without CTM =1. Data are mean ± SEM n=3. Note that the scales of the 
Y axis in C&D are dissimilar reflecting the induced expression of genes in hypoxia. 
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4.2.2 HIF-1α shows hypoxia-inducible nuclear import 
In order to verify the presence of HIF-1α in normoxic and hypoxic CLL cells, 
primary CLL cells were immuno-stained using HRP and fluorescent antibodies 
(Figures 4.3-4.5). HIF-1α was detected in both oxygenated and hypoxic CLL cells, a 
finding consistent with previous reports of HIF-1α activity in circulating CLL cells 
despite the normoxic environment of peripheral blood (Ghosh, Shanafelt et al. 2009). 
HRP staining demonstrated that although HIF-1α was detected in both oxygenated 
and hypoxic conditions, there was a difference in the localisation as well as in the 
strength of the HIF-1α signal (Figure 4.3). In cells incubated in normoxia, HIF-1α was 
detected only in the scant cytoplasm, while in cells incubated for 6 hours in 0.1% O2, 
the staining signal was more intense and localised in the nucleus for the majority of 
cells. Confocal microscopy images (Figures 4.4 and 4.5) show the same phenomenon. 
It has been reported that only a small proportion of CLL cells incubated in normoxia 
showed detectable levels of HIF-1α localised in the cytoplasm, while hypoxic cells 
exhibited elevated levels of HIF-1α in the nucleus stained by DAPI and the B-cell-
specific nuclear transcription factor PAX-5 (Desouki, Post et al. 2010). HIF-1α 
hypoxia-inducible nuclear import has previously been reported in a range of cell 
types, for example COS7 and Caco-2 cells but not in CLL cells (Kallio, Okamoto et al. 
1998; Huang, Kuo et al. 2013).  
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Figure 4. 4. HIF-1α is present at a low level in the cytoplasm of normoxic CLL cells. 
Normoxic CLL cells cytospins stained with anti HIF-1α antibody (red), anti PAX-5 (blue) 
and DAPI (white). A) Isotype control for rabbit (red) and goat (blue) IgG. B) HIF-1α 
staining. C) DAPI staining. D) PAX-5 staining of B-cells. E) Merged HIF-1α and PAX-5. 
F) Merged nuclei, HIF-1α and PAX-5. 
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Figure 4. 5. HIF-1α is present in the nuclei of hypoxic CLL cells. 
Cytospins of CLL cells incubated for 6 hours in 0.1% O2 stained with anti HIF-1α 
antibody (red), anti PAX-5 (blue) and DAPI (white). A) Isotype control for rabbit (red) 
and goat (blue) IgG. B) HIF-1α staining. C) DAPI staining. D) PAX-5 staining of B-cells. 
E) Merged HIF-1α and PAX-5. F) Merged nuclei, HIF-1α and PAX-5. 
 
 
 
 
A B C 
D E F 
Chapter Four – Metabolic plasticity of CLL cells 
149 
 
4.2.3 Primary CLL cells exhibit reversible metabolic plasticity during 
the transition between different oxygen environments 
The observations described previously (Chapter 3) identified that CLL cells 
can rapidly adapt to an environment of depleted oxygen by applying coordinated 
changes in metabolism and activation of HIF-1α. In vivo, CLL cells cycle from 
hypoxic and normoxic tissue compartments (see Figure 1.3), thus if the changes 
observed in our experiments are physiologically relevant it would be expected that 
they are plastic and reversible. To test this hypothesis CLL cells were cultured under 
conventional conditions containing abundant oxygen, transferred to hypoxic 
conditions for 24 hours (cycle 1), and retuned to high oxygen conditions for a further 
24 hours before NMR analysis of a second transition to hypoxia (cycle 2) (Figure 4.6 
and 4.7). The viability of cells was unaffected after the second cycle of transition from 
oxygenated conditions to hypoxia (Figure 4.6 B). As shown in Figure 4.7 and in Table 
4.1, the kinetics of glucose and glutamine consumption, as well as lactate, glutamate 
and alanine production during a primary or secondary exposure to normoxia, were 
comparable. Moreover, oxygen was consumed at a similar rate, suggesting that 
mitochondrial functions were not affected by severe hypoxia or by re-oxygenation. 
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Figure 4. 6. Viability of CLL cells is not affected by extreme changes in oxygen 
levels. 
A) Scheme of the experiment performed. Primary CLL cells were isolated from 
peripheral blood and incubated for 24 hours in normoxia. Then the sample was split into 
two parts. One was analysed by NMR for 24 hours in hypoxia, the second was incubated 
for 24 hours in hypoxia, then for another 24 hours in normoxia and finally analysed by 
NMR in hypoxia for a further 24 hours. The first sample was cycled between normoxia 
and hypoxia once, while the second sample was cycled twice. B) Viability data for 5 
primary CLL samples. Percentage of Annexin V negative cells were compared between 
cells which had undergone one or two hypoxic cycles.  
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Table 4. 1. Kinetics of metabolic changes in CLL cells measured by the NMR 
during two normoxia-hypoxia cycles.  
Using the time series analysis user interface (TSATool) in the MetaboLab program, the 
kinetic functions were applied to fit the data in order to describe the changes in 
metabolite concentrations. For lactate, alanine, glutamate and 3-hydroxybutyrate we 
assumed first order kinetics according to: I(t)=I0-I1*e-rt where I(t) is the current metabolite 
concentration at time point t, I0 the theoretical metabolite concentration at infinite time, I0 
- I1 the concentration at time point 0 and r the rate of change; for lactate before hypoxia 
I0*(1-exp(-r*t)) kinetics were applied as the concentration at time point 0 was close to 0; 
for glucose and glutamine the assumed kinetics was a bi-exponential decay to: I(t)=I0*e-rt 
+I1-r1t where again I(t) is the metabolite concentration at the current time point t, I0 + I1 is 
the starting concentration and r and r1 are the rate constants describing the glucose 
usage. For hypoxanthine the x=a+r*t function was used to approximate the linear part of 
a mono-exponential kinetics like the one assumed for lactate. r again represents the rate 
constant. 
 
Metabolite 
First cycle Second cycle 
I
0
 I
1
 r r2 I0 I1 r r2 
Lactate (before 
hypoxia) 0.079  0.046  0.062  0.051  
Lactate (in 
hypoxia)   3.971  4.325 0.0451  3.072 3.42 0.065  
Glucose 0.136 0.507 0.287 0.005 0.123 0.468 0.303 0.005 
Glutamine  0.071 0.092 0.517 0.0009 0.0332 0.095 0.825 0.0009 
Alanine  0.0758 0.058 0.088  0.07 0.058 0.118  
Glutamate 0.058 0.043 0.209  0.038 0.019 0.2  
Pyruvate 0.069 0.052 0.37  0.056 0.037 0.437  
3-Hydroxy 
butyrate 0.028 0.02 0.07  0.025 0.021 0.094  
Hypoxanthine 0.0004  0.038  0.0004  0.049  
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4.2.4 HIF-1α inhibition reverses changes in metabolism associated 
with hypoxia. 
Key metabolites displayed bi-phasic kinetics as oxygen became depleted, with 
rate changes being tightly associated with the transition to hypoxia (Figure 4.8). 
These included increased accumulation of lactate and an accompanied accelerated 
consumption of glucose consistent with a transition to elevated anaerobic glycolysis. 
This indicates that CLL cells display adaptive metabolic alternations depending on 
oxygen availability. There was also a marked onset of alanine synthesis upon entry 
into hypoxia (Figure 4.8), suggesting hypoxia induced alanine aminotransferase 
activity. These tight associations of coordinated metabolic-rate shifts with the onset 
of severe hypoxia (0.8-0.1% O2) required investigation of their dependence on HIF-
1α.  Two concentrations of chetomin 20 nM and 100 nM (which have been shown to 
decrease the expression of the chosen HIF-1α target genes in hypoxia (Figure 4.2)) 
were tested showing a dose dependent effect of metabolic adaptations to hypoxia in 
CLL cells. Enhanced glutamine consumption was detected following CTM treatment 
and the consumption of glucose was attenuated as a result of HIF-1α inhibition. 
Thus, although HIF-1α activity promoted anaerobic glycolysis in hypoxia and the 
consumption of glucose, it acted to suppress overall utilisation of glutamine. After 
CTM treatment, glutamine uptake may compensate for the blocked HIF-1α 
dependent glycolysis pathway. 
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Figure 4. 8. Metabolic adaptation of CLL cells to hypoxia involves HIF-1α. 
NMR time course data for the control CLL experiment and cells treated with 20 nM and 
100 nM chetomin (CTM). Cells were pre-treated with CTM for 3 hours before starting the 
NMR experiment. Graphs present changes of chosen metabolites over time: Lactate, 
Glucose, Glutamate, Glutamine and Alanine. The broken blue line on the lactate graph 
shows the oxygen changes inside the NMR tube. The top left corner depicts an enlarged 
representation of the first 6 hour portion with the visible shift of lactate kinetics after 
oxygen depletion, which is inhibited by CTM.  
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4.2.5 HIF-1α inhibition by chetomin is toxic to CLL cells regardless of 
the oxygen level 
The next goal was to determine whether CTM caused preferential killing of 
CLL cells in hypoxia. However, exposure of CLL cells to CTM for 48 hours induced 
cell death in the presence and absence of hypoxia (Figure 4.9.A). CTM inhibits the 
formation of functional HIF-1α/HIF-1β/p300 (CBP) transcriptional complexes by 
acting upon the p300 coactivator (Cook, Hilton et al. 2009). The actions of p300 as a 
coactivator are not restricted to HIF signalling and other targets in CLL include the 
NFκB pathway (Pekarsky, Palamarchuk et al. 2008). It is therefore likely that cell 
death induced by CTM exposure relates to this or some other non-HIF function of 
p300 that is constant between normoxia and hypoxia. 
Nonetheless, the CTM data described, suggests that at least in the first 24 
hours of exposure to hypoxia, activation of HIF signalling was not required for 
survival. Although the reason for this is unclear, it is notable that at a protein level, 
equivalent amounts of HIF-targets GLUT1, LDHA and VEGF were expressed in cells 
prior to and after 24 hours exposure to hypoxia; perhaps indicating that circulating 
CLL cells are primed to survive the immediate transition to hypoxia (Figure 4.2.B).    
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Figure 4. 9. HIF-1α inhibition by chetomin is toxic to CLL cells in both normoxia 
and hypoxia. 
A) Viability of CLL cells after 48 hours of incubation with CTM in normoxia and 
hypoxia. Cells were pre-treated with CTM for 3 hours before entering hypoxia. Data are 
mean of n=4 ± SEM; *p < 0.05 by student’s t-test for paired data. The CTM killing curves 
for both 24 and 48h are shown in Appendix 3. B) Effect of CTM on the metabolism of 
CLL cells based on the NMR time course data. Lower glucose consumption, decreased 
lactate and alanine secretion, increased glutamine uptake and increased glutamate 
secretion, which may be a result of higher intracellular glutamate accumulation was 
seen. Decreased alanine extraction and increased glutamate accumulation may indicate 
the lower activity of alanine aminotransferase (ALAT).  
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4.2.6 Alanine aminotransferase is not involved in the mechanism of 
hypoxic adaptation. 
Time course NMR data, recorded on CLL cells treated with chetomin showed 
decreased alanine secretion correlated with higher glutamate export. The only 
enzyme using alanine and glutamate as its substrates is alanine aminotransferase – 
ALAT (a diagram of these reactions is shown in Figure 4.10.A). A possible hypothesis 
for the observed changes is the loss of ALAT activity. In order to test this, two ALAT 
inhibitors, cycloserine and β-chloro-l-alanine, were used to investigate how they 
affect the metabolism of CLL cells. NMR analysis of CLL cell culture media after 24 
hour treatment with ALAT inhibitors showed that both compounds were able to 
inhibit alanine production at concentrations as low as 10 μM (Figure 4.10.B). 
Interestingly, the concentration of extracellular glutamate was unaffected by the 
blocked ALAT transformation of glutamate to α-ketoglutarate. This may be 
explained by the high complexity of glutamate metabolism compared to that of 
alanine, as the latter has only one precursor - pyruvate. An example of the 
complexity of glutamate metabolism is the alternative reaction that converts 
glutamate to α-KG, catalysed by aspartate aminotransferase (AST). One possibility is 
that the production of glutamate as an end product of the TCA cycle exceeds the 
conversion of pyruvate to alanine, with concurrent conversion of glutamate to α-KG. 
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Alternatively it is also feasible that the process of glutaminolysis is blocked, leaving 
larger amounts of glutamate unprocessed. 
Beside the previously described differences in metabolite levels in CLL cell 
medium incubated in normoxia/hypoxia, no additional significant changes were 
observed after treatment with ALAT inhibitors (Figure 4.10.B). However, pyruvate 
showed slight (statistically insignificant) increases in hypoxia consistent across all 
samples, which may be a consequence of the reduced transformation of pyruvate to 
alanine. The reduced (statistically insignificant) accumulation of pyruvate in 
normoxia may be explained by the utilisation of pyruvate in the TCA cycle, a process 
which is blocked by HIF-1α in hypoxia. Neither cycloserine nor β-chloro-l-alanine at 
low and high doses affected the viability of cells either in normoxia or in hypoxia 
over 48 hours (Figure 4.11). In addition, supplementation with cell membrane 
permeable octyl-α-ketoglutaric acid did not have a significant effect on the viability 
of CLL cells with inhibited ALAT metabolism (Figure 4.12). These observations 
combined suggest that alanine aminotransferase was not the essential enzyme for 
CLL cell survival and/or adaptation to hypoxia. It is possible that CLL cells can 
retrieve required alanine from the degradation of proteins or peptides.  
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Figure 4. 10. Alanine aminotransferase (ALAT) inhibition in CLL cells. 
A) ALAT catalyses the transfer of an amino group from L-alanine to α-ketoglutarate, the 
products of this reversible transamination reaction being pyruvate and L-glutamate. B) 
The ALAT inhibitors cycloserine (cyclo) and β-chloro-l-alanine (b-chloro), were used at 
two concentrations - 10 μM and 250 μM. Cells were incubated with inhibitors for 24 
hours in normoxia and hypoxia. The concentration of metabolites in medium was 
subsequently measured using 1H NMR. Selected metabolites are presented. Values are 
normalised to the normoxia control =1. Data are mean of n=3 ± SEM. Data were analysed 
by student’s t-test for paired data and no significant difference was obtained for any 
metabolite for any treatment compared to control cells. 
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Figure 4. 12. Membrane permeable αKG did not affect ALAT inhibition. 
Cells were incubated with ALAT inhibitors +/- octyl-α-ketoglutaric acid (aKG) for 24 
hours in normoxia and hypoxia, then the concentration of metabolites in medium was 
measured using 1H NMR. 10 μM ALAT inhibitors were used: cycloserine (cyclo) and β-
chloro-l-alanine (b-chloro). Values are normalised to the normoxia control =1. Data are 
mean of n=3 ± SEM. 
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4.3 DISCUSSION 
The influence of the microenvironment on CLL cells is important, particularly 
in the context of apoptotic resistance and induction of cell proliferation. Many recent 
studies have been focused on the interactions of CLL cells with supportive cells such 
as bone marrow stromal cells and endothelial cells, as well as transgenic fibroblasts 
expressing CD40 ligand (CD40L) which in vivo, is delivered by T helper cells and 
stimulates CLL cell proliferation. In order to replicate cytokines secreted by T cells, 
soluble factors such as IL-21 and IL-4 have also been added to co-culture systems to 
replicate the in vivo microenvironment of CLL cells (Ghia, Circosta et al. 2005; 
Ahearne, Willimott et al. 2013). This allows for the induction of cell activation, 
division and enhanced survival of cells. The present study on the other hand, focuses 
on the physical cues of the cellular microenvironment - oxygen and extracellular pH- 
which play roles just as important as biological factors in the regulation of cellular 
responses and metabolism. 
The effect of hypoxia in cancer cell metabolism has been widely investigated 
in the last decade, however the vast majority of studies have been conducted on solid 
tumours. Adaptations of cancer cells to low oxygen environments have been shown 
to be responsible for anti-drug resistance as well as defence against ionising 
radiation-induced DNA damage (Wachsberger, Burd et al. 2003; Adamski, Price et al. 
2013). Moreover, hypoxic tumour cells promote tumour progression and metastasis 
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through a variety of direct and indirect mechanisms. It has also been shown that 
patients with primary tumours that contain high proportions of hypoxic cells have 
decreased disease-free and overall survival rates after surgical resection of the 
primary tumour (Fyles, Milosevic et al. 2002; Vergis, Corbishley et al. 2008). Until 
recently there had been little interest in the investigation of the effect of hypoxia on 
leukaemic cells. This study postulates that CLL can potentially constitute a model for 
the metabolic studies of other metastatic cancers.    
It has previously been reported that CLL cells express HIF-1α in normoxic 
conditions (Ghosh, Shanafelt et al. 2009) and the importance of its target gene VEGF 
has been investigated. An increase in microvessel density was observed in CLL bone 
marrows and lymph nodes, suggesting the increased tissue site angiogenesis in CLL 
(Chen, Treweeke et al. 2000; Kini, Kay et al. 2000) and VEGF has been shown to be 
elevated in serum and urine of some CLL patients (Menzel, Rahman et al. 1996; 
Molica, Vitelli et al. 1999; Aguayo, O'Brien et al. 2000). Moreover, upregulation of 
mRNA encoding VEGF and its receptors (Kay, Jelinek et al. 2001) suggest that 
angiogenic factors are important in the biology of the malignant B-cell clone. The 
present study showed an almost immediate increase of HIF-1α protein in hypoxia, 
correlated with increases of transcription of its target genes (Figures 4.1. and 4.2.A). 
However, only low levels (not detectable by Western blot analysis) of HIF-1α 
localised in the cytoplasm (Figures 4.3.-4.4.) were detected in CLL cells incubated in 
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normoxic conditions. Similar to previous reports, the translocation of HIF-1α to the 
nucleus in hypoxic cells was observed (Figure 4.5.) (Chilov, Camenisch et al. 1999). 
Comparable levels of LDHA and GLUT1 proteins in normoxia and hypoxia (Figure 
4.2.B) may be the consequence of the longevity of these proteins or the stability of 
their mRNA. This data suggests that CLL cells are pre-programmed for quick oxygen 
depletion, which enables them to immediately adapt their metabolism to hypoxic 
conditions. 
This pre-programming may be the key to the plasticity of CLL cells which 
allows them to circulate between different oxygen environments. This study has 
investigated how the transitions between normoxia and hypoxia influence the 
metabolism of CLL cells and multiple adaptations. Metabolic plasticity- which could 
be described as metabolic flexibility, enabling prioritisation of metabolic pathways to 
match anabolic and catabolic demands of evolving phenotype during cell fate 
determination- was widely described in stem cell research (Folmes, Dzeja et al. 2012) 
but has not been extensively investigated in primary CLL cells. 
The NMR time course analysis proved to be a useful method to investigate the 
metabolism of primary cells using cycling experiments. Firstly, this proves that this 
NMR technique is very reproducible and experiments performed on different days 
can provide comparable metabolic data characterised by very similar kinetics. 
Secondly, the viability and the oxygen consumption rates proved not only that CLL 
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cells are metabolically plastic, but also that the NMR experiment does not affect their 
metabolism. Cells were able to re-set their metabolic pathways during the re-
oxygenation without causing damage to mitochondria as observed in endothelial 
cells (Dhar-Mascareno, Carcamo et al. 2005).  
In order to distinguish which metabolic pathways are controlled by HIF-1α, 
chetomin a well-known HIF-1α inhibitor was used (Kung, Zabludoff et al. 2004). 
Beyond the well-described toxic effect of CTM on hypoxic cells, the kinetic changes 
of CTM treated cells were monitored. The data presented in this chapter suggest that 
alongside the well understood inhibition of lactate production and glucose 
consumption (as a consequence of GLUT1 down regulation), HIF-1α upregulates 
glutaminolysis as the alternative source of carbon when glucose metabolism is 
blocked. Sun and Denko proposed an interesting model connecting HIF-1α with 
glutamine metabolism (Sun and Denko 2014). They identified the mechanism by 
which HIF-1 activation results in a dramatic reduction of the activity of 
mitochondrial enzyme complex α-ketoglutarate dehydrogenase (αKGDH). HIF-1 
activation promotes SIAH2 targeted ubiquitination and proteolysis of the subunit of 
the αKGDH complex. Therefore inhibition of HIF-1 may reverse the hypoxic drop in 
αKGDH activity and stimulate glutamine oxidation, inducing its uptake as a 
consequence.  
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Another interesting consequence of HIF-1α inhibition was the decreased 
alanine production. The hypothesis that ALAT may have been deactivated by HIF-1α 
blockage did not prove to be correct in CLL cells. Alanine is often described as a by-
product of the metabolism of pyruvate (DeBerardinis and Cheng 2010), which 
concurs with the data from the present investigation showing that ALAT inhibitors 
did not affect the viability of cells or have a significant effect on cell metabolism, even 
though alanine production was profoundly inhibited (Figure 4.10. and 4.11.). 
Knowing that ALAT inhibition does not increase glutamate secretion, the glutamate 
accumulation after CTM treatment, remains unexplained. MacIntyre et al. reported 
higher levels of glutamate and pyruvate in the serum of CLL patients compared to 
that of healthy donors, suggesting decreased activity of ALAT as a possible 
explanation (MacIntyre, Jimenez et al. 2010). The results presented in this chapter 
however dispute the theory that ALAT inhibition causes such an effect. 
While others studies have reported that ALAT inhibition in lung carcinoma 
cells impaired glucose uptake (Beuster, Zarse et al. 2011), this relation in CLL cells 
was not observed in this investigation. Moreover it has been shown that ALAT 
inhibitors induced impaired growth of the cell line and reduced tumour mass in the 
xenograft mouse model, while no cytotoxic effect was observed in the present study. 
This may indicate the difference in alanine metabolism between quiescent and 
proliferating cells. Alternatively, CLL cells may use proteolysis in order to fulfil their 
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alanine demand. This is however not supported by our metabolic data showing no 
increase of essential amino acids. 
We have demonstrated that treatment with 100mM CTM for 48h resulted in 
significant decrease of CLL cells viability (Figure 4.9 A) in both normoxia and 
hypoxia with suggests strong HIF-1α independent toxicity of high CTM dose. This 
suggests that the effect of 100nM CTM demonstrated on the figure 4.8 could result 
from cell death rather than a specific metabolic change or the combination of both. 
The first metabolic shift of the CLL cells treated with CTM can be observed after only 
5 (when hypoxia is reached) therefore measurement of CLL cells viability after 5h of 
treatment with 100nM CTM should help to distinguish if those changes were 
triggered by cell death or only the Hif-1α inhibition. 
Not only malignant B-cells, but all immune cells are exposed to low oxygen 
tensions as they develop and migrate between blood and different tissues, and the 
mechanisms by which lymphocytes adapt to hypoxia are poorly understood. A study 
by Kojima et al. showed that B-cells but not T-cells were strongly dependent on HIF-
1α. The HIF-1α deficient T-cells showed unchanged phenotype (compared to the 
wild-type), while dramatic distortions in phenotype of HIF-1α deficient B-cells were 
observed (Kojima, Gu et al. 2002). Recent studies have shown that lymphocyte 
activation has strong links with altered metabolism. Activation of T- lymphocytes, 
combined with increased cell proliferation increases their bioenergetic and 
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biosynthetic demands, forcing cells to adapt their metabolism. Changes in the 
microenvironment resulting from limitations of nutrient and oxygen require further 
metabolic reprogramming (Pearce, Poffenberger et al. 2013). It has been shown that 
Naïve T cells are metabolically quiescent and use oxidative phosphorylation as the 
main source of ATP. As they are activated, they consume more nutrients and 
increase their glycolysis and gutaminolysis rates, but fully activated memory T cells 
are characterised by quiescent metabolism with oxidative phosphorylation mainly 
fuelled by fatty acid oxidation and increased mitochondrial mass which suggest they 
are metabolically primed to respond during the next infection (van der Windt, 
O'Sullivan et al. 2013). 
The fact that other immune cells need to reprogram their metabolism 
depending on the environment suggests that CLL cells may be a good model to 
investigate the biology of B-cells in general. This study intended to compare 
observations regarding both the plasticity of CLL cells and the effect of CTM on their 
metabolism, with similar analysis conducted on healthy B-cells. The difficulty was 
that NMR spectroscopy as a relatively insensitive method requires reasonably large 
amounts of cells to obtain a good signal to noise ratio. Therefore primary CLL cells, 
although quiescent and unable to increase the biomass by division, are a very good 
model as CLL patient blood samples provide large amounts of B-cells which are 
otherwise difficult to obtain. 
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5.1 INTRODUCTION 
Pyruvate is known to play an important role in protecting cancer cells from 
hypoxic stress (Roudier and Perrin 2009; Huang, Kuo et al. 2013; Cipolleschi, Marzi 
et al. 2014). Some of the signals from metabolites shown in the 1D 1H-NMR spectrum 
(Figure 3.1) are represented by distinct separated peaks, while others are more 
difficult to assign and analyse because of overlapping chemical shifts with 
neighbouring peaks. One of the more difficult metabolites to identify in spectra 
obtained in the previous chapter was pyruvate.  
Many studies have linked pyruvate metabolism with hypoxia. The most direct 
link between hypoxia and pyruvate metabolism is the fact that HIF-1α directly 
activates the gene encoding pyruvate dehydrogenase kinase 1 (PDK1). PDK1 
inactivates the TCA cycle enzyme, pyruvate dehydrogenase (PDH), which converts 
pyruvate to acetyl-CoA (Kim, Tchernyshyov et al. 2006) (See Figure 6.17). Active 
suppression of mitochondrial pyruvate catabolism resulting in decreased respiration 
is partially compensated by increased anaerobic glycolysis promoted by HIF-1α 
(Seagroves, Ryan et al. 2001). However, increased ATP production may not be 
sufficient for hypoxic adaptations since hypoxia causes oxidative stress from 
uncontrolled mitochondrial generation of reactive oxygen species (ROS), which may 
affect cell survival. ROS which is a by-product of mitochondrial respiration arising 
from electron transfer to O2, can be efficiently neutralized by catalase, 
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peroxiredoxins, and superoxide dismutase. In hypoxia however, perturbation in 
electron transport is associated with leakage of electrons from the respiratory chain, 
resulting in increased ROS that could be toxic to cells if ROS levels are not attenuated 
(Kim, Tchernyshyov et al. 2006).  
Pyruvate and its derivatives have been shown to be important endogenous 
scavengers of certain reactive oxygen species (ROS), especially hydrogen peroxide 
(H2O2). Pyruvate scavenges H2O2 by virtue of a non-enzymatic oxidative 
decarboxylation reaction, which was first described by Holleman in 1904 (Holleman 
1904): 
CH3-CO-CO2-H + HO-OH  CH3-CO-OH + CO2H-OH  CH3-CO-OH + CO2+H2O 
Scavenging of H2O2 by endogenously generated pyruvate has been shown to be the 
key cellular defence against oxidative stress in proliferating cells (Brand and 
Hermfisse 1997).  
In addition to H2O2, other important cellular reactive oxygen species include 
superoxide radical anion (O2•-), hydroxyl radical (OH•), and peroxynitrite (ONOO-) 
(Fink 2002). Although O2•- is only moderately reactive, it can undergo a one-electron 
reduction forming H2O2, or react with nitric oxide (NO) to form the potent oxidising 
and nitrosating agent, ONOO- (Pacher, Beckman et al. 2007). Evidence has been 
shown to support the hypothesis that pyruvate is not only capable of scavenging 
H2O2, but also OH• (Ervens et al. 2003) and peroxynitrite (Varma and Hegde 2007). 
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It has been previously reported that pyruvate (together with glutamate) was 
increased in the serum of CLL patients compared to the serum of healthy donors 
(MacIntyre, Jimenez et al. 2010). Suggested causes of the elevated levels of pyruvate 
included deficiencies in thiamine- of which the physiologically active form (thiamine 
pyrophosphate) acts as a coenzyme in pyruvate decarboxylation (Seligmann, Levi et 
al. 2001); decreased activity of alanine aminotransferase (discussed in the previous 
chapter) and  elevated serum levels of pyruvate kinase type M2 (Oremek, 
Teigelkamp et al. 1999). 
The aim of this part of the study was to compare pyruvate kinetics in 
normoxic and hypoxic conditions in CLL cells, to investigate its importance for the 
metabolic adaptations and to test the hypothesis of its role in ROS protection. The 
analysis of pyruvate in 1H-NMR spectra is challenging as there is only a singlet 
representing the methyl group in a crowded region of the spectrum, and its chemical 
shift changes with pH. Despite this challenge, this work aimed to investigate its 
kinetics in CLL cells. 
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5.2 RESULTS 
5.2.1 Analysis of pyruvate changes during the NMR time course.  
Figure 5.1 shows the pyruvate and glutamate resonances during the 1H-NMR 
time course experiment with CLL cells. The glutamate multiplet H-C4 consists of 6 
signals, two of which overlap with the pyruvate signal when it shifts upfield (to the 
lower ppm values) as a consequence of a decreasing pH. In order to assess the 
concentration of extracellular pyruvate in the NMR tube, Chenomx software was 
used. Chenomx has a build-in library of pH dependent spectra for many metabolites 
and can stimulate spectra of overlapping signals for deconvolution. First, glutamate 
resonances were assigned in Chenomx, using intensities from the non-overlapping 
glutamate signals to obtain correct intensities for overlapping resonances. 
Subsequently the pyruvate signal was assigned and its intensity was estimated by 
adjusting the sum of the glutamate and pyruvate signals until the overall signal was 
reasonably well represented. In order to obtain the pyruvate concentration, the 
glutamate concentration was subtracted from the sum (Figure 5.1.B). In order to 
confirm the assignment of pyruvate, the same sample was spiked with additional 
pyruvate (Figure 5.1.C,D). The pyruvate signals of the sample overlapped and spiked 
pyruvate exhibited the same pH dependent signal shift, moving towards the 
glutamate signals. Chenomx analysis showed that the additional spiked pyruvate 
was also taken up by CLL cells in hypoxic conditions (Figure 5.1.C,D). 
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Figure 5. 1. Analysis of the pyruvate concentration during the time course with 
CLL cells. 
A) Superimposed time course spectra with the pyruvate peak. As the pH decreased the 
pyruvate signal shifted upfield causing overlap with one of the glutamate resonances. B) 
Pyruvate intensities (green signal 1) were derived using the Chenomx and glutamate 
signal intensities (purple signals 2ab, 3ab, 4ab). The glutamate concentration 
(corresponding to area under the curve) was estimated using glutamate signals 2b, 3ab 
and 4ab. In order to estimate the pyruvate concentration, from the area under the overall 
signal arising from the overlapping pyruvate-glutamate signals, the estimated area 
under the signal 2b was subtracted. C) The sample with CLL cells was spiked with 
pyruvate, the same pH dependent shift was observed. D) The concentration of glutamate 
and pyruvate was estimated accordingly using Chenomx software. 
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5.2.2. CLL cells export pyruvate in normoxia and take it up again in 
hypoxia. 
Across the 24 hours of recording the NMR spectra, lactate continued to 
accumulate and glucose was continually consumed. Similarly, once initiated in 
hypoxia, alanine accumulation continued throughout the experiment. In stark 
contrast, pyruvate kinetics were more complex. During the early stages, prior to 
complete oxygen depletion, pyruvate signals were seen to increase and then to fall 
during the period in hypoxia, suggesting a key differential functional importance of 
this metabolite in oxygenated and hypoxic conditions (Figure 5.2). Pyruvate uptake 
occurred after an average of 1.5-2 hours following oxygen consumption (Figure 5.2 
B). Footprint analysis of media taken from CLL cells cultured in oxygenated 
conditions and hypoxia demonstrated that CLL cells release pyruvate in the presence 
of oxygen but not in hypoxia, suggesting that the fall in pyruvate in hypoxia relates 
to the re-uptake of pyruvate by CLL cells. Consistent with this, incubation of CLL 
cells with [2,3-13C]pyruvate in hypoxia demonstrated pyruvate uptake by CLL cells 
with the label being detected in both lactate and alanine (Figure 5.2 C,D). 13C 
incorporation to lactate was very quick and by the time the first spectrum was 
recorded, the label incorporation had reached a plateau at around 50%. This suggests 
that around 50% of lactate was produced from pyruvate that had been taken up by 
cells, while the remaining 50% was produced from the unlabelled glucose. Although 
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the incorporation of 13C into the alanine signal was visibly increasing in the spectrum 
containing only signals originating from protons bound to 13C compared to the 
spectrum containing NMR signals originating from all protons in the sample, it was 
not possible to calculate the 13C incorporation due to the pyruvate keto tautomer 
signal overlapping with alanine resonance (Muller, Baumberger 1939) (See 5.2.7 for 
more information about the pH dependent pyruvate tautomerisation). 
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Figure 5. 2. Flux of pyruvate. 
A) The extracellular pyruvate concentration together with the oxygen decrease during 
the NMR time course experiment derived from Chenomx analysis of 1H-NMR spectra. B) 
The time difference between the oxygen depletion and the start of pyruvate uptake in 8 
different experiments. C) The scheme of the experiment performed. 5 mM of the [2,3-
13C]pyruvate was added to the CLL cells and the NMR time course was performed. As a 
result a build-up of the label incorporation into alanine and lactate was observed. D) 
Graph shows the 13C label incorporation to the total pool of pyruvate and lactate. 
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5.2.3 Pyruvate dynamics were not HIF-1α dependent. 
Exposure of CLL cells to CTM indicated the transition in pyruvate dynamics 
was not tightly dependent on HIF-1α activation (Figure 5.3). The two chetomin 
concentrations investigated, 50 nM and 100 nM, did not alter the pyruvate profile in 
a concentration dependent manner. Secretion of pyruvate in normoxia declined 
slightly, following HIF-1α inhibition, which may be a consequence of the increased 
PDH activity, allowing pyruvate to enter the TCA cycle. However pyruvate uptake 
in hypoxia was not affected by chetomin, suggesting its importance in the 
metabolism of CLL cells independently from HIF-1α activation.  
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Figure 5. 3. The transition in pyruvate dynamics was independent of HIF-1α 
activation. 
The NMR timecourse data for the control CLL experiment and cells treated with 20 mM 
and 100 nM CTM. Cells were pre-treated with CTM for 3 hours before starting the NMR 
experiment. Graph presents changes of extracellular pyruvate concentration over time. 
Concentration values were calculated using Chenomx software. 
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5.2.4 Inhibition by MCT1 prevents pyruvate re-uptake and causes 
apoptosis of CLL cells. 
Pyruvate has recently been demonstrated to directly protect cells against 
hypoxic stress (Cipolleschi, Marzi et al. 2014). It was therefore hypothesised that CLL 
cells utilise pyruvate in hypoxia as a defence mechanism against hypoxia induced 
ROS. To test this hypothesis, investigations into the dependence of hypoxic CLL cells 
on pyruvate uptake were conducted using the inhibitor α-cyano-4-
hydroxycinnamate (CHC). This inhibitor prevents the cellular uptake of pyruvate via 
the monocarboxylate transporter 1 (MCT1) (Figure 5.4). As shown in Figure 5.4 C, 
CHC concentrations of 2 mM and 5 mM only slightly diminished the rate of pyruvate 
accumulation whilst oxygen was available, but completely reversed its re-uptake 
upon entry into hypoxia. Exposure to CHC also reduced cell viability in a dose 
dependent fashion (Figure 5.4.B). As the role of MCT1 is to transport both lactate as 
well as pyruvate (through cellular and mitochondrial membranes), it was possible 
that lactate kinetics would also be affected by CHC. In fact, the time course data 
demonstrated a decrease of lactate export but not its complete blockage (Figure 5.5). 
Lactate and alanine secretion is decreased in hypoxia which could be linked to the 
lower uptake of the extracellular pyruvate. The observed lower glutamine and 
glucose consumption may reflect the decreased cell viability. Interestingly, glutamate 
production was not affected by CHC. 
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Figure 5. 5. Metabolic changes during CHC treatment. 
NMR time course data for the control CLL experiment and cells treated with 2 mM CHC. 
Cells were pre-treated with CHC for 3 hours before starting the NMR experiment. The 
signal intensities of chosen metabolites (lactate, alanine, glutamate, glutamine and 
glucose) over time are presented in the graphs.  
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5.2.5 Methyl pyruvate does not rescue CLL cells from CHC. 
It was observed that CHC also had an effect on the viability of CLL cells in 
oxygenated conditions. As MCT1 is not a pyruvate-specific transporter, an 
investigation was conducted to determine whether the toxicity of CHC was solely a 
consequence of pyruvate transport inhibition. CLL cells were supplemented with 2 
mM methyl pyruvate before CHC treatment. Methyl pyruvate is a permeable 
derivative of pyruvate entering cells through the cell membrane without the need for 
a specific transporter. In this experiment, if cell viability decreased as a result of 
blocked extracellular pyruvate uptake through MCT1, a decrease of apoptosis after 
supplementing cells with methyl pyruvate would be seen. However, addition of 
methyl pyruvate did not rescue cells from apoptosis caused by CHC, suggesting that 
blocked pyruvate transport was not the sole cause of cell death (see figure 5.6). 
Interestingly, ROS levels were significantly decreased in cells supplemented with 
methyl pyruvate, supporting the hypothesis that CLL cells take up the extracellular 
pyruvate in order to use it as an anti-ROS defence. In contrast, levels of 
mitochondrial ROS – mitochondrial superoxide (mitosox) – did not decrease when 
membrane permeable methyl pyruvate was added. It is possible that methyl 
pyruvate is able to cross both cellular and mitochondrial membranes, therefore the 
absence of mitosox decreases suggest that methyl pyruvate must have been 
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demethylated or degraded in some other way, preventing its entrance into the 
mitochondria.  
The reduced viability of CLL cells after CHC treatment may also have been a 
consequence of lactate build up inside cells, reducing the intracellular pH.  
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Figure 5. 6. Methyl pyruvate does not rescue cells from CHC induced apoptosis. 
A) Methyl pyruvate did not rescue cells from CHC induced apoptosis. B) Methyl 
pyruvate decreased ROS in CLL cells treated with CHC. C) Methyl pyruvate increased 
mitosox in CLL cells treated with CHC. Data are mean of n=3 ± SEM, *p < 0.05 by 
student’s t-test for paired data. 
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5.2.6 Exogenous pyruvate reduces mitosox and ROS levels in CLL 
cells. 
The demonstration of the ability of CLL cells to utilise the availability of 
exogenous pyruvate for protection against stress, required the exacerbation of stress 
and supply of exogenous MCTI-transport dependent pyruvate. As shown in Figures 
5.7 and 5.8, exposure of CLL cells to H2O2 for 24 hours resulted in elevated levels of 
mitosox and other ROS in both hypoxic and normoxic conditions. However, supply 
of exogenous sodium pyruvate significantly diminished both measures of cellular 
stress. Likewise, provision of exogenous pyruvate reversed H2O2-induced CLL cell 
killing. These data suggest that CLL cells do not only alter their metabolism in 
relation to the availability of oxygen, but that they can also modulate their utilisation 
of available metabolites, when experiencing ROS-induced stress. Cytospins stained 
with Jenner-Giemsa stain clearly presented the H2O2-induced apoptosis and rescue of 
cell phenotype when sodium pyruvate was added to the medium (Figure 5.7 D). 
There was no morphologically visible difference between cells treated in normoxia, 
from those in hypoxia (0.1% of O2). However, histograms presented in Figure 5.8 
show that levels of both mitosox and ROS were elevated in hypoxia.  
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Figure 5. 7. Exogenous pyruvate reduces mitosox and ROS levels in CLL cells. 
CLL cells were incubated for 24 hours with H2O2 and Na pyruvate in normoxia or 
hypoxia (0.1% O2) prior to harvesting, transferring to the FACS tube, washing and 
incubating with A) MitoSOX for 10 minutes, B) H2DCFDA for 40 minutes or C) 
AnnexinV/PI for 15 minutes and analysed by FC. Data are the mean ± SEM from n=5 
patients; *p < 0.05 by student’s t-test for paired data. D) Cytospins of CLL cells from each 
treatment stained with Jenner-Giemsa. 
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Figure 5. 8. Exogenous pyruvate reduces mitosox and ROS levels in CLL cells. 
CLL cells were incubated for 24 hours with H2O2 and sodium pyruvate in normoxia or 
hypoxia (0.1% O2) prior to harvesting, transferring to the FACS tube, washing and 
incubating with A) MitoSOX for 10 minutes, B) H2DCFDA for 40 minutes and analysed 
by FC. 
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5.2.7 Keto-enol tautomerism of pyruvate 
Pyruvate can appear in one of two tautomer forms depending on the pH. The 
pyruvate keto ion has two C=O double bonds which are conjugated (see figure 5.9 
A). The enol form tautomer of the pyruvate ion has one C=C double bond and a C=O 
group which is also conjugated. Unfortunately, metabolomics NMR databases such 
as HMDB do not provide the information about the keto tautomer and present only 
one peak in the pyruvate spectrum (at 2.46 ppm) corresponding to the enol form, 
described as a keto form. Using the NMR time course setup as described previously, 
a set of two 1D-1H 13C decoupled NMR spectra of CLL cells enriched with 5 mM [2,3-
13C]pyruvate was recorded. The acquired spectrum was edited in order to contain 
only signals originating from protons bound to 13C, allowing for the observation of 
clearly identifiable peaks corresponding to keto and enol forms, without the 
background noise of other peaks (Figure 5.10). Using the intensities of pyruvate 
peaks, it was possible to calculate changes in the ratio of keto : enol forms throughout 
the time course. pH changes were calculated using the histidine peak (as shown in 
chapter 3.2.7) from spectra containing NMR signals from all protons in the sample. 
From these, the correlation between the tautomer changes and decreasing pH were 
described. During 19 hours of the time course, pH changed from 7.79 to 6.33, while 
the enol form of the protons decreased from 89.4% to 86.4% and the keto form 
increased from 10.6% to 13.6% (Figure 5.9 and 5.10). Although there was a strong 
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correlation between pH changes and tautomerisation and pH changed substantially 
for 1.46 units, the 3% change in the ratio of tautomers did not have an impact on the 
metabolic interpretation of the pyruvate kinetic data shown previously. 
Nevertheless, it is important to be aware of the possible tautomer balances while 
interpreting NMR spectra. 
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Figure 5.9. Keto-enol pyruvate tautomerism.  
A) Pyruvate undergoes tautomerization depending on pH. B) 5 mM of the 
[2,3-13C]pyruvate was added to the CLL cells and the NMR time course 
experiment was carried out. The percentage of enol and keto tautomers of 
pyruvate was calculated and the changes during the time course were plotted. 
C) pH Changes during the same time course  experiment. 
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Figure 5. 10. Keto-enol pyruvate tautomerism in the NMR spectrum. 
CLL cells were measured over 24 hours with 13C pyruvate. As lactate was produced and 
pH subsequently decreased, the level of the enol tautomer of pyruvate declined due to 
its transformation to the keto form. 1D-1H NMR spectra containing only signals 
originating from protons bound to 13C are presented. The first specturm of the time 
course is shown in blue, the last spectrum in red. Spectra were scaled to the total amount 
of the 13C pyruvate in the spectrum. 
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5.3 DISCUSSION  
One of the difficulties of accurate assignment and quantification of metabolite 
NMR spectra arises from the problem of chemical shift degeneracy of individual 
metabolites. This chapter presents solutions to overcome this obstacle and to extract 
the relevant data from overlapping signals. The focus of the investigation was the 
methyl resonance of pyruvate at 2.46 ppm at pH 7. Keto-enol tautomerisation of 
pyruvate at acidic pH, with a related increase in the proportion of the enol form, at 
1.47 ppm in the 1H NMR spectrum, was observed. This has been taken into account 
for the analysis of the real-time changes in the NMR spectra with changing pH.  
Using the Chenomx software, the precise quantification of pyruvate 
concentrations was possible from overlapping signals and signal multiplets, by 
stimulating spectra and subtracting glutamate resonances. The data produced 
showed that primary CLL cells secrete pyruvate while in normoxia and take it up 
after approximately 2 hours of incubation in hypoxic conditions. Export of pyruvate 
by CLL cells has previously been reported in studies detecting increased serum 
pyruvate in CLL patients when compared to healthy donors (MacIntyre, Jimenez et 
al. 2010). One of the proposed explanations for the elevated pyruvate level in 
MacIntyre’s study (MacIntyre, Jimenez et al. 2010) is a deficiency in thiamine, which 
in its physiologically active form - thiamine pyrophosphate- acts as a coenzyme in 
pyruvate decarboxylation (Seligmann, Levi et al. 2001). Although thiamine deficiency 
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has been reported in CLL patients, it is unlikely that CLL cells used in the present in 
vitro investigation suffered from lack of thiamine, as RPMI medium contains 1 mg/l 
of thiamine hydrochloride and cells were suspended in fresh medium for each NMR 
time course experiment. 
It has also been shown that human fibroblasts, as well as breast 
adenocarcinoma cell lines, secrete pyruvate when incubated in pyruvate-free 
medium (O'Donnell-Tormey, Nathan et al. 1987). This pyruvate secretion was 
attributed to protection from ROS. Although it is surprising that primary cancer cells 
divert a substantial portion of their potential energy supply by export of pyruvate, 
there is an obvious advantage for cells in scavenging exogenous H2O2 before it 
reaches the cell. Under the experimental conditions of the present study, the oxygen 
level decreased from the 0 time point, therefore the level of ROS may have been 
gradually rising. After about 100 minutes of hypoxia, intracellular ROS must have 
been substantially increased, inducing the uptake of pyruvate to scavenge ROS and 
mitosox inside cells.  
Considering that the pyruvate NMR signal observed in this experiment 
reflected only the extracellular pyruvate, a subsequent investigation was conducted 
to determine whether the metabolite was indeed taken up and used by cells (and not 
degraded or used in some biochemical reaction outside cells). A 1H and proton 
filtered 13C 1D spectra approach was used to detect 13C-incorporation from 
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extracellular pyruvate into lactate and alanine in real time. The pulse sequence was 
recently developed in our NMR group and real time experiments with CLL cells 
were the first time course spectra obtained using this method. During the 
optimisation of the method keto-enol tautomerism of pyruvate was observed, 
although it did not significantly influence the overall intensities within the pH range 
observed for the samples used (max 3%). 
Pyruvate uptake has been reported as an important factor that correlates with 
cancer invasiveness. It has been shown that more invasive ovarian cancer cells 
exhibit higher pyruvate uptake than their less invasive counterparts (Caneba, 
Bellance et al. 2012). Moreover, pyruvate had an effect on the migration ability of 
highly invasive ovarian cancer cells. Pyruvate uptake has therefore been suggested to 
be potentially used in cancer diagnostics. The possible suggested explanation of this 
phenomenon was that pyruvate may fuel the TCA cycle and may play a role in the 
increased oxygen consumption rate. A possible mechanism is that pyruvate can be 
converted into glycerate 2-phosphate in the glycolysis pathway. Pyruvate and serine 
are taken up to create hydroxypyruvate (in the transamination reaction), which is 
then converted to glycerate via NADPH and further into glycerate 2-phosphate 
through conversion of ADP into ATP (Mazurek 2011). In this way, pyruvate may be 
another metabolite consumed during glycolysis. 
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Although pyruvate uptake in CLL cells in the time course experiments 
presented here was driven by hypoxia and considering that hypoxia induces MCT1 
expression (De Saedeleer, Porporato et al. 2013), the data shown above demonstrates 
that pyruvate uptake is independent of HIF-1α activation and is not affected by 
chetomin treatment. In order to disrupt pyruvate import, the monocarboxylate 
transporter 1 (MCT1) inhibitor CHC was used. Blockage of this transporter resulted 
in the complete inhibition of pyruvate uptake and partial decrease of lactate export. 
As both lactate and pyruvate are transported by MCT1, it is not possible to 
specifically inhibit pyruvate transport. MCT1 treatment resulted in dose dependent 
apoptosis which was not the sole cause of the blockage of pyruvate uptake, as the 
addition of the membrane soluble pyruvate derivative - methyl pyruvate did not 
rescue cells. Although methyl pyruvate did not increase cell viability, it decreased 
the ROS levels significantly. Importantly, lactate export was not completely blocked 
by CHC, therefore the mechanism of CLL cell apoptosis resulting from MCT1 
inhibition may be more complex than just the inhibition of lactate and pyruvate 
transport. Although the metabolic consequences of MCT1 inhibitors are not yet 
completely clear and little is known about its regulation by typical parameters of the 
tumour microenvironment (Asada, Miyamoto et al. 2003; Kennedy and Dewhirst 
2010; Halestrap and Wilson 2012), the first MCT1 inhibitor is currently undergoing 
clinical trials for treatment of various types of cancer (Porporato, Dhup et al. 2011; 
Polanski, Hodgkinson et al. 2014).  
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Finally the current investigation revealed that the addition of extracellular 
sodium pyruvate to CLL cells treated with H2O2 resulted in decreased ROS and 
mitosox levels and helped to rescue cells from apoptotic death. Therefore we sustain 
the hypothesis that CLL cells take up extracellular pyruvate in hypoxia for ROS 
protection. Interestingly, it was shown that ROS is responsible for the re-oxygenation 
damage of endothelial cells (Dhar-Mascareno, Carcamo et al. 2005) which also 
suggests that CLL cells may protect themselves from apoptosis after entering the 
oxygenated environment, by storing the ROS scavenging pyruvate.  
Recently, additional studies have emphasised the importance of the ability of 
Chronic Lymphocytic Leukaemia in fighting ROS. Another proposed adaptation of 
CLL cells to intrinsic oxidative stress is the up-regulation of the stress-responsive 
heme-oxygenase-1 (HO-1). New data indicates that HO-1 is also, involved in 
promoting mitochondrial biogenesis beyond its function as an antioxidant. Thus 
ROS, adaptation to ROS and mitochondrial biogenesis appear to form a self-
amplifying feedback loop in CLL-cells. Taking advantage of such altered metabolism, 
it may be possible to selectively target CLL cells. Targeting the respiratory chain (by 
blocking the mitochondrial F1F0-ATPase) and promoting mitochondrial ROS, the 
benzodiazepine derivative PK11195 has recently been shown to induce cell death in 
CLL cells (Jitschin, Hofmann et al. 2014). These findings, together with the work 
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presented in this chapter, suggest that bioenergetics and redox characteristics could 
be therapeutically exploited for CLL treatment. 
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6.1. INTRODUCTION 
Metabolic Flux Analysis (MFA) involving 13C-labelled tracers requires a large 
number of cells, as the sensitivity of NMR to detect 12C carbon is 4 times lower than 
that of protons due to the difference in the gyromagnetic ratio of 13C nuclei compared 
to 1H. The signal intensity in NMR spectra is a product of metabolite concentration, 
percentage of 13C incorporation and several physical properties including the 
gyromagnetic ration and relaxation rates, and for proton observed HSQC spectra also 
heteronuclear scalar coupling constants between 1H and 13C. For this reason, an 
additional unlabelled cell sample is needed as a control for investigations of 13C 
incorporation in tracer based analyses (13C natural abundance is 1.07%). Therefore in 
standard procedures, the number of cells required is higher. Chronic lymphocytic 
leukaemia is clinically extremely heterogeneous and some patients are characterised 
by very high white blood cell counts, which indicate that their blood samples may 
provide a lot of biological material. One purpose of this study was to investigate if B-
cells purified from 14 ml of peripheral blood from a CLL patient would provide 
enough biological material to perform good quality MFA. To date, this is the first 
such study performed on primary human CLL cells.  
So far, investigation of the metabolism of CLL cells presented in this thesis has 
mainly been based on the examination of extracellular metabolites being taken up 
from or secreted into the media. This chapter describes in greater depth the analysis 
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of metabolic flux carried out using cell extracts using expression metabolic flux 
analysis (MFA). This is an approach in which the distribution of individual atoms 
through metabolic networks is observed, employing isotopically labelled metabolic 
precursors such as glucose and glutamine as tracers. Using MFA, it is possible to 
follow isotopic labels to investigate the pathways that are favoured in specific 
conditions for a particular cell type. For example, the labelled carbons of glucose 
would distribute differently to lactate carbons, depending on the pathway through 
which they are metabolised (See Figure 6.1). This chapter presents the use of an MFA 
approach for further investigations into the metabolic adaptations of CLL cells to 
different oxygen environments. The 2D 13C-1H HSQC analysis of CLL cells incubated 
in normoxia and hypoxia in medium containing [1,2-13C]glucose and [3-
13C]glutamine will be presented.  
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Figure 6. 1. 13C labelled glucose flux to lactate through glycolysis and PPP. 
The distribution of labelled carbons differs depending on whether glucose is metabolised 
through glycolysis or through the pentose phosphate pathway. 
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When multiple neighbouring carbon atoms are labelled, complex multiplet 
patterns of NMR signals arise (Figure 6.2), and the degree of the label incorporation 
into the adjacent carbons can be interpreted. In the case of one-dimensional 13C-
observed spectra, these multiplets are directly observed in the spectra. For this, the 
1H-13C coupling must be removed using a decoupling sequence. The disadvantage of 
directly observed 13C NMR spectra is lower sensitivity. Two-dimensional 1H-13C-
HSQC spectra, offer a significantly improved sensitivity over 13C-observed spectra by 
starting and ending on 1H. The second dimension (ω1) in 1H-13C-HSQC spectra 
matches that of 13C-observed spectra for 13C atoms bound to protons, whereas the 
observed dimension (ω2) represents an 1H spectrum showing only resonances of 
protons bound to 13C. HSQC spectra require large numbers of increments (at least 
4096) in order to be able to observe the 13C-13C scalar couplings in the incremented 
dimension, which prolongs the acquisition times to > 4 hours. This is however still 
faster than acquiring 13C spectra, and provides additional spectral information 
through the 1H resonances. 13C-13C scalar couplings provide valuable information 
about adjacent label incorporation.  
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6.2 RESULTS 
In order to obtain good quality spectra with a good signal-to-noise ratio, 
~180x106 CLL cells had to be extracted for each sample. Cells were obtained from a 
single patient (characterized by high white cell counts in blood) and individual 
samples were used for a single experiment which consisted of the 6 following 
conditions: 
 
Cells incubated for 24h 
in normoxia 
Medium lacking 
labelled tracers 
Medium with  
[1,2-13C]glucose 
Medium with  
[3-13C]glutamine 
Cells incubated for 24h 
in hypoxia (1% O2) 
Medium lacking 
labelled tracers 
Medium with  
[1,2-13C]glucose 
Medium with  
[3-13C]glutamine 
 
Labelled tracers replaced unlabelled precursors present in the control medium at the 
same concentrations. 
 
6.2.1 [1,2-13C]glucose flux through Glycolysis and Pentose Phosphate 
Pathway 
Figure 6.4 presents the theoretical label distribution from glucose, when the 
PPP is involved and when it is not active. Depending on the pathway, distinctly 
labelled species of metabolites will be formed. After the multiple TCA cycle rounds, 
the pattern combinations became very complex, as an example the label distribution 
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in the glutamate molecule coming from the [1,2-13C]glucose after  multiple TCA 
rounds is shown on the Figure 6.5. 
 
 
Figure 6. 4. Simplified presentation of 13C labelling patterns of metabolites after 
incubating cells with [1,2-13C]glucose. 
A) Overview of the principal metabolic pathways. B) Labelling patterns in lactate, 
alanine, glutamate, glutamine and aspartate after metabolism of [1,2-13C]glucose. Circles 
symbolise the carbon backbone of the molecules. Red crosses mark the position of the 
label resulting from glycolysis, followed by conversion to acetyl-CoA by PDH where 
applicable. Purple crosses indicate that the pyruvate (resulting from glycolytic 
metabolism) has instead undergone pyruvate carboxylation before being converted to 
the metabolite in question. Green circles represent labelling from the PPP, also followed 
by conversion to acetyl-CoA by PDH where applicable. Blue ovals indicate that the 
pyruvate (resulting from the metabolism in the PPP) has instead entered the TCA cycle 
via PC. After PC, the metabolite can undergo back-flux from oxaloacetate to succinate. 
BF, back-flux; GS, glutamine synthetase; P, phosphate; PAG, phosphate activated 
glutaminase; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PPP, pentose 
phosphate pathway. Adapted from (Brekke, Morken et al. 2014). 
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Figure 6. 5. The theoretical label distribution in the glutamate molecule derived 
from [1,2-13C]glucose, after  multiple TCA rounds. 
The label distribution is different when only PC is active compared to the situation when 
both PC and PDH are active. Labelled distributions after 1, 2 and 3 TCA cycle rounds are 
presented. Adapted from a presentation made by C. Ludwig. 
 
# TCA 
Cycles: 23
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Figure 6.6 shows the analysis of the labelled glucose flux in normoxic 
conditions in CLL cells. Carbons C-1 and C-2 were transferred from the glucose 
molecule through the process of glycolysis, to pyruvate, then to lactate and finally to 
alanine, with labelled carbons in positions C-2 and C-3. Moreover, in depth analysis 
of the lactate and alanine line shapes revealed additional label in position C-3, 
derived from glucose metabolised through the pentose phosphate pathway, leading 
to lactate species labelled either in the C-3 position only, or simultaneously in 
positions C-1 and C-3 (see Figures 6.1 and 6.4). 13C in position C-1 of both lactate and 
alanine molecules could not be seen in proton edited HSQC NMR spectra, as they are 
not protonated and both species (molecules with C-1 labelled and unlabelled) result 
in the same NMR spectrum. Therefore only the visible C-3 labelled lactate and 
alanine species were used as an indicator of PPP activity. 
In common with the glucose flux in normoxia, in hypoxic conditions, carbon 
nuclei in lactate and alanine were labelled in positions C-2 and C-3 (Figure 6.7). The 
PPP activity, investigated by the multiplet analysis of C-3 in lactate and alanine, was 
shown to be less pronounced in hypoxia than in normoxia (Figure 6.8). For 
quantitative HSQC analysis 1D slices of HSQC spectra were evaluated using in 
house built software by C. Ludwig based on the MetaboLab software (Gunther, 
Ludwig et al. 2000; Ludwig and Gunther 2011) using a quantum mechanical spin 
system simulation, using the pygamma library (Smith, Levante et al. 1994). 
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Figure 6. 6. Glucose flux in CLL cells in normoxia. 
Label distribution in metabolites arising from [1,2-13C]glucose under normoxic 
conditions. CLL cells were incubated for 24 hours in a normoxic incubator in RPMI 
medium with [1,2-13C]glucose. Cells were extracted and the polar fraction was analysed 
by NMR spectroscopy. 1H13C – HSQC and 1D 1H spectra were recorded. Data were 
analysed using the NMRlab software.   
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Figure 6. 7. Glucose flux in CLL cells in hypoxia. 
Label distribution in metabolites arising from [1,2-13C]glucose under hypoxic conditions. 
CLL cells were incubated for 24 hours in a hypoxic incubator (1% O2) in RPMI medium 
with [1,2-13C]glucose. Cells were extracted and the polar fraction was analysed by NMR 
spectroscopy. 1H13C – HSQC and 1D 1H spectra were recorded. Data were analysed 
using the NMRlab software.  
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Figure 6. 8. Pentose Phosphate Pathway is more active in normoxia. 
A) Comparison of the lactate peak line shape in spectra recorded from extracts of CLL 
cells incubated in normoxia (green) and hypoxia (purple). B) After scaling spectra 
intensities, the middle peak was higher in normoxia (1.1% label incorporation) than in 
hypoxia (0.08% label incorporation). This peak reflects the higher amount of label in 
position C-3 which came from the labelled glucose metabolised through the pentose 
phosphate pathway. C) Enlarged middle peak. 
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6.2.2 Pyruvate carboxylase is active only in hypoxic conditions 
The labelling pattern of aspartate arising from [1,2-13C]glucose informs about 
the entry of pyruvate into the TCA cycle. If the entry point is via pyruvate 
dehydrogenase (PDH) and the TCA cycle turns entirely clockwise (Figure 6.4.), the 
C-1,2 or C-3,4 positions should be labelled. For the anaplerotic pathway via pyruvate 
carboxylase (anti-clockwise entry to the TCA cycle) oxaloacetate would be labelled in 
position C-2,3, and consequently aspartate also in the position C-2,3 as it is directly 
derived from OA. It is well-known that malate can be formed from OA with the TCA 
cycle proceeding anti-clockwise, at least for these steps, in which case malate would 
show the same labelling pattern as aspartate. Labelling gets more complex if the PC 
product runs clockwise through the TCA cycle, but the product from PC activity and 
anti-clockwise operation is always unique. 
Aspartate signals were sufficiently strong to distinguish the label in positions 
C-2 and C-3, but a lack of a 2JCC coupling in the 13C-dimension suggests that 
neighbouring positions C-2 and C-3 were not labelled in the same molecule. 
Therefore two species of labelled aspartate must have been present: [1,2-13C] and [3,4-
13C]aspartate. However, multiplet analysis of aspartate also revealed the presence of 
a third species, [2,3-13C]aspartate (Figure 6.9). Comparison of J-coupling between C-2 
aspartate peaks was used to distinguish labelling patterns. As the splitting value 
depends on the properties of the neighbouring atom (aliphatic-aliphatic - lower 
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value, aliphatic- carbonyl – higher value), the size of the coupling constant is smaller 
for [2,3-13C]aspartate (J=36,4 Hz) than the coupling constant for 1,2-13C (J=50 Hz) (see 
Figure 6.9 B). 
In contrast to normoxic conditions, spectra from hypoxic samples showed 
approximately two times higher pyruvate carboxylase (PC) activity based on the 
percentage of [2,3-13C]aspartate (Figure 6.9 C). Unfortunately it was not possible to 
determine label incorporation ratios by comparing signal intensities between HSQC 
spectra from labelled and unlabelled samples because the sensitivity in spectra of 
unlabelled samples was too low.  
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Further proof of PC activity arose from the glutamate spectrum, which 
suggested the presence of [2,3-13C]glutamate with approximately 0.15% label 
incorporation in hypoxia but much lower incorporation under normoxic conditions. 
Because the values were so low, it was difficult to quantify the label incorporation 
under these circumstances. However, the line shape analysis shown in Figures 6.10 
and 6.11 showed the differential line broadening due to the simultaneous presence of 
[1,2-13C] and [2,3-13C]glutamate in hypoxia but not in normoxia, further confirming 
higher PC activity in hypoxia. The formation of [2,3-13C]glutamate isotopomer is a 
specific indicator for PC activity when [1,2-13C]glucose is used as a tracer (Brekke, 
Morken et al. 2014). 
 
 
 
 
 
 
 
 
Chapter Six – Metabolic Flux Analysis of CLL cells in different oxygen environments 
217 
 
 
 
Figure 6. 10. The glutamate HSQC signal proves pyruvate carboxylase activity in 
CLL cells is higher in hypoxia than in normoxia. 
CLL cells were incubated for 24 hours in a hypoxic incubator (1% O2) in RPMI medium 
with [1,2-13C]glucose. Cells were extracted and the polar fraction was analysed by NMR 
spectroscopy. 1H13C – HSQC and 1D 1H spectra were recorded. Data were analysed 
using the NMRlab software. Red arrows indicate the differential line broadening due to 
the simultaneous presence of [1,2-13C]glutamate and [2,3-13C]glutamate. [2,3-
13C]glutamate is derived from the pyruvate carboxylase pathway. 
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Figure 6. 11. A 1D 13C column from the HSQC experimental data proves pyruvate 
carboxylase activity in CLL cells is higher in hypoxia than in normoxia. 
CLL cells were incubated for 24 hours in a hypoxic incubator (1% O2) in RPMI medium 
with [1,2-13C]glucose. Cells were extracted and the polar fraction was analysed by NMR 
spectroscopy. 1H13C – HSQC and 1D 1H spectra were recorded. Data were analysed 
using the NMRlab software. Red arrows indicate the differential line broadening due to 
simultaneous presence of [1,2-13C]glutamate and [2,3-13C]glutamate. [2,3-13C]glutamate is 
derived from the pyruvate carboxylase  pathway. 
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6.2.3 Glucose flux into the TCA cycle via PDH/PC 
The majority of TCA cycle intermediates were identified with larger intensities 
in the HSQC spectrum obtained from cells incubated with labelled glucose, 
compared to those from the unlabelled sample, suggesting the incorporation of the 
label into TCA cycle intermediates. This was the case under both, normoxic and 
hypoxic conditions. However, the signal of unlabelled peaks was too low in both 
cases, which meant it was not possible to accurately calculate the label incorporation 
percentage.  
Glutamate appeared highly abundant in HSQC spectra, therefore it was 
possible to quantify its label incorporation by comparing intensities in spectra of 
labelled and unlabelled cells. [4,5-13C]glutamate indicates one round of the TCA cycle 
involving PDH, and 4.5% of this species was detected in normoxic samples, which 
was higher than in hypoxia (3%) (Figures 6.6 and 6.7). The presence of [1,2-13C], [3-
13C] and the triple labelling [3,4,5-13C]glutamate suggests that the label from [1,2-
13C]glucose went through several rounds of TCA cycles (Figure 6.5), these species 
were observed in both normoxic and hypoxic samples (data were analysed using the 
spin system simulations). The higher percentages in normoxic samples, suggest 
slower TCA rounds in hypoxia. On the other hand, the higher percentage of [2,3-
13C]glutamate indicates increased PC activity in hypoxia. Interestingly, higher 
percentages of [1,2-13C]glutamate and [3-13C]glutamate detected in normoxic 
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conditions compared to hypoxia indicate that more rounds of the TCA cycle were 
performed in normoxia 
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6.2.4 13C-3-Glutamine flux 
Analysis of label distributions arising from [3-13C]glutamine revealed 
glutaminolysis in both normoxic and hypoxic conditions (Figures 6.12 and 6.13). The 
label was detected in TCA cycle intermediates such as α-KG, succinate, fumarate, 
malate, oxaloacetate and citrate as well as in aspartate (positions C-2 in some 
compounds and C-3 in others). In the case of active reductive carboxylation of 
glutamine, [3-13C]citrate would be labelled. However the only carbons it is possible to 
detect using NMR are C-2 and C-4. Therefore the only indication of labelled C-3 can 
be the splitting from C-3 to C-2. In the presented study, no splitting was observed 
which may suggest that the reductive carboxylation of glutamine did not occur in 
normoxia and hypoxia, or that the absolute level of label incorporation was not high 
enough to detect it.  
 
 
 
 
 
 
Chapter Six – Metabolic Flux Analysis of CLL cells in different oxygen environments 
222 
 
 
 
Figure 6. 12. Glutamine flux in CLL cells in normoxia. 
CLL cells were incubated for 24 hours in a normoxic incubator in RPMI medium with [3-
13C]glutamine. Cells were extracted and the polar fraction was analysed by NMR 
spectroscopy. 1H13C – HSQC and 1D 1H spectra were recorded. Data were analysed 
using the NMRlab software.   
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Figure 6. 13. Glutamine flux in CLL cells in hypoxia. 
CLL cells were incubated for 24 hours in a hypoxic incubator (1% O2) in RPMI medium 
with [3-13C]glutamine. Cells were extracted and the polar fraction was analysed by NMR 
spectroscopy. 1H13C – HSQC and 1D 1H spectra were recorded. Data were analysed 
using the NMRlab software.   
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Lack of the label in lactate and alanine identified by the absolute incorporation 
of label into C-3 of lactate via 1D spectra, suggests the absence of the malic enzyme 
activity which transforms malate into pyruvate (Figures 6.14 and 6.15). In addition 
lactate labelled from glucose in normoxia and hypoxia is produced in a similar 
percentage (Figure 6.16).  
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Figure 6. 14. In normoxia lactate can be labelled from glucose but not from 
glutamine in CLL cells. 
1D 1H NMR spectra were recorded on CLL cell extracts. The red line represents the 
spectrum of cells fed with the [2,3-13C]glucose; the blue line represents the spectrum 
recorded on extracts of cells fed with [3-13C]glutamine and the black spectrum was 
recorded on extracts of cells fed with standard RPMI medium, without labelled tracers. 
Cells were incubated for 24 hours in normoxia. The label incorporation in satellites was 
approximately 0.5% for the (blue line) sample labelled from glutamate (which is the 
natural abundance 1%: two satellites = 0.5%). In the case of sample labelled from glucose 
(red line), the percentage of labelling was above 0.5 indicating transfer of the label from 
glucose to lactate. In the case of the unlabelled spectrum (black line), the percentage was 
also higher than 0.5% but this was the result of other overlapping peaks. 
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Figure 6. 15. In hypoxia lactate can be labelled from glucose but not from 
glutamine in CLL cells.  
1D 1H NMR spectra were recorded on CLL cell extracts. The red line represents the 
spectrum of cells fed with the [2,3-13C]glucose; the blue line represents the spectrum 
recorded on the extract of cells fed with [3-13C]glutamine and the black spectrum was 
recorded on  extracts of cells fed with standard RPMI medium, without labelled tracers. 
Cells were incubated for 24 hours in 0.1% O2. The label incorporation in satellites was 
approximately 0.5% for the (blue line) sample labelled from glutamate (which is the 
natural abundance 1%: two satellites = 0.5%). In the case of sample labelled from glucose 
(red line), the percentage of labelling was above 0.5 indicating transfer of the label from 
glucose to lactate. In the case of the unlabelled spectrum (black line) the percentage was 
also higher than 0.5% but this was the result of other overlapping peaks. 
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Figure 6. 16. In CLL cells, lactate can be labelled from glucose in similar 
percentages in both normoxia and hypoxia.  
1D 1H NMR spectra were recorded on the CLL cell extracts. Cells were fed with the [2,3-
13C]glucose and incubated for 24 hours in normoxia (blue line) or in 0.1% O2 (green line). 
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6.3 DISCUSSION 
Although it is difficult to obtain large amounts of primary cells, and the size of 
CLL cells is relatively small due to their scant cytoplasm, HSQC analysis of CLL cell 
extracts provided some information about their metabolic flux. Use of labelled 
glucose and glutamine precursors revealed differences between normoxic and 
hypoxic metabolism (see Figures 6.17 and 6.18). 
CLL cells consumed glucose and glutamine in both normoxic and hypoxic 
conditions and incorporated their carbons to newly produced metabolites. 
Interestingly, early studies examining glucose uptake by CLL cells show that they 
consume less glucose than normal B lymphocytes (Brody, Oski et al. 1969). Moreover, 
studies using fluorodeoxyglucose positron emission tomography (FDG-PET) to 
visualise CLL cells in vivo, have yielded poor results; the sensitivity of detection was 
53% and the extent of disease was often underestimated (Karam, Novak et al. 2006). 
This may be because CLL is composed of malignant cell fractions with different 
proliferative activities, whereby recently divided cells and older/quiescent cells may 
have different glucose requirements. This notion is supported by a report indicating 
that CLL patients have two populations of circulating malignant cells with different 
degrees of mitochondrial polarization and dependencies on glucose (Gardner, Devlin 
et al. 2012). FDG-PET has been used effectively in CLL management with respect to 
the detection of Richter’s transformation (Bruzzi, Macapinlac et al. 2006). Regarding 
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the methods used in the present study, as yet, it has not been possible to obtain 
sufficient numbers of healthy B-cells after the purification of CD19 positive cells to 
accurately perform metabolic analysis including measurements of glucose 
consumption. It would be interesting to see if the kinetics of glucose and glutamine 
consumption by CLL cells differs from the kinetics shown by healthy B-cells.  
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Figure 6. 17. Metabolic shift of CLL cells entering hypoxia. 
A) In well oxygenated CLL cells, the pentose phosphate pathway is active, pyruvate is 
converted to acetyl-CoA by PDH to enter into the TCA cycle and PC activity is low. B) In 
hypoxia, HIF-1α is imported to the nucleus and activates the transcription of several 
genes: glucose transporter (GLUT1), glycolytic enzymes, lactate dehydrogenase (LDHA) 
or pyruvate dehydrogenase kinase (PDK1). As a result, more glucose is consumed and 
more lactate is produced as the pyruvate conversion to acetyl-CoA is blocked. As an 
alternative path of pyruvate entry to the TCA cycle, pyruvate carboxylation (PC) is more 
active than in normoxia. On the other hand, PPP activity is decreased compared to 
normoxia. Glutamine consumption is increased. Reactions marked in grey have not been 
investigated. 
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Figure 6. 18. Glycolysis is interconnected with PPP in CLL cells. 
In CLL cells, PPP is more active in normoxia compared to hypoxia, while glycolysis 
increases in hypoxia. HK2: hexokinase 2, GPI: glucose-6-phosphate isomerase, PFKP: 6-
phosphofructokinase, ALDOC: aldolase C, TPI1: triosephosphate isomerase 1, GAPDH: 
glyceraldehyde-3-phosphate dehydrogenase, PGK1: phosphoglycerate kinase 1, PGAM1: 
phosphoglycerate mutase 1, ENO1: enolase 1, PKM2: pyruvate kinase M2, LDHA: lactate 
dehydrogenase A, PDHA: pyruvate dehyrogenase, G6PD: glucose-6-phosphate 
dehydrogenase, PGLS: 6-phosphogluconolactonase, PGD: 6-phosphogluconate 
dehydrogenase, RPE: ribulose-5-phosphate 3-epimerase, RPIA: ribose-5-phosphate 
isomerase, TKT: transketolase, TALDO1: transaldolase 1, NADPH: nicotinamide adenine 
dinucleotide phosphate. 
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The observations presented in this study indicate that CLL cells use the 
pentose phosphate pathway (PPP) in normoxia but it appeared to be down regulated 
in hypoxia. A similar phenomenon has been reported in a study using glioblastoma 
stem-like cells, where an upregulation of genes involved in PPP in normoxia, 
combined with a downregulation of glycolytic enzymes and reciprocal adaptive 
switch between induction of glycolysis and PPP in hypoxia was shown (Kathagen, 
Schulte et al. 2013). Previous studies of the metabolism of CLL cells showed 
decreased levels of glucose consumption as well as diminished levels of [1-
14C]glucose-derived 14CO2 compared with healthy cells (Brody, Oski et al. 1969). This 
suggests lower activity of the PPP pathway in CLL lymphocytes. This may be a 
consequence of the lower levels of PPP enzymes such as glucose-6-phosphate 
dehydrogenase and 6-phosphogluconate dehydrogenase, which were shown to be 
decreased in CLL (Beck 1958; Ghiotto, Perona et al. 1963; Brody, Oski et al. 1969). 
Moreover, it has been shown that in CLL, certain oxidative and glycolytic enzymes 
may not be correctly spatially oriented which would prevent substrate binding 
(Koshland 1963). This abnormality may be analogous to the defective mechanism 
responsible for the impaired assembly of new ribosomes in CLL (Rubin 1971).  
The Pentose phosphate pathway synthesises precursors of nucleotides and 
amino acids which are required for tumour cell growth and proliferation. When cells 
do not require these precursors, intermediates of the pentose phosphate pathway 
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(fructose-6-phosphate and glyceraldehyde-3-phosphate) can be recycled back into 
glycolysis to produce pyruvate and lactate. Based on observations described in the 
previous chapter, it was hypothesised that CLL cells in hypoxia are exposed to high 
levels of ROS and are in high demand for ROS scavenging pyruvate. Therefore, 
rather than utilising the PPP, it would be more beneficial for CLL cells to use 
fructose-6-phosphate and glyceraldehyde-3-phosphate in the glycolytic pathway to 
produce more pyruvate. This is an interesting observation as other cancer cells use 
PPP to reduce ROS (through the generation of NADPH) (Jiang, Du et al. 2014). It 
seems to be a particular feature of CLL cells to reduce PPP in hypoxia.  
Many of the macromolecular precursors for cell growth such as lipids, 
nucleotides and nonessential amino acids are generated within the TCA cycle. The 
TCA cycle uses pyruvate as its main fuel but can also use glutamine. The latter is 
often referred to as an anaplerotic pathway. Another anaplerotic reaction is the usage 
of pyruvate via pyruvate carboxylation (PC) providing oxaloacetate, the metabolite 
which forms the cycle’s canonical entry point following condensation with acetyl-
CoA. The HSQC analysis showed that under hypoxic conditions, pyruvate 
carboxylase activity increases in CLL cells. It was shown that in many tumours 
pyruvate carboxylase is required for glutamine- independent growth (Cheng, 
Sudderth et al. 2011). Glutamine is the preferred anaplerotic precursor in some 
transformed cell lines, contributing up to 90% of the OAA pool (Portais, Voisin et al. 
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1996); DeBerardinis, Mancuso et al. 2007), therefore when the contribution of 
glutamine is reduced, cells require an alternative source of OAA which may be 
pyruvate. Consequently, cancer cells exhibiting high PC activity did not require 
glutamine for survival and growth (Cheng, Sudderth et al. 2011). The data presented 
in this chapter show that PC activity was more pronounced in hypoxia and 
glutamine consumption was lower after oxygen depletion – supporting the 
previously described relation.  
[1,2-13C]glutamate and [3-13C]glutamate derived from [1,2-13C]glucose in 
normoxia is evidence of the TCA cycle having passed multiple rounds during 24 
hours of label exposure. In contrast, spectra recorded on hypoxic cell extracts showed 
much lower intensions of these labelling patterns. This suggests that, compared to 
normoxia, in hypoxic conditions CLL cells slow down their TCA cycle metabolism. 
This observation is consistent with the common view that in hypoxia, cells switch 
their metabolism from oxidative phosphorylation to glycolytic flux, leading to the 
accumulation of lactate. Hypoxia promotes glycolytic flux, in part due to the 
activation of HIF-1α and its downstream target genes, which include many glycolytic 
enzymes (Tennant, Frezza et al. 2009). Both hypoxia and ROS decrease the flux of 
glucose through pyruvate dehydrogenase into the TCA cycle, through activation of 
pyruvate dehydrogenase kinase (PDK). In such cases, the TCA cycle can be fed by 
alternative substrates such as glutamine. It has been shown that some cancer cells use 
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glutamine in conjunction with a reverse TCA cycle activity for acetyl-CoA 
production which is the substrate for lipid synthesis (Metallo, Gameiro et al. 2012). 
CLL cells fed with labelled glutamine did not contain citrate labelled in the C-3 
position suggesting that neither in normoxia, nor in hypoxia, the reverse TCA cycle 
occurs in CLL cells. 
It would have been interesting to compare the metabolic characteristics of CLL 
cells observed in the present study, with data from healthy human B-cells, but the 
high number of cells required for the carbon NMR analysis proved to be an 
insurmountable obstacle. 
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7.1 General discussion 
Until relatively recently, CLL was considered the ‚Cinderella‛ of leukaemia, 
receiving less attention from biologists and clinicians than many other malignancies 
and in particular other haematological malignancies (Caligaris-Cappio 2009). 
However, in recent years this has changed dramatically. Studies of the genetics and 
physiology of CLL has uncovered novel targets for clinical exploitation using 
monoclonal antibodies (MoAbs), engineered T cells, or kinase inhibitors (Kharfan-
Dabaja, Wierda et al. 2014). Ibrutinib, an inhibitor of Bruton's tyrosine kinase which 
signals downstream of the B-cell receptor (BCR) signalling pathway, is showing great 
promise in high-risk patients, whether alone or as an adjunctive therapy with MoAbs 
or chemotherapy. Similarly PI3K-δ, inhibitors are showing promise (Aalipour and 
Advani 2013; Danilov 2013). Despite this, for the overwhelming majority of patients 
the disease remains incurable. Furthermore, the hope that BTK and/or PI3K-δ 
inhibitors will become the ‘imatinib’ (blockbuster therapeutic for the treatment of  
CML) of CLL is perhaps as yet prematurely optimistic.  
Unlike CML, which is defined by a single defining founding mutation that can 
be targeted by imatinib (Breccia, Efficace et al. 2011), CLL is genetically 
heterogeneous (Landau and Wu 2013). Previous knowledge of the successes in the 
development of cancer medicine indicates that combination therapies provide the 
most efficacious cures and remission rates and that having a pathway of treatments 
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available at first and subsequent relapses, prolongs both survival and with increasing 
commonality quality of life (Hallek 2013). It is therefore likely that new agents and 
new treatment strategies are still required for  CLL.  
From another point of view, there is a required urgency to study CLL as a 
generic model of human B-cell malignancies and of human cancer in general. The 
accessibility of CLL cells provides a unique opportunity to study primary human 
cancer cells that is not afforded to such studies in any other setting. However, the 
forecasted arrival of an arsenal of drugs and therapeutic approaches that may in the 
near future achieve increased survival by driving down tumour burden and halting 
disease progression means that this opportunity will thankfully be short lived 
(Hallek 2013). 
Many agents that are effective in CLL are also effective in B cell lymphomas, 
for example the CD20 targeting antibody rituximab (Keating 2010). Therefore, 
studies in CLL are likely to provide additional information for the development of 
therapies in settings beyond this disease where outcomes remain poor. However, I 
believe that CLL cells provide a wider model of human cancer with particular 
advantages in the study and understanding of  the processes of metastasis.  
Although when circulating, CLL cells remain out of the cell cycle, the majority 
of these cells have previously undergone cell divisions within malignant lymph 
nodes (Chiorazzi 2007). This indicates that CLL cells can alternate between being ‘in’ 
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and ‘out’ of the cell cycle. Cells that are ‘out’ of the cell cycle are often described as 
‘quiescent’. However, in the age of metabolomics, the definition of quiescence is 
likely to change. ‘Quiescence’ relates to the state of being ‘out’ of the cell cycle, 
termed G0. However not all ‘out of cell cycle’ cells may be metabolically quiescent. 
The transition to cell cycle quiescence in primary human fibroblasts has been shown 
to be associated with changes in gene expression, histone modification and the 
extension of chromatin compaction, although there is no evidence that these events 
regulate the cell cycle in cells (Evertts, Manning et al. 2013). However, entry to the 
quiescent state is almost certainly associated with dramatic changes in metabolism as 
the requirements of proliferating and quiescent cells are vastly different. Evidence 
that cell cycle quiescence may not be associated with metabolic quiescence has again 
been shown in ‘out of cycle’ fibroblasts that maintain comparable metabolic rates to 
proliferating cells (Lemons, Feng et al. 2010)  
To date, little is known about quiescent haematological cancer cells. 
Experiments presented here demonstrate that ‘out of cell cycle’ primary CLL cells 
also maintain a high level of metabolic activity. Data presented here describe a 
reversibly adaptive Warburg effect in these cancer cells where glucose consumption 
and lactate production were present in oxygenated conditions but became elevated 
upon transition to hypoxia as shown by increased lactate production. At the same 
time, TCA cycle activity appeared to be supported by a shift towards glutaminolysis 
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in hypoxia as evidenced by consumption of glutamine associated with production of 
glutamate, pyruvate, lactate and alanine. However, it is interesting to note that the 
HIF-1α inhibitor CTM had an effect on hypoxia induced CLL cell glutaminolysis by 
accelerating glutamine consumption and glutamate production in hypoxia. In 
contrast, CTM diminished glucose consumption and lactate production. These 
findings suggest that hypoxia induced HIF-1α activity acts to sustain glycolysis and 
‘spare’ glutaminolysis, as CLL cells transit from oxygenated to hypoxic environments 
and that lactate production is largely mediated by the consumption of glucose.   
A key observation was the discontinuous kinetics of pyruvate; being 
externalised early in the experiments and then reabsorbed in hypoxia. Pyruvate 
reabsorbtion was halted by CHC, implicating the MCT1-transporter in this process. 
Importantly, provision of exogenous pyruvate diminished the production of ROS 
and mitosox in response to stress induced by reactive oxygen species (H2O2) and 
reversed CLL cell killing by H2O2. These data are the first to demonstrate that CLL 
cells not only display metabolic plasticity in response to environmental change but 
also change their utilisation of metabolites under different conditions and can do so 
to enhance their survival. 
The study presented here is one of a growing number of studies that have 
analysed metabolism in living cells. A recent study used 13C-pyruvate formulations 
in a comparative flux study of pyruvate metabolism between a glioblastoma and a 
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hepatocarcinoma cell line (Yang, Harrison et al. 2014). Similarly, hyperpolarised 13C 
NMR studies of glucose metabolism in living T47D breast cancer cell cultures have 
also been recently described (Harris, Degani et al. 2013). However, the work 
presented here  provides a significant progression of this type of study.  
To the author’s knowledge this is the first report of real-time NMR 
measurements using primary patient cancer cells purified from the blood of patients 
but not otherwise modified nor cultured. Using these cells, fast metabolic 
adaptations to niche conditions using a simple model of oxygen depletion were 
observed. By embedding cells in a dilute agarose matrix in an NMR tube, oxygen 
access was restricted, while cells were preserved in a stable ‘out of cell cycle’ state. 
The agarose matrix prevented the cells from sinking to the bottom of the NMR tube, 
thus preserving the homogeneity of the NMR sample (in which the CLL cells account 
for less than 10% of the overall volume), which is important to obtain high resolution 
NMR spectra. Line widths of 1-1.5 Hz in 0.1% agarose were obtained, suggesting that 
the matrix preserves the mobility of small molecules, probably arising from large 
cavities in the polymer. Using 1H-NMR spectra, sufficient sensitivity to obtain one-
dimensional spectra in 7-10 minutes in a standard 5 mm NMR tube with a volume of 
just 550 μl was achieved. 
However, the integration in this study of advanced NMR technologies with 
both cancer and cell biological expertise has been of equal importance. This 
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multidisciplinary approach allowed for the interrogation of previously unknown 
aspects of the physiology of CLL cells that underpin this complex disease. Moreover, 
it  has provided insight to new therapeutic avenues in combating not only CLL but 
more generally all metastatic cancers. Beyond this, potential evidence that the basal 
metbolism of CLL cells displays heterogeneity from patient to patient has been 
identified; an observation that would not be possible using established cell lines. A 
future, larger scale study would permit correlation of kinetic metabolic activity with 
disease parameters such as prior or ongoing treatment, as well as correlative studies 
with disease progression and association with prognostic markers.  
Finally, the methodology presented here has considerable potential for 
applications in personalised medicine. Unlike most other analytical technologies, 
NMR is completely non-invasive and preserves cells. This opens new avenues to test 
the effect of treatment options ‘ex vivo’, using primary cells from patients which can 
be further characterised afterwards. 
7.2 Future work 
 
1. Knowing that the presented real time metabolic analysis method can detect 
differences in the metabolic profiles of CLL cells treated under a range of specific 
conditions reproducibly, it would be interesting to select different "types" of CLL 
patients. For example, stage A indolent vs relapsed refractory CLL patients, to 
Chapter Seven –General Discussion 
243 
 
distinguish possible differences between the cells isolated from the groups. Larger 
numbers of samples would be required to perform statistical analysis.   
 
2. This study compared the metabolism of CLL cells in oxygenated and in hypoxic 
conditions. Lymph nodes, (where CLL cells proliferate (Herishanu, Perez-Galan et 
al. 2011)) are likely to be hypoxic, however, to fully prove that the metabolism of 
CLL cells in lymph nodes corresponds to the metabolism of CLL cells in hypoxia 
described in the present study, measurements of CLL cells derived directly from 
the lymph nodes would be required. Such analyses are feasible and should be 
performed after obtaining biopsy samples under appropriate ethical approval. 
 
3. Assessment of the metabolism of heathy B-cells is also required to identify the 
differences and commonalities with CLL cells. Crucially, the comparisons of the 
metabolic plasticity and the adaptation to hypoxic environments must be made to 
elucidate the specificity of the alternations presented here and whether they are 
solely recorded in malignant B-cells. 
 
4. It would be interesting to investigate whether the system of real time NMR 
analysis can be applied to other cell types. Preliminary studies using the 
proliferating KG1a cell line have been carried out and results suggest that these 
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cells are tolerant of NMR real time measurements and changes in metabolism 
upon transition to hypoxia can be observed. 
 
5. A considerable experimental improvement of the NMR probe could be the 
addition of a flow cell, where cells can be kept temperature controlled, with a 
defined oxygen status and would allow for the possibility of drug 
supplementation in real time. This would remove the necessity of using agarose as 
cells could be kept in suspension by carefully adjusting the flow of medium in the 
NMR cell. 
 
7.3 The future of NMR Metabolomics for beating cancer  
Recently, there has been a shift in the way that cancers are being described 
and treated. Currently, tumours are defined not only by where they exist (e.g. lung, 
blood or breast), but also by their molecular characteristics. Mutations in oncogenes 
or those coding for receptors such as K-RAS in colorectal tumours or HER-2 in breast 
cancer, are an important factor to consider when choosing the treatment plan (Aiello, 
Vella et al. 2011; Orphanos and Kountourakis 2012). However, for the majority of 
tumour types, no markers have been identified so far. Patients who receive the same 
diagnosis react very differently to the same treatment and as a consequence, have 
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different outcomes. Therefore, there is a need for targeted therapeutics, characterised 
by higher specificity and efficiency, combined with fewer side effects.  
In recent years, NMR spectroscopy has been successfully used to evaluate 
existing and potential therapies, as well as to analyse toxicology, sensitivity, optimal 
doses and biological mechanisms of therapeutic compounds (Coen, Holmes et al. 
2008; Bayet-Robert, Morvan et al. 2010; Dewar, Keshari et al. 2010). NMR 
metabolomics has also been used to assess the efficiency of both radiation and 
chemotherapy treatments (Blankenberg, Katsikis et al. 1997; Lyng, Sitter et al. 2007). 
Moreover, it can provide a metabolic insight into different tumour subtypes as well 
as their responses to drugs, indicating for which groups of patients therapies are 
likely to be the most effective, or in which groups substantial side-effects will 
manifest. Identification of pre-treatment metabolic profiles correlating with the 
aforementioned data can be very useful for tumour treatment, leading effectively to 
more tailored medicine and giving rise to personalised treatments in the future.  
One of the fields in which NMR metabolomics is rapidly expanding is the 
identification of specific cancer biomarkers in blood. Simple blood testing providing 
metabolic biomarker information, is considerably cheaper than genome sequencing 
or complete proteome analysis, and is equally informative, providing indications for 
early cancer detection and the information needed for selecting optimal treatments. 
Moreover, because of its high sensitivity and quick response to environmental 
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changes, the metabolome often reflects the phenotype more accurately than 
information derived from other –omics techniques such as genomics and proteomics 
(Putri, Nakayama et al. 2013). At present there is still no FDA approved 
metabolomics tests for cancer, however metabolomics is used by the FDA in 
biomarker discovery (FDA, 2006).   
The identification of cancer specific metabolic patterns or alterations can 
accelerate the process by which new molecular targets are defined. Metabolomics 
approaches can also be used to evaluate drugs that are already in use. Obtaining a 
deeper understanding of the mechanism of action of drugs, will enhance the 
identification of new combinations of drugs with higher potency and/or lower 
toxicity, as well as identifying diseases that may respond to unconventional drug. 
Such a strategy will lead to novel and better use of exisiting therapeutics.  
To date, a limited number of approved anticancer drugs have been 
investigated using metabolomics methods. However, recent improvements have 
opened new avenues for NMR metabolomics approaches in the context of drug 
discovery and patient stratification. Investigating unique molecular characteristics, 
will provide sensitive indicators of how drugs are tolerated and how this in turn 
influences the outcome of the patient. By using more specific molecular targeted 
drugs and suitable stratification of patients, cancer treatments can become better 
tailored towards the individuality of the tumor and patient. The ability to quickly 
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identify the best drug for a particular patient will lead to more efficient treatment, 
reduced patient suffering and enhanced health-economical benefits. The complete 
mechanisms of action of many drugs is still poorly understood, which leads to less 
than optimal usage, but NMR (as well as MS) metabolomics can provide much better 
insight. Moreover, metabolomics studies are constantly improving our 
understanding of tumor biology, as shown by the recent identification of new 
potential biomarkers. Ultimately, recognition of the specific drug targets will lead to 
a new generation of rationally-designed drugs. 
7.4 Concluding remarks 
 
The metabolomics era has garnered a return of interest in cancer cell 
metabolism. At the same time, the cancer field has become increasingly interested in 
the tumour cell niche. It is believed that these areas will yield the next step change in 
therapeutic benefits for cancer patients. The study presented here is among the first, 
to address the interplay between the micro-environment and cancer cell metabolism 
in living primary cancer cells. 
Understanding the complexity of the cancer cell niche is challenging. 
However, reductionist approaches can provide invaluable insights. The present 
study addressed the important issue of oxygen supply as part of the cancer cell niche. 
The unusual, perhaps unique, availability of CLL cells to work as a primary cancer 
cell model has been exploited. However, whilst an important cancer in its own right, 
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CLL cells also provide the opportunity to study the more general cancer 
characteristic of metastasis. This is because CLL cells continually recirculate between 
the oxygenated blood stream and hypoxic tissues, a process that metastatic cells have 
to recapitulate to populate new tumour sites. The demonstration of metabolic 
plasticity and the differential utilisation of pyruvate presented in this study has a 
potential to foster new research which may lead to new therapeutic approaches. The 
observation that CLL cells appear to have heterogeneous basal metabolism that may 
relate to disease state, may be further developed in the area of biomarker discovery, 
prognostication and treatment stratification. 
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Appendix A1: Buffers and Recipes 
2.3.2 Cell Cycle Buffer 
30µg PI, 0.1mM NaCl2, 1% (w/v) sodium citrate, 0.1% Triton X100 in ddH2O 
2.8.4 10x TBE Buffer 
108g Tris base, 55g Boric acid, 9.3g EDTA made up to 1L in ddH2O. Diluted to 1 x before 
use. 
2.9.1 RIPA buffer 
1% (v/v) NP40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS in distilled water. Kept 
at 4ºC. Protease inhibitor added prior to use. 
2.9.2 Buffers and gels used for SDS PAGE and Western Blot 
4x SDS gel loading buffer 
62.5mM Tris HCl pH6.8, 25% ( v/v) glycerol, 2% (v/v) SDS, 5% (v/v) 2-β-ME, Bromophenol 
Blue, in distilled water. Stored at RT. 
10% Resolving gel 
30% Bis/Acrylamide (Geneflow) 3.3ml 
1.5M Tris HCl pH8.8 2.5ml 
10% (v/v) SDS 0.1ml 
Distilled water 4.1ml 
10% Ammonium persulphate ((w/v)APS; Sigma) 60µl 
TEMED (VWR international) 4.5µl  
Stacking gel 
30 % Bis/Acrylamide 440µl 
0.5M Tris HCl pH6.8 830µl 
10% (w/v)SDS 33µl 
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distilled water 2.03ml 
10% (w/v)APS 16.7µl 
TEMED 1.7µl 
1x SDS gel running buffer 
25mM Tris, 192mM glycine, 3.5mM SDS in distilled water 
2.9.3 Solutions used for the Protein Transfer 
Transfer buffer 
25mM Tris, 192mM glycine, 20% (v/v) methanol in distilled water 
TBS-T 
137mM NaCl, 20mM Tris HCl pH 7.6, 0.2% (v/v) Tween20 in distilled water 
5% blocking solution 
5% (w/v) milk powder (Marvel) in TBS-T 
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